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Summary 
 
Gliomas are the most common brain cancers, characterized by an exceptionally 
wide cellular heterogeneity and extreme migratory features. The structural development 
of these neoplasms renders surgical removal of the tumoral mass almost prohibitive and 
inefficient. Moreover, these tumors are often resistant to chemotherapy treatments as a 
result of the onset of survival mechanisms occurring during astrocytes malignant 
transformation and counteracting the induction of apoptotic cell death. An alternative 
therapeutic approach relies on the use of autonomous parvoviruses. These small, non 
enveloped, single-stranded DNA viruses are endowed with the capacity to kill malignant 
cells while being non-cytopathic towards healthy tissues. 
In particular, recent analyses on low passage cultures of human gliomas have 
demonstrated that the rodent parvovirus H-1 (H-1PV) induces death in cells resistant to 
conventional anticancer compounds. Among these, NCH82 cells have been chosen in this 
study to investigate the mechanisms of parvovirus H-1-induced glioma cell death. It has 
been observed that H-1PV triggers the formation of autophagic vesicles that are 
eventually involved in the cytosolic activation of lysosomal cathepsins B and L. The virus 
promotes efficient killing even in glioma cells overexpressing Bcl-2, an oncogene 
interfering with both apoptosis and autophagy induction. Besides, H-1PV-induced 
cathepsin B cytosolic activity is favoured by the down-regulation of cystatin B and C, two 
cathepsins inhibitors, and modulates caspase 3 induction. Glioma cells are protected from 
the viral lytic effect by autophagy inhibition, cathepsin B or L inactivation or cystatin B 
overexpression. Finally, cathepsin B in vivo activation upon parvovirus H-1 infection is 
associated with the regression of rat glioma cells intracranially implanted into recipient 
animals.  
To set the basis for an extensive future study on the identification of the key 
genetic alterations that render tumor cells permissive to H-1PV, a preliminary analysis 
has been conducted on rat embryo fibroblasts (REFs). Different immortalized and 
transformed phenotypes have been induced in these cells by overexpressing c-myc, SV40 
large T antigen and activated Ha-ras oncogenes, or by inactivating the anti-oncogene 
p53. Programmed cell death activation has been further analyzed in this model system to 
correlate the genetic determinants of H-1PV sensitiveness with specific molecular events 
leading to virus-induced cell killing. This work demonstrates that c-myc overexpression is 
sufficient to render REFs permissive to H-1PV-mediated cytolysis. While the virus 
accomplishes cytosuppression of ras*/p53dn-transformed REFs by activating classical 
apoptosis, it triggers in all the other transfectants a non-apoptotic death pathway 
characterized by the cytosolic accumulation of autophagic vesicles and active cathepsin B. 
These observations indicate parvovirus H-1 as a potential novel therapeutic tool 
for cancer treatment through its ability to efficiently hijack both autophagic/cathepsins 
and apoptotic pathways, thus jeopardizing tumor cells survival. 
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Zusammenfassung 
 
Gliome sind die häufigsten Hirntumoren. Sie weisen eine sehr hohe zelluläre 
Heterogenität auf und sind sehr stark migratorisch. Die strukturelle Entwicklung dieser 
Neoplasmen macht die chirurgische Entfernung des kompletten Tumorgewebes fast unmöglich. 
Desweiteren sind diese Tumoren oft resistent gegenüber Chemotherapien. Dies ist auf 
Mechanismen zurückzuführen, die das Übereleben der Zellen gewährleisten und die sich 
während der Entartung von Astrozyten zu bösartigen Tumorzellen entwickeln. Diese 
Mechanismen unterdrücken den apoptotischen Zelltod. Einen alternativen Therapieansatz stellt 
der Einsatz von autonomen Parvoviren dar. Diese kleinen, hüllenlosen, einzelsträngigen DNS 
Viren können maligne Zellen töten ohne dabei gesundes Gewebe zu gefährden. 
Vor allem neuere Untersuchungen an Kurzzeitkulturen menschlicher Gliome zeigen, 
dass das Nager Parvovirus H-1 (H-1PV) Zelltod in Zellen induziert, die resistent gegenüber 
konventionellen Therapien sind. Die NCH82 Zellen wurden in der vorliegenden Arbeit 
ausgewählt, um die Mechanismen des parvovirus-induzierten Zelltods von Gliomzellen zu 
untersuchen. Es wurde beobachtet, dass H-1PV die Bildung von autophagischen Vesikeln 
auslöst. Diese Vesikel sind dann an der zytosolischen Aktivierung der lysosomalen Cathepsine 
B und L beteiligt. Das Virus führt selbst in Gliomzellen, die Bcl-2, ein antiapoptotisches Protein, 
das auch Autophagie verhindern kann, überexprimieren, zu einer hohen Zelltodrate. Außerdem 
wird die H-1PV induzierte zytosolische Cathepsin B Aktivität durch die Herunterregulierung von 
Cystatin B und C, zwei Cathepsin Inhibitoren, begünstigt und moduliert die Caspase 3 
Induktion. Die Inhibition der Autophagie, Cathepsin B oder L Inhibition sowie Cystatin B 
Überexpression schützen Gliomzellen vor der Virus-bedingten Lyse. Die in vivo Aktivierung von 
Cathepsin B nach Parvovirus H-1 Infektion führt zu einer Regression von intracranial 
implantierten Gliomzellen der Ratte. 
Um die Basis für intensive Untersuchungen zu schaffen hinsichtlich der Identifikation 
der wichtigsten genetischen Veränderungen, die dazu führen, dass Tumorzellen permissiv für 
H-1PV sind, wurde eine vorläufige Analyse an Fibroblasten von Rattenembryos (REFs) 
durchgeführt. Verschiedene immortalisierte und transformierte Phänotypen wurden in diesen 
Zellen induziert, indem die Onkogene c-myc, SV40, das large T antigen und aktiviertes Ha-ras 
überexprimiert wurden beziehungsweise das Tumorsuppressorgen p53 inaktiviert wurde. Die 
Aktivierung des programmierten Zelltods wurde in diesem Model weiterhin untersucht, um die 
genetischen Determinanten der H-1PV Sensitivität mit molekularen Ereignissen, die zu Virus-
induziertem Zelltod führen, zu korrelieren. Diese Studie zeigt, das die Überexpression von      
c-myc ausreicht, um REFs permissiv gegenüber H-1PV vermittelter Zelllyse zu machen. 
Während das Virus in ras/p53dn-transformierten REFs klassische Apoptose induziert, löst es in 
all den anderen transformierten Zellen einen nicht apoptotischen Weg des Zelltods aus, der 
sich durch zytosolische Akkumulation autophagischer Vesikel und aktives Cathepsin B 
auszeichnet. 
Diese Beobachtungen offenbaren das Parvovirus H-1 als ein potenziell neues Werkzeug 
in der Krebstherapie, da es sowohl autophagische/Cathepsin-abhängige als auch apoptotische  
Wege des Zelltods in Tumorzellen induziert. 
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  Introduction 
 
1 
1.1. Gliomas 
 
During vertebrate embryogenesis, stem cells that originate in the 
dorsal lip of the neural tube undergo epithelial-to-mesenchymal transition 
and migrate outwards to give rise to all cells of the peripheral and central 
nervous systems, including neurons, astrocytes and oligodendrocytes. When 
the developmental process is complete, neurons cease to proliferate and only 
a small compartment of stem cells remains, while glial cells retain the ability 
to propagate throughout life (Teng and Labosky, 2006). The most common 
adult neurological tumors are termed gliomas as they arise from glial cells, 
which are all non-neuronal cells of the nervous system and provide neurons 
with structural support and insulation, nutrients and oxygen supply, 
protection from pathogens. Gliomas encompass neoplasms composed 
predominantly of oligodendrocytes (oligodendrogliomas), astrocytes 
(astrocytomas), mixtures of various glial cells (i.e. oligoastrocytomas) and 
ependymal cells (ependymomas) (Kleihues and Cavenee, 2000). 
Neurological tumours include also cancers derived from non-glial cells of the 
central nervous system (CNS), like medulloblastoma, and from cells of the 
peripheral nervous system (PNS), the most common being neurofibroma and 
Schwannoma (Fig. 1). Neurological tumours have been classified on the 
basis of morphological and immunohistochemical criteria that identify their 
predominant cell type(s) (Zhu and Parada, 2002). This classification could 
result obsolete in the perspective of more recent findings demonstrating that 
brain tumours might be originating from brain-cancer stem cells arisen from 
normal CD133+ stem or early progenitor cells (Singh et al., 2004). 
Gliomas are short lasting cancers characterized by an exceptionally 
wide cellular heterogeneity and extreme migratory features. Surgical 
removal of the tumoral mass is almost prohibitive and inefficient, since these 
neoplasms infiltrate diffusely along the structural interfaces of the brain such 
as the corpus callosum, meninges, and the ventricular lining (Tysnes and 
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Mahesparan, 2001). Invasion of the surrounding tissue occurs via passive 
flowing within the cerebrospinal fluid or by active cell migration mediated by 
cell surface receptors (Pedersen et al., 1993; Thorsen and Tysnes, 1997). 
Moreover, the accumulation of multiple genetic alterations renders brain 
tumor cells resistant to death-inducing agents and in particular to 
chemotherapy treatments (Tysnes and Mahesparan, 2001). The prognosis 
for diagnosed gliomas is generally poor, even though it can differ according 
to clinical factors such as the age of the patient, the grade and the position 
of the tumour (Cooper, 2004). In England and Wales these neoplasms 
account for 1.6% of all cancers, being respectively the twelfth and fifteenth 
most frequent tumors in males and females, with survival rates around 12–
13% for males, 15% for females (Cooper, 2004). In the United States, about 
17.000 new malignant brain cancer cases are diagnosed each year, and 
more than 13.000 deaths are attributed to these cancers (American Cancer 
Society Surveillance Research, 2002). Worldwide, the median survival for 
primary glioblastomas patients is less than one year (Maher et al., 2001) 
while 20% are the long-term survivors, referred to as brain tumor cases with 
a life expectancy of more than 5 years (Wrensch et al., 2002).  
 
Figure 1. Development of neuroectodermal cells and genesis of neurological tumors. Adapted 
from Zhu and Parada (2002) The molecular and genetic basis of neurological tumours.  
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Altogether, gliomas seem to have withstood all attempts for curative 
treatment, and alternative therapeutic approaches are therefore eagerly 
sought. 
 
 
1.2. Genetic alterations in gliomas 
 
Brain cancer can progress de novo from glial cells to primary 
glioblastomas or from astrocytic tumors towards a more malignant 
phenotype and finally to secondary glioblastomas. The World Health 
Organization (WHO) grading system classifies gliomas into grades from I to 
IV by scoring their malignancy degree on the basis of histopathological 
identification (Fig. 2). Astrocytic brain tumours (WHO grade I) are generally 
benign neoplasms and might be in many cases circumscribed, whereas low-
grade astrocytomas (WHO grade II) show diffuse infiltration capacities and 
tend to progress over a period of 5–10 years towards a more malignant 
phenotype. Astrocytomas account for more than 60% of all diagnosed brain 
tumours. Anaplastic astrocytomas (WHO grade III) have more pronounced 
invasive features and acquire migratory capacity, finally turning into 
secondary glioblastomas (WHO grade IV) that share histopathological and 
biological characteristics with primary glioblastomas (WHO grade IV). 
Primary and secondary gliomas, generically referred as glioblastoma 
multiforme (GBM), are considered the most malignant form of infiltrating 
brain cancers, and ranked among the most aggressive human tumors 
(Holland, 2001; Kleihues and Cavenee, 2000; Maher et al., 2001; Zhu and 
Parada, 2002). 
Gliomagenesis results from the accumulation of multiple genetic 
alterations which cooperate in promoting uncontrolled proliferation, 
expanded migration, apoptosis evasion and a striking resistance to 
conventional drug treatments. Despite the extremely broad glial cell 
heterogeneity, it is possible to divide the mutations occurring with the 
highest frequency into five groups: inactivation of p53-dependent pathways, 
enhancement of RTK-activated pathways, interference with pRb-mediated 
cell cycle regulation, loss of PTEN locus, and promotion of the interactions 
between integrins and the extracellular matrix (Fig. 2). 
 3
Introduction 
 
Figure 2. Multiple genetic alterations during gliomagenesis. Histological sections from Tysnes
and Mahesparan (2001) Biological mechanisms of glioma invasion and potential therapeutic 
targets. Alterations proven to be associated with glioma evolution and progression are marked 
in blue. For abbreviations refer to text.
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1.2.1. Inhibition of p53-dependent signalling 
 
p53 has multiple functions (Vogelstein et al., 2000), including cell 
cycle control in response to DNA damage (Kastan et al., 1991), DNA repair 
(Smith et al., 1995), and induction of apoptosis (Lowe et al., 1993). p53 is   
directly inactivated in low-grade gliomas, anaplastic astrocytomas, and 
secondary glioblastomas by allelic loss of chromosome 17p or missense 
mutations targeting crucial residues for DNA binding (Maher et al., 2001). 
Moreover, loss of p53 leads to glial cell immortalization (Mathon et al., 
2001). In mammals, p53 modulates cell response to DNA damage by 
blocking cell cycle progression through p21-dependent inactivation of G1 
phase cyclin/cyclin-dependent kinases (CDK) complexes (Waldman et al., 
1995). p53 also acts as a sequence-specific DNA binding protein which 
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activates the transcription of target genes, such as the pro-apoptotic protein 
Bax (Miyashita et al., 1994). Nevertheless, mutations in p53 downstream 
targets such as p21 and Bax have not been documented in gliomas (Maher 
et al., 2001). Frequently detected in primary glioblastomas is the gene 
amplification or overexpression of Mdm2 (Biernat et al., 1997a), which 
inhibits p53 transcriptional activity by direct binding and promotes p53 
ubiquitination (Kubbutat et al., 1997). In addition, 40% of primary 
glioblastomas carry deletions of the INK4 locus (Zhu and Parada, 2002), 
whose alterative splicing product p19ARF (Sherr, 2001) stabilizes p53 by 
blocking Mdm2 (Pomerantz et al., 1998). Remarkably, p53 direct mutation 
and indirect inactivation seem to be mutually exclusive (Fulci et al., 2000). 
Furthermore, p53 mutations occur in the early phases of glioma 
development, in contrast to quite all the other human cancers having p53 
mutations associated with the advanced stages (Zhu and Parada, 2002). This 
might reflect the need for astrocytoma cells to evade apoptosis in order to 
migrate and survive in adverse microenvironments, and could partially 
explain why gliomas, while being extremely invasive, are not metastatic 
(Tysnes and Mahesparan, 2001). 
 
1.2.2. Activation of RTKs-mediated pathways 
 
Receptor tyrosine kinases (RTKs) are transmembrane proteins with 
intrinsic tyrosine kinase activity, which control multiple downstream 
signalling pathways. Upon binding of diffusible growth factors, RTKs dimerize 
and initiate an autophosphorylation process that recruits adaptor proteins 
like Shc, which in turn mediate Ras activation. Three main downstream 
effector pathways can be triggered by Ras: the Raf/Mitogen Activated Protein 
Kinases (MAPKs) signalling cascade controls cell proliferation and 
differentiation, the phosphotidylinositol-3 kinase (PI3K) / protein kinase B 
(PKB/Akt) pathway promotes cell survival, and the CDC42/Rho signalling 
mediates gene expression and cytoskeletal organization (Heldin, 1996; 
Hunter, 2000; Sahai and Marshall, 2002). Despite being one of the most 
frequently mutated genes in human cancers, ras aberrations are not found in 
gliomas (Bos, 1989; Sahai and Marshall, 2002). Instead, platelet-derived 
growth factor (PDGF) seems to be a key regulator of glial cells development, 
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particularly oligodendrocytes (Yeh et al., 1993), and low-grade astrocytomas 
overexpress both PDGF ligands and receptors, possibly through the onset of 
an autocrine stimulatory loop synergizing with p53 inativation (Hermanson et 
al., 1992; Hermanson et al., 1996). In low-grade tumors, uncontrolled PDGF 
signalling is however not exerting a proliferative in vivo effect, perhaps 
because PDGF isophorms can associate in different dimeric receptors 
complexes and may preferentially activate the Ras-independent PI3K- and 
phospholipase C gamma (PLCγ) - signalling pathways, which trigger cell 
migration (Maher et al., 2001). Epidermal growth factor receptor (EGFR) 
may have a role in astrocyte differentiation, and appears to be necessary for 
sustained proliferation of neural stem cells. EGFR activation might be 
responsible for driving the transformation process toward high-grade 
gliomas, since EGFR gene is amplified in 50% of glioblastomas and in around 
7% of anaplastic astrocytomas (Bigner et al., 1990; Lang et al., 1994; 
Schlegel and al., 1994). In addition, almost 40% of gliomas with EGFR gene 
amplification express a variant activated mutant form that lacks part of the 
extracellular ligand-binding domain and is constitutively autophosphorylated 
(Humphrey et al., 1990; Wong et al., 1992). 
 
1.2.3. Disruption of pRb-mediated cell cycle regulation 
 
The retinoblastoma family of tumour suppressors (pRbf) consists of 
the three proteins pRb, p107 and p130 that are key regulators of the G1/S 
cell cycle checkpoint. In quiescent cells, pRbf are maintained in a 
hypophosphorylated status that sequester E2F-family transcription factors, 
whereas in response to proliferative stimuli pRbf get phosphorylated by 
cyclin-dependent kinases (CDK2/4/6), thus releasing E2F transcription 
factors that promote G1/S transition and DNA synthesis initiation. CDKs 
activity is positively regulated by formation of functional complexes with 
specific cyclins. Negative regulators of the pRbf pathway are generic cyclin-
dependent kinase inhibitors (CKIs) such as p21 and p27, and specific cyclin 
D - CDK4/6 complex inhibitors like p16INK4a and p15INK4b (Malumbres and 
Barbacid, 2001). The pRb regulatory circuit is disrupted in 80% of 
glioblastomas (Zhu and Parada, 2002), mainly via either loss of INK4a locus, 
loss of pRb or CDK4 amplification (He et al., 1995), but also through CDK6 
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and cyclin D1/E overexpression (Buschges, 1999; Costello, 1997) or E2F1 
downregulation (Chakravarti, 2001). These genetic alterations are frequently 
mutually exclusive, but are rare in low-grade astrocytomas and therefore 
considered to be implicated not in glioma initiation but rather in tumour 
progression (Zhu and Parada, 2002). 
 
1.2.4. Loss of PTEN 
 
PTEN (phosphatase and tensin homology) gene encodes for a protein 
with a double phosphatase activity. PTEN controls cell migration and invasion 
by focal adhesion kinase (FAK) dephosphorylation through its N-terminal 
domain, which is highly homologous to tensin and auxilin, two proteins 
involved in interactions with actin filaments (Tamura et al., 1998). Besides, 
PTEN regulates cell proliferation and survival by blocking phosphatidylinositol 
(3,4,5)-triphosphate-dependent activation of the PKB/Akt pathway through 
its central domain, which shows homology to the catalytic region of protein 
tyrosine phosphatases (Maehama and Dixon, 1998). Loss of heterozigosity 
(LOH) on the long arm of chromosome 10, where PTEN maps, is found in 
75–90% of high-grade gliomas, and PTEN mutations occur in 30–44% of 
anaplastic astrocytomas and glioblastomas (Maher et al., 2001). 
Furthermore, a recent study has proven that PTEN heterozygosity 
accelerates astrocytoma progression with a possible dose-dependent effect, 
and that Akt is regionally activated by serine 437 phosphorylation in 72% of 
these tumors (Xiao et al., 2002a). The discrepancy between LOH of 10p and 
mutation frequency of PTEN gene suggests that other glioma suppressor 
genes reside in this region. In this perspective, on the long arm of 
chromosome 10 maps a member of the Mad family of proteins, which are 
potent antagonists of c-Myc in vivo (Schreiber-Agus et al., 1998) and appear 
to be involved in neuronal differentiation (Queva et al., 1998). The impact of 
c-Myc disruption on gliomagenesis is controversial, since c-myc amplification 
is rarely detected in high-grade gliomas (Maher et al., 2001), but c-Myc is 
expressed at elevated levels in 78% of glioblastomas compared to normal 
brain tissues (Herms et al., 1999). 
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1.2.5. Integrins overexpression and cell migration 
 
To migrate away from the tumor formation site, a glioma cell has to 
detach from neighbouring cells, digest the extracellular matrix (ECM) and 
move along a supporting surface (Uhm et al., 1999). Virtually all ECM 
proteins are localized in the normal adult brain at the perivascular space to 
form the blood–brain barrier (Carbonetto, 1984). High-grade glioma 
migration may take advantage of the ECM secreted by the normal 
surrounding tissue, even if ECM production is stimulated in these tumor cells. 
On the contrary, many members of the integrin family, in particular integrin 
α3β1, are found overexpressed in gliomas, and control cellular locomotion by 
disassembling focal adhesions and reorganizing the actin filaments (Tysnes 
and Mahesparan, 2001). This effect is further enhanced by the cross-talk 
between the ECM/integrin and the RTKs signalling pathways via direct 
proximal clustering among integrins and growth factors receptors or through 
connecting proteins such as the focal adhesion kinase (FAK) (Uhm et al., 
1999). Moreover, gliomas degrade different ECM basement components by 
overexpressing matrix metalloproteinases (MMP) 2 and 9 (Nakagawa et al., 
1994), cysteine proteinases cathepsin B and L (Rempel et al., 1994), and the 
urokinase-type plasminogen activator (uPA) (Landau et al., 1994). 
 
 
1.3. Standard therapies for glioma treatment 
 
Currently, the standard therapeutic protocol for patients with high-
grade malignant glioma is maximal resective surgery complemented by 
radiation therapy. However, total tumor resection is often not possible due to 
the critical localization of the neoplasm, which spreads in and surrounds the 
healthy portions of the brain. Incomplete removal of the cancerous mass has 
been shown to potentially induce early and aggressive tumor recurrence 
phenomena (DeAngelis, 2003; Giese and Westphal, 2001; Tysnes and 
Mahesparan, 2001). Radiotherapy is used as adjuvant treatment to increase 
patient survival expectances. Iridium and iodine-125 are the most commonly 
used radionuclides. In conventional radiotherapy protocols, patients are 
exposed to external beam radiation doses of 60 Gy (gray) in single daily 
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fractions of 1.7-2 Gy, five times a week. Approximately 50% of atrocytomas 
and 25% of glioblastomas decrease in size following radiotherapy (Leibel et 
al., 1989). In the treatment of tumor recurrence, stereotactic techniques are 
used to place catheters containing high-energy radioactive isotopes within 
brain tumors; this procedure is called brachytherapy and delivers an 
additional radiation dose of 50-60 Gy without tumoricidal effect on normal 
brain tissues (Castro et al., 2003). Stereotactic radiosurgery is a more recent 
and less invasive approach to treat well-defined lesions with a first 50 Gy 
dose and a second 15 Gy re-irradiation respectively applied right after tumor 
resection and 10 months later. Although preliminary results seem promising 
(Combs et al., 2005), adjuvant radiotherapy increases patients’ lifespan of 
14–36 weeks only (Grossman and Batara, 2004). 
Nitrosoureas are lipid-soluble agents that cross the blood-brain barrier 
and have been employed in the chemotherapy of brain tumors as adjuvant 
treatment. Several strategies have been established for local delivery of 
chemotherapeutic compounds, including intra-arterial placement of 
microcatheters, implantation of slow-release biodegradable polymers, and 
use of convection-enhanced catheters to force the drug into non-resectable 
tumors (Castro et al., 2003). Despite being non curative and causing 
haematological, hepatic and pulmonary toxicity, the use of 
chemotherapeutics has been associated with improved survival (Giese and 
Westphal, 2001). Recently, the oral alkylating agent temozolomide has been 
demonstrated to increase survival when used in concomitance to radiation 
therapy in newly diagnosed glioblastoma patients. In addition, several 
biological modifiers such as anti-angiogenic agents and matrix 
metalloproteinase inhibitors have been tested in different clinical trials 
(Chamberlain, 2006). Nonetheless, the median overall survival of patients 
treated according to this advanced chemoradiotherapy protocol is improved 
of 2 months only compared to individuals receiving radiotherapy alone (Siker 
et al., 2006). 
 
 
 
 
 
 9
Introduction 
1.4. Gene therapy and glioma treatment 
 
Given the striking resistance of brain tumors to conventional therapy, 
alternative therapeutic approaches are urgently required. Gene therapy is 
the insertion of genetic material into an individual's cells and tissues to treat 
a disease. Current attempts in this direction imply the direct in vivo delivery 
of therapeutic agents at the time of tumor resection by means of stereotactic 
injections, or the ex vivo genetic manipulation of the target cells that are 
subsequently implanted at the tumor site (King et al., 2005). Replacement 
gene strategy aims at the incorporation of functional genes to restore the 
activity of defective or absent genes, such as the tumor suppressors p53 or 
pRb (Riley et al., 1996). Another approach is to induce the expression of 
beneficial proteins, as angiostatin or endostatin, to inhibit endothelial 
proliferation and tumor-promoted angiogenesis (Ma et al., 2002; Peroulis et 
al., 2002). Antisense cDNA or oligodeoxynucleotides constructs have been 
also designed to block the expression of cancer genes by anti-parallel 
hybridization of the mRNA of interest. Several antisense constructs have 
been tested in glioma gene therapy, particularly against cellular growth 
factors such as bFGF, IGF-1, TGF-β, and VEGF (Engelhard, 1998). In parallel, 
gene therapy strategies have been studied with the aim to stimulate immune 
system activation against the tumor. Among others, have been evaluated the 
activation of T cells via tumor antigens upregulation (Parney et al., 1997) or 
induction of interleukins production (Okada et al., 1999), and the 
mobilization of dendritic cells through ex vivo manipulation (Aoki et al., 
2001) or co-delivery with an interferon-α expressing vector (Tsugawa et al., 
2004). Finally, a slightly different approach is to deliver a non toxic prodrug 
to the patient, and to force in tumor cells the expression of a specific enzyme 
that will convert the prodrug into a toxic product. A number of non-viral 
gene delivery systems have been developed for this technique (GDEPT - 
Gene-Directed Enzyme Prodrug Therapy), including naked DNA, liposomes, 
peptides and polymers. However, non-viral gene transfer has been 
increasingly replaced by the use of viral vectors modified by recombinant 
DNA technology to be more selective and efficient (Schepelmann and 
Springer, 2006). The prodrug ganciclovir has been administered in several 
glioma pre-clinical and clinical trials in combination with thymidine kinase 
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(TK) gene expression. Thymidine kinase phosphorylates the prodrug 
generating a nucleotide analogue that blocks DNA polymerase, thus inducing 
target cell death. Replication-defective adenoviruses (Immonen et al., 2004), 
bicistronic adeno-associated viral vectors (Okada et al., 1996), ex vivo-
transduced retroviruses (Ezzeddine et al., 1991), intratumorally-implanted 
retrovirus-producing cells (Rainov et al., 1996), and replication-defective 
herpes simplex viral vectors (Miyatake et al., 1997; Moriuchi et al., 2005) 
have been all tested as conveyance methods. 
 
 
1.5. Oncolytic viruses 
 
Oncolytic viruses are replicating microorganisms endowed, either 
naturally or through appropriate engineering, with the capacity to infect and 
kill tumour cells. Oncolytic viruses selectively target cancer cells because 
they can take advantage of frequent tumour-specific mutations, be 
dependent on signalling pathways or transcriptional programmes that are 
constitutively activated in tumours, recognize cellular antigens that are 
unique or overexpressed on the tumour cell surface (Chiocca, 2002). Tumour 
cell is killed by the oncolytic virus as it takes over the cellular translational 
and/or transcriptional machinery, eventually inducing cell death through the 
activation of either necrotic or apoptotic pathways. Over the last decade, due 
to a better understanding of the molecular events ruling tumorigenesis, an 
oncolytic virotherapy platform has been developed (Bell et al., 2003). Up to 
the year 2005, an increasing number of different types of oncolytic viruses 
have been tested in preclinical trials, more than 50 phase I or II clinical trials 
have been conducted (Parato et al., 2005) and a phase III study has been 
published (Xia et al., 2004). The first tumor-selective lytic virus to 
demonstrate antitumor activity in a clinical setting was the adenoviral 
derivative ONYX-015; numerous viruses have been afterwards explored as 
tumor-selective replicating vectors, including herpes simplex virus (HSV), 
adenovirus, Newcastle disease virus (NDV), reovirus, poxvirus, vesicular 
stomatitis virus (VSV), and poliovirus (Nemunaitis and Edelman, 2002; 
Parato et al., 2005). 
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1.5.1. HSV-1 
 
Herpes simplex virus type 1 (HSV-1) is a nuclear replicating, 
icosahedral, enveloped, double-stranded DNA virus belonging to the 
Herpesviridae family. HSV-1 is a human pathogen that generally causes 
gingivo-stomatitis and chronic skin keratitis (Lerner, 1980). HSV-1 is a 
neurotropic virus that has been therefore investigated for gene therapy 
treatments of malignant gliomas. Viral genome is linear, 152 kbp long, 
encoding for approximately 90 unique genes, half of which are essential for 
viral replication in permissive tissue cultures. Multiple transgenes can be 
simultaneously delivered and expressed in engineered HSV-1 mutants by 
deleting up to 30 kbp of viral genome. HSV-1 has a very wide host range, is 
highly infectious and efficiently expressing transgene products, and does not 
integrate its DNA into the cellular genome, eliminating the problem of 
insertional mutagenesis side effects. Two types of HSV-1 vectors have been 
used in cancer treatment. Replication-defective vectors express therapeutic 
genes inserted in amplicon plasmids containing HSV-1 packaging/cleavage 
signals and origin of replication, but are able to replicate only in cells that 
complement the deleted viral functions in trans. Conditionally replicating 
vectors are deleted for non-essential viral genes and preferentially infect, 
replicate in, and kill tumor cells (Shen and Nemunaitis, 2006). On the one 
hand, HSV-1 has been used for the delivery of suicide or therapeutic genes, 
such as native HSV-1 thymidine kinase combined with ganciclovir (Spencer, 
2000), p53 (Rosenfeld et al., 1995), tissue inhibitor of metalloproteinase 2 
(Hoshi et al., 2000), interleukins and interferons (Kim et al., 2000a). On the 
other hand, different strategies have been studied to genereate tumor-
selective replication-conditional oncolytic HSV-1. Mutations and/or deletions 
have been inserted in one or more of the genes encoding thymidine kinase, 
DNA polymerase, uracil DNA glycosylase, and ribonucleotide reductase (Lou, 
2003). Intratumoral administration of the TK-deleted strains has been shown 
to induce tumor necrosis and regression in several rat glioma models (Jia et 
al., 1994), but to lack tumor specificity in immunodeficient mice (Valyi-Nagy 
et al., 1994). ICP34.5 gene deletion results in the production of strains that 
are replication-defective in neurons but replicate efficiently in transformed 
cells (Andreansky et al., 1996). One of these, HSV1716, has been tested in 
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clinical trials involving high-grade glioma patients, and has proved to reduce 
the tumor size and to partially spread at distal tumor sites, without exerting 
clinical toxicity (Harrow et al., 2004). G207 is a second generation oncolytic 
HSV-1 virus that carries deletions in both ICP34.5 alleles and contains a 
detectable histochemical marker (Mineta et al., 1992). Animal experiments 
have demonstrated that multiple injections can be applied without inducing 
immune resistance to the virus, and phase I clinical trials in patients with 
malignant glial tumors are giving promising results (Markert et al., 2000). 
Further improvements consider the use of tumor- and/or tissue-specific 
promoters or surface proteins to alter viral tropism (Chung et al., 1999; 
Laquerre et al., 1998). 
 
1.5.2. From Onyx-015 to chimeric adenoviruses 
 
Most oncolytic adenoviral vectors are based on wild-type adenovirus 
serotype 5 (Ad5), a non-enveloped, double-stranded DNA virus with a 36 
kbp linear genome (Bett et al., 1993). Onyx-015 is a modified adenovirus 
deleted for the E1B-55K gene product that replicates only in cells lacking 
p53,  thus  being  selective  for  cancerous  tissues  (Heise et al., 1997).  
Onyx-015 potential efficacy and safety have been evaluated in different 
phase I and II studies for the treatment of malignant glioma and head & 
neck cancers (Chiocca et al., 2004; Khuri et al., 2000). The tropism of 
second generation conditionally replicating adenoviruses has been 
successfully redirected towards cancer cells by constraining essential viral 
genes under the control of heterologous promoters, enhancers, and silencers 
that are specifically active in tumour cells (Ko et al., 2005). In example, 
adenoviral derivatives have be engineered to be transcriptionally regulated 
by the prostate-specific antigen (PSA) (Schuur et al., 1996), E2F 
transcriptional factor (Parr et al., 1997) or the human telomerase reverse 
transcriptase (hTERT) (Iwamaru et al., 2006). In addition, chimeric viruses 
between different adenovirus serotypes have been generated to overcome 
Ad5 virus limited efficacy, due to the wide expression of its natural surface 
receptor in normal cells. For instance, have been tested chimeras based 
mainly on Ad5 genome, but expressing Ad3 fibre-knob protein that can 
selectively and efficiently infect ovarian cancer cells (Breidenbach et al., 
 13
Introduction 
2004). The first gene therapy-associated death occurred in a patient 
suffering from a genetic disease and treated with a high dose of adenovirus 
(Lehrman, 1999); since then adenoviral vectors have been improved to limit 
their potential capacity to trigger a strong immunoresponse (Yla-Herttuala 
and Alitalo, 2003). To date, a subset of transcriptionally regulated selectively 
replicating oncolytic adenoviruses has proceeded to the completion of a 
phase III trial in China and a proposed phase III study in the United States, 
thus representing one of the most advanced candidates for virotherapy (Aghi 
and Martuza, 2005). 
 
1.5.3. NDV and reoviruses 
 
Newcastle disease virus (NDV) is an avian enveloped single-stranded 
16 kb RNA paramyxovirus. Despite being potentially fatal to birds, NSV can 
infect humans causing only minor illnesses such as fever or flu-like 
symptoms (Alexander and Allan, 1974). Several lytic strains show enhanced 
replication efficiency in cancer cells and have been therefore tested for a 
possible clinical application. It has been proposed that NSV strains display a 
conditionally replication-competent behaviour because of Ras signaling 
pathway activation in neoplastic cells, as it has been demonstrated for 
reoviruses (Lorence et al., 1994a). NDV has undergone preclinical animal 
studies to test its efficacy against human gliomas (Lorence et al., 1994b), 
and is currently studied for the treatment of various cancers with different 
administration regimens (Schirrmacher et al., 2001). Some serious adverse 
events, including a patient’s death, have been noted in a phase I trial with 
PV701 oncolytic strain (Phuangsab et al., 2001). On the contrary, MTH-68/H 
strain has been successfully used in a desperate case of a 14-year-old boy 
with a recurrent glioblastoma (Csatary and Bakacs, 1999). NDV has shown 
much more potential as a cancer vaccine therapy, where the virus is used as 
adjuvant to boost the host immune system (Schirrmacher et al., 1998). NDV 
replicates in the host cell cytoplasm with strong cell-binding properties, and 
enhances in infected tumors cells the recruitment and activation of natural 
killer and cytotoxic T cells (Haas et al., 1998). 
Reoviruses are non-enveloped viruses with a 18-30 kbp segmented, 
double-stranded RNA genome (Fields et al., 1996). In infected cells, a 
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specific protein kinase (PKR) recognizes the double-stranded RNA and 
activates a host response against the virus. Hence, reoviruses have tropism 
for tumors cells where Ras signaling pathway, which interferes with PKR 
activation, is disrupted. Indeed, cells that are resistant to reovirus infection 
become susceptible after transformation with factors involved in the Ras 
signaling cascade (Strong et al., 1998). Reovirus infections tend to be 
asymptomatic, despite some cases of reported mild respiratory or 
gastrointestinal tract symptoms (Fields et al., 1996). Thus, reovirus efficacy 
as potential replication-competent virus in the treatment of gliomas has been 
investigated in vitro, in vivo, and ex vivo, using an immune-competent  
mouse model and even challenging animals with reovirus prior to tumor 
implantation (Coffey et al., 1998; Wilcox et al., 2001). Albeit a serious 
toxicity has been reported in immunodeficient mice, no dose-limiting 
toxicities have been recorded in phase I trials of reovirus (Reolysin™) 
administered via direct intratumoral inoculation in patients with recurrent 
malignant glioma (Oncolytics Biotech Press, 2006). 
 
1.5.4. Vaccinia and myxoma viruses 
 
Poxviruses are a family of enveloped, double-stranded, linear DNA 
viruses that present the uniqueness of remaining in the cytoplasm of infected 
cells for the entire life cycle, without translocating in the nucleus during DNA 
replication and transcription. Producing their own transcriptional machinery, 
poxviruses resist host cell’s attempts to counteract infection, and have been 
studied for application in virotherapy (Moss, 1996). 
Vaccinia virus (VV) is a member of the Poxviridae family that has 
been scrutinized as agent against malignant gliomas. The genome consists of 
192 kbp with inverted terminal repeats and is packed in a particle of 200 nm 
in diameter and 300 nm in length (Smith and Vanderplasschen, 1998). VV 
has a distinct history as a vaccine used for the eradication of smallpox, and 
no known natural host has been identified so far (Baxby, 1985; Parrino and 
Graham, 2006). This virus has tropism for the ovary and tumor tissues, 
perhaps because the leaky vascular barrier surrounding tumors and ovarian 
follicles allows a better viral escape from the circulation (Goede et al., 1998). 
Though VV was extensively studied for its utilization as vaccine for anti-
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cancer therapy, researchers have more recently evaluated the oncolytic 
ability of this virus to make vaccinia an anti-tumor agent (Parato et al., 
2005). A recombinant vaccinia virus expressing p53 (rVV-p53) has been 
positively tested as potent apoptosis inducer and direct oncolytic agent in 
several human and rat glioma cell lines (Timiryasova et al., 1999a) and in 
the C6 rat glioma model in combination with radiation therapy (Gridley et al., 
1998; Timiryasova et al., 1999b). Other recombinant vaccinia vectors 
expressing the murine interleukins IL-2 and IL-12 have been proven in vitro 
and in vivo to enhance VV oncolytic effect (Chen et al., 2000; Chen et al., 
2001). Furthermore, vaccinia growth factor (VGF) and thymidine kinase 
genes single or double deletions have been used as tool to attenuate vaccinia 
virus and render the vector tumor-selective (Buller et al., 1985; Puhlmann et 
al., 1999). 
Myxoma virus is an oncolytic poxvirus that has a narrow rabbit-
specific tropism and is non-pathogenic in humans (McFadden, 2005), but has 
been shown to kill several human tumor cell lines (Sypula et al., 2004), 
including glioblastoma-derived cultures (Lun et al., 2005). Myxoma virus 
expresses gene products that counteract rabbit interferons but are unable to 
antagonize interferons from other species, including mice and humans. 
Hence, in normal human cells myxoma virus infection is blocked at a very 
early stage while the virus is able to replicate and exert a lytic effect in 
interferon-non-responsive human tumour cells (Wang et al., 2004a). 
 
1.5.5. VSV and poliovirus 
 
Vesicular stomatitis virus (VSV) is a 11 kilobases negative-stranded 
RNA virus belonging to the Rhabdoviridae family. VSV glycoprotein (G) is a 
major antigen responsible for type specificity and provides the virus with a 
wide tropism, ranging from vertebrates to invertebrates and even plants.  
VSV replicates in the cytoplasm of infected cells, does not undergo genetic 
recombination or reassortment, has no known transforming potential and 
does not integrate any part of its genome into the host (Dietzschold et al., 
1996). Evidences indicate that VSV endocytosis occurs via binding to 
phosphatidylserine (PS) residues on the target membrane, while a drop in 
endosomal pH causes the release of the viral core into the cytoplasm 
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(Carneiro et al., 2002). VSV non-lethal infections may occur in farm animals, 
while the virus exerts a neuropathic action in mice (van den Pol et al., 2002) 
but is essentially asymptomatic for humans (Dietzschold et al., 1996). 
Besides, VSV replicates to high levels in numerous types of transformed and 
malignant tissue cultured cells, and rapidly induces apoptotic cell death. VSV 
has been now reported to be efficacious against cancers that are associated 
with persistent viral infection, such as hepatocellular carcinoma (Suriawinata 
and Xu, 2004), but also malignant glioma, melanoma, breast 
adenocarcinoma, and prostate cancers (Livingston et al., 1985; Obuchi et 
al., 2003). VSV oncolytic action has been correlated to defects in the innate 
immune responses of these cell types (Balachandran and Barber, 2004; 
Stojdl et al., 2003), either in interferon induction or signalling cascade 
activation (Dunn et al., 2002; Persing and Prendergast, 1999).  
Poliovirus is a non-enveloped, RNA enterovirus with a positive-
stranded genome of 7500 nucleotides in length, and can cause illnesses 
ranging from minor symptomatic infection to aseptic meningitis or paralytic 
poliomyelitis (Racaniello, 2006). Replacing the internal ribosomal entry site 
(IRES) located at the 5´-untranslated region of viral genome with a non-
pathogenic but structurally related element of human rhinovirus type 2 
attenuates the virus without affecting its ability to grow in non-neuronal cells 
(Gromeier et al., 1996). This intergeneric poliovirus, designated as 
PV1(RIPO), is not neuropathogenic and has been tested as oncolytic virus in 
brain cancer therapy. It has been demonstrated that human glioma cells 
susceptibility to poliovirus PV1(RIPO) depends on the expression of the 
human poliovirus receptor CD155 (Mendelsohn et al., 1989) but the virus 
has to be inoculated intratumorally in order to exert an efficient anti-tumor 
action (Gromeier et al., 2000). To improve poliovirus vectors´ safety for 
administration in the central nervous system as a possible treatment for 
gliomas, alternative candidate oncolytic agents derived from poliovirus have 
been designed (Jackson et al., 2001). Poliovirus genome is engineered to 
generate replicons that have deleted the gene encoding the capsids protein 
P1 and are therefore incapable to generate infectious progeny particles 
(Hagino-Yamagishi and Nomoto, 1989). Replicons are produced by 
complementation in trans of the capsid protein from a recombinant vaccinia 
virus (Ansardi et al., 1991) and induce oncolysis in different human 
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glioblastoma cell lines and low-passage cultures from patients (Ansardi et 
al., 2001). Besides, replicon oncolytic effects have been further potentiated 
by replacing the capsids P1 gene with a therapeutic gene, like the murine 
TNF-α (Bledsoe et al., 2000) or interleukin-2 (Basak et al., 1998). 
 
 
1.6. Autonomous parvoviruses 
 
The work conducted in the past by the group of Prof. J. Rommelaere 
has shown that autonomous parvoviruses circumvent tumor cell escape 
mechanisms and do kill tumor cells, thus yielding promising candidates for 
innovative cancer virotherapy (Rommelaere and Cornelis, 2001).  
Parvoviruses are among the smallest animal DNA viruses. The family 
Parvoviridae is divided into two subfamilies: the Densovirinae, which infect 
invertebrates, and the Parvovirinae, which infect vertebrates and include the 
three genera Parvovirus, Erythrovirus, and Dependovirus (Muzyczka and 
Berns, 2001). Dependoviruses or adeno-associated viruses (AAVs) 
incorporate several different serotypes, and infect many types of cells and 
tissues of various species, including humans (Shaughnessy et al., 1996). 
AAVs efficiently infect the host cell but require a helper adenovirus or 
herpesvirus to supply functions needed for complete replication. When 
inoculated in cells alone, the genome may integrate into the host 
chromosome in a site-specific manner thus establishing latency (Chiorini et 
al., 1996). On the contrary, autonomous parvoviruses, Parvovirus and 
Erythrovirus, do not need a helper virus but require factors of the cellular   
S-phase for their replication (Rommelaere and Cornelis, 2001). 
The erythrovirus B19 is the only family member demonstrated to be 
pathogenic in humans. This virus causes arthropathy in adults, aplastic 
anaemia in patients with sickle cell disease or childhood fifth disease 
(erythema infectiosum), and rare foetal infections (Brown et al., 1994). 
Rodent parvoviruses [minute virus of mice (MVM), LuIII, parvovirus H-1   
(H-1PV) and Kilham rat virus (KRV)] generally infect rodent cells, but are 
able to replicate in a variety of different cells from other species, including 
humans. In the natural host, parvovirus infections of foetuses or neonates 
often term fatally, and are characterized by several symptoms such as 
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enteritis, hepatitis, cerebellar hypoplasia and ataxia, leucopoenia, 
haemorrhages of the liver, lung, brain, and intestine (Brownstein et al., 
1991; Jacoby et al., 1996). On the contrary, parvoviruses are non-
pathogenic in adult animals and seem to be associated with low or no 
immunogenicity. In humans, rodent parvoviruses infection causes viremia 
and seroconversion without pathological implications (Rommelaere and 
Cornelis, 2001). Parvoviruses are unique among DNA viruses in that they do 
not have any tumorigenic members (Berns, 1996). Moreover, these viruses 
have been shown to have oncosuppressive effects, inhibiting the formation of 
spontaneous as well as chemically or virally induced tumours in laboratory 
animals (Rommelaere and Cornelis, 2001). 
 
1.6.1. Capsid structure and genome organisation 
 
Autonomous parvoviruses are small (20-25 nm in diameter), non-
enveloped, nuclear-replicating single-stranded DNA viruses. Parvoviral capsid 
is icosahedral, consisting of 60 subunits assembled with the three structural 
proteins VP1 (83-86 kDa), VP2 (64-66 kDa), and VP3 (60-62kDa) 
(Agbandje-McKenna et al., 1998). VP2 and VP3 constitute the majority of 
capsid proteins in full virions, VP2 being the most abundant (80%) and VP3 
absent in empty particles (Tattersall et al., 1976). VP1 comprises the         
C-terminal 64 kDa region of VP2, and its N-terminal domain is required for 
the nuclear export of full virions (Valle et al., 2002). VP3 is formed in full 
capsids by cleavage of 25 amino acids at the N-terminus of VP2, which are 
exposed outside the particle (Weichert et al., 1998). Despite only about nine 
VP1 molecules are inserted per viral capsid, this polypeptide has been show 
to be essential for infectivity because its N-terminal sequence contains a 
phospholipase A2 (PLA2) motif
 which appears active when released from the 
capsid (Zadori et al., 2001). X-ray crystallography studies on parvovirus 
three-dimensional conformation have revealed the presence of a cylindrical 
structure surrounded by a canyon-like depression at about the fivefold axes, 
spike protrusions at the icosahedral threefold axes, and a dimple-like 
depression at the twofold axes (Agbandje-McKenna et al., 1998; Hernando et 
al., 2000) (Fig. 3A). The expression of specific sequences on the capsid 
surface allows some parvoviruses to infect several hosts and a variety of 
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tissues, in contrast to many parvoviruses that have tightly controlled host 
ranges and tissue tropisms (Agbandje-McKenna et al., 1998; Hueffer et al., 
2003). 
Viral genome consists of approximately 5150 nucleotides linear DNA, 
flanked by palindromic sequences that can form hairpin structures and serve 
as self-priming origins of DNA replication. The open reading frame (ORF) at 
the left side is controlled by the strong P4 promoter and directs the 
expression of the non-structural proteins NS1 and NS2. The coding 
sequences for the N-terminus of NS1 and NS2 overlap and the two proteins 
are produced after differential messenger RNA (mRNA) splicing. The right-
hand promoter (P38) controls a second ORF driving the expression of the 
structural proteins of the capsid, which are translated using two distinct 
initiation codons as a result of differential splicing of the precursor mRNA 
(Cotmore and Tattersall, 1987) (Fig. 3B). NS1 is a 83 kDa nuclear 
phosphoprotein that is required for replication of the viral genome after 
Figure 3. Autonomous parvoviruses. (A) 
Surface rendered model of the canine 
parvovirus capsid. Structural elements are 
indicated; one asymmetric unit of the 
capsid is shown (red triangle). From 
Hueffer and Parrish (2003) Parvovirus host 
range, cell tropism and evolution. (B) MVM 
and H-1PV genomes; some restriction sites 
and the internal replication sequence  (grey 
box) are indicated. Adapted from 
Brandenburger and Velu (2004) 
Autonomous parvovirus vectors: preventing 
the generation of wild-type or replication-
competent virus. 
B.
A.
H-1PV (5176 bp)
MVM (5149 bp)
 
phosphoprotein that is required for replication of the viral genome after 
incoming single-stranded DNA has been converted into a duplex form. NS1 is 
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a multifunctional protein that exerts helicase, DNA nicking, ATPase, sequence 
specific DNA binding, and endonuclease activities. In addition, NS1 is a 
transcriptional factor trans-activating the P38 promoter (Rhode, 1985), and 
is considered the major mediator of parvovirus-induced cytotoxicity (Caillet-
Fauquet et al., 1990; Li and Rhode, 1990). Importantly, NS1 phosphorylation 
has been demonstrated to be mediated by members of the protein kinases C 
family (PKC) and to control both the replicative and cytotoxic functions of 
this viral protein (Corbau et al., 2000; Lachmann et al., 2003; Nüesch et al., 
1998). NS2 function has been studied mainly in mouse cells infected with 
MVM, where it has been observed to be involved in the synthesis of viral DNA 
replicative form, in progeny production, in VP1 and VP2 proteins assembly 
(Cotmore et al., 1997). NS2 seems to be non-essential in cells from other 
species and therefore influence parvoviral life-cycle in a host-specific manner 
(Naeger et al., 1990). 
 
1.6.2. Parvovirus life cycle 
 
Autonomous parvovirus infection occurs upon recognition of a target 
cell surface rerceptor. The human parvovirus B19 virus replicates only in 
human erythroid progenitor cells after binding to the erythrocyte P antigen 
(globoside) cellular receptor (Brown et al., 1993). Both canine parvovirus 
(CPV) and feline panleukopenia virus (FPV) bind to N-glycolyl neuraminic 
acid-containing glycoproteins expressed by most of their host cells in a 
temperature and pH dependent manner (Barbis et al., 1992; Tresnan et al., 
1995). However, cell infection by CPV and FPV is dependent on the 
interaction with the transferrin receptor and following clathrin-mediated 
formation of endocytic vesicles (Suikkanen et al., 2002). Parvoviruses H-1 
and MVM bind to ubiquitous N-acetylneuraminic acid (sialyl)-containing 
glycoproteins located at the cell surface. Viral genome is likely to be 
transported via late endosomes to perinuclear vesicular compartments, and 
released from capsids into the nucleus by the VP1-specific PLA2 activity 
(Zadori et al., 2001). The initiation of parvovirus genome replication is       
S-phase dependent, as it requires the activity of the host cyclinA/CDK2 
kinase complex to convert input single-stranded DNA into a duplex 
replication form (Bashir et al., 2000). Duplex parvoviral DNA serves as a 
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template for P4 promoter-driven synthesis of NS proteins mRNAs. A 
continuous elongation mechanism, promoted by NS1 and other host factors, 
results in the formation of multimeric double stranded intermediates that do 
not integrate in the host genome (Rommelaere and Cornelis, 2001). NS1 is 
covalently attached to the 5’-end of viral DNA and operates the production of 
a single stranded full length DNA progeny, in synchronization with the 
encapsidation process (Berns, 1996). Despite packaging signals have not 
been described for autonomous parvoviruses, CPV viral genome is bound to 
the interior of the capsid by 11 nucleotide oligomers (Chapman and 
Rossmann, 1995) that could be involved in the correct packaging of viral 
progeny (Tsao et al., 1991). Parvovirus replication in permissive cells leads 
to the release of progeny virions and is usually associated with cell death 
(Rommelaere and Cornelis, 2001). 
 
1.6.3. Parvovirus oncotropism 
 
Parvoviruses, in particular H-1PV and MVM, preferentially infect 
highly proliferating and generally poorly differentiated cells (Cotmore and 
Tattersall, 1987). Anyway, transformed cells are more sensitive to virus-
induced cell killing because they set up an environment favourable to 
parvovirus multiplication. Indeed, the proportion of cells enabling NS1 
nuclear accumulation is considerably lower in non-transformed cultures than 
in their transformed derivatives (Dinsart et al., 1996). However, in normal 
cells parvovirus uptake is not enhanced by the transformation process, 
indicating that transformed cells are more sensitive to viral infection because 
they are capable to better sustain a productive parvovirus cycle by 
influencing in particular DNA amplification, gene expression and cell killing 
(Rommelaere and Cornelis, 2001). As matter of fact, ras oncogene 
transformation mediates a strong induction of the P4 promoter via binding of 
transcription factors of the ATF/CREB, Ets, and Sp1 families (Fuks et al., 
1996; Perros et al., 1995), while Simian vacuolating virus 40 (SV40) large T 
antigen activates P4 through the modulation of a distinct subunit of the 
transcription factors nuclear factor Y (NF-Y) (Gu et al., 1999). Moreover, P4 
promoter activity is dependent on cellular transcription factors of the E2F 
and ATF family that normally control the G1/S cell cycle transition (Deleu et 
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al., 1998). Hence, oncogenic transformation is accompanied by cell cycle and 
differentiation deregulations (Hanahan and Weinberg, 2000) that stimulate 
the generation and expression of viral transcription templates and explain 
autonomous parvoviruses privileged tropism for cell of tumoral origin. 
Parvovirus oncotoxicity has been well documented in tumor-derived and in 
vitro-transformed human and rodent cell lines, but also in short-term 
cultures of human breast and liver carcinoma cells and malignant gliomas. 
Remarkably, parvoviruses selective oncolytic effect has not been described in 
the corresponding normal non-transformed counterparts (Cornelis et al., 
1988; Faisst et al., 1989; Herrero y Calle et al., 2004; Lin et al., 1989; 
Salomè et al., 1990; Van Pachterbere et al., 1993). 
 
1.6.4. Recombinant parvoviruses for gene therapy 
 
Genetic engineering of parvoviruses has been tested with the aim of 
retaining the oncolytic and oncotropic properties while improving the 
infection efficacy for applications in cancer prevention or established tumors 
eradication. Recombinant vectors have been derived from the autonomous 
parvoviruses H-1, LuIII and MVM, but LuIII-derived vectors are less efficient 
since do not express NS proteins and therefore do not amplify (Maxwell et 
al., 2002). Parvoviral genome dimensions limit the insertion of therapeutic or 
reporter genes to a capacity of 800 bases without consequences, or up to 
1600 bases but affecting vector production by markedly reducing viral titer 
(Kestler et al., 1999). All currently proposed recombinant vectors (NS+VP-) 
maintain the NS transcriptional unit in order to exert all the oncolytic and 
oncotropic features of parvoviruses. The capsid proteins encoding region is 
removed or truncated and replaced with target transgenes under the control 
of the P38 promoter, so that their expression is restrained to cells that also 
express NS1; VP proteins are produced either from a helper plasmid or in 
packaging cells (Brandenburger and Velu, 2004). The major problem 
encountered with these vectors is the generation of wild-type or replication-
competent virus (RCV) through recombination with helper plasmids 
(Brandenburger et al., 1999). To decrease homology, sequence modifications 
in the vector upstream as well as downstream of the transgene have been 
studied. Alternative approaches have been also taken into consideration, 
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since autonomous parvoviruses limited genome and the presence of 
overlapping coding regions render it difficulty to remove all homology. 
Recombination phenomena have been partially limited by the combined use 
of vectors carrying minimal sequences required for their replication and 
helper plasmids with degenerated codons (Dupont et al., 2001). Besides, the 
construction of chimeric H-1PV/MVM vectors (Palmer and Tattersall, 2000), 
the use of two separate helpers for VP1 and VP2 expression (Brown et al., 
2002), and vector pseudotyping has been investigated (Wrzesinski et al., 
2003). 
Suicide genes encoding for toxins like HSV-1 thymidine kinase (TK) 
and chicken anemia virus Apoptin are within the size limits required for 
proper capsid packaging, and have been tested in vitro to evaluate their 
potential in increasing parvovirus lytic action (Dupont et al., 2000; 
Olijslagers et al., 2001). In addition, H-1PV or MVM vectors have been 
designed to express immune modulators in order to expose cells that are not 
directly hit by the vector to the cytotoxic response elicited by neighbouring 
cells. In example, parvoviral vectors harbouring interleukin-2 (IL-2) gene 
have been used to inhibit tumor formation in both nude and immuno-
competent mice, upon implantation of human or mouse carcinoma cells. 
When vectors are inoculated to tumor cells prior to implantation (ex vivo), 
IL-2 is secreted within the tumor and induces natural killer (NK) cells 
recruitment and activation, while tumor-free mice develop anti-tumor 
immunity and are protected against a second challenge with tumor cells     
(El Bakkouri et al., 2000; Haag et al., 2000). A similar tumorsuppressive 
effect is observed when mouse melanoma cells are grafted in nude mice 
after infection with an H-1PV-based vector expressing the human monocyte 
chemotactic protein 3 (MCP-3), which triggers macrophages and NK cells 
activation (Wetzel et al., 2000). Furthermore, the mouse anti-angiogenic 
chemokine IP-10 (interferon γ – inducible protein 10), has been introduced in 
a MVM-backbone and the anti-metastatic potential of this parvoviral vector 
has been evaluated in a mouse hemangiosarcoma model. While wild-type 
MVM inhibits the formation of metastases only when tumor cells are infected 
ex vivo, recombinant MVM transducing IP-10 has a protective effect even 
when intratumorally administered in vivo to mice bearing neoplastic lesions 
(Giese et al., 2002). 
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1.6.5. Basis for the use of parvovirus H-1 in glioma therapy 
 
Given the properties of autonomous parvoviruses outlined so far, 
wild-type parvovirus H-1 has been scrutinized for its possible use in oncolytic 
brain tumour therapy. Cell permissiveness to H-1PV infection has been 
analysed in established glioblastoma cell lines of human and rat origin as 
well as in short-term and low-passage cultures of human brain tumours. In 
the malignant glial cells tested, parvovirus H-1 induces an efficient and dose-
dependent killing even at low multiplicities of infection. Moreover, progeny 
virions are released from these infected cells, indicating that H-1PV might 
spread its oncolytic effect through successive rounds of infection (Herrero y 
Calle et al., 2004). Parvovirus H-1 infections have been further analyzed in 
extracts from normal tissue to confirm the specificity of viral cytopathic 
effect for neoplastic cells. Supporting the rationale that the normal adult 
brain is not a mitotically active organ and therefore not prone to parvovirus 
cytotoxicity, human brain cells isolated from epileptic patients are not 
permissive to H-1PV, and intracerebral injections of the virus do not cause 
damage in the brain of immunocompetent adult rats (Geletneky et al., 
2005). Finally, no pathologic side effects have been reported in early times 
clinical trials with parvovirus H-1 in patients with advanced disseminated 
cancer (LeCesne et al., 1993; Toolan et al., 1965).  
 
 
1.7. Programmed cell death 
 
Tumor cells differently react to autonomous parvoviruses infections; 
according to cell type and to limiting environmental conditions, different 
death pathways can be triggered by these viruses. Besides, several 
programmed cell death mechanisms can be activated by glioma cells in 
response to diverse stimuli, such as chemotherapy toxic action or ionizing 
radiation-induced damage. 
Programmed cell death (PCD) is a term used to define a genetically 
controlled death program, executed by active cellular processes that can be 
intercepted by interfering with intracellular signalling. PCD is by definition 
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opposed to passive or accidental cell death that is necrosis induced by 
pathological stimuli. Initially referred to phenomena occurring during 
development or aging, the expression ´programmed cell death´ was for a 
long time considered as synonym of apoptosis (Danial and Korsmeyer, 
2004). Indeed, a first cell death classification based on ultrastructural data 
suggesting the existence of alternative types of PCD was almost ignored by 
the scientific community (Schweichel and Merker, 1973), and only 20 years 
later it became evident that the classic distinction between apoptosis and 
necrosis was an oversimplification of the processes promoting cell death 
(Clarke, 1990). More recently, the editors of Cell Death and Differentiation 
have established the Nomenclature Committee on Cell Death (NCCD) and 
proposed unified criteria for the definition of different types and 
morphologies of cell death (Kroemer et al., 2005). 
Type I cell death refers to apoptosis, which is characterized by cell 
shrinkage, chromatin condensation, nucleosomal DNA degradation, little or 
no ultrastructural modification of cytoplasmic organelles, plasma membrane 
blebbing, and cell disintegration into small fragments called apoptotic bodies 
(Kerr et al., 1972). The appearance of these morphological features is often 
accelerated by or even dependent on the activation, at biochemical level, of 
the caspase family of cysteine proteases. At the end of the apoptotic 
process, apoptotic cellular debris are phagocyted by neighboring cells. 
Anoikis is historically defined as death in response to loss of attachment to 
the matrix or to neighbouring cells, but this process is at a molecular level 
undistinguishable from apoptosis (Kroemer et al., 2005). 
Type II cell death corresponds to autophagy, which is distinguished by 
the absence of chromatin condensation or caspases activation, and the 
appearance of double or multimembrane vesicles engulfing bulk cytoplasm 
and organelles that are eventually degraded after the fusion of autophagic 
vesicles with lysosomes (Levine and Klionsky, 2004). Autophagy main task is 
to recycle long-lived proteins and organelle components, and cells that 
undergo excessive autophagy are triggered to die in a non-apoptotic manner 
(Gozuacik and Kimchi, 2004). At this regard, the NCCD pinpoints that 
autophagic cell death may be a misleading term as it may imply that cell 
death is occurring through autophagy, while it simply describes cell death 
with autophagy (Kroemer et al., 2005). As counterproof, in vivo knockdown 
 26
Introduction 
or knockout of genes required for autophagy does not reduce cell death 
(Boya et al., 2005). 
Type III cell death is defined as non-lysosomal vesiculate degradation 
or paraptosis. This death process is dependent on the activation of RTKs or a 
member of the tumor necrosis factor (TNF) receptor family, which trigger 
MAPKs-mediated swelling of mitochondria and the endoplasmic reticulum, 
and final cytoplasmic diffuse vacuolization. In addition, paraptosis occurs 
independently of caspases and seems to be initiated in response to variations 
in intracellular calcium concentrations (Fombonne et al., 2006; Sperandio et 
al., 2000; Sperandio et al., 2004; Wang et al., 2004b). 
Mitotic catastrophe is triggered by mitotic failure caused by defective 
cell cycle checkpoints or mitosis dysregulation in proliferating aneuploid cells. 
Mitotic catastrophe results in the formation of micronuclei, which often are 
misallocated chromosomes or chromosome fragments, or multinuclei due to 
deficient separation during cytokinesis (King and Cidlowski, 1995). This 
death pathway has been observed to be promoted upon DNA damage or 
treatment with microtubule stabilizing or destabilizing agents, and occurs 
either independently or partially dependently on p53 activation (Roninson et 
al., 2001). Whether mitotic catastrophe is fundamentally different from 
apoptosis or not, it is still a matter of debate. Indeed, this process has been 
reported to be associated with mitochondrial membrane permeabilization and 
caspase activation, but caspase inhibition or Bcl-2 overexpression fails to 
prevent its initiation (Castedo et al., 2004; Lock and Stribinskiene, 1996). 
Three very specific forms of programmed cell death are excitotoxicity, 
Wallerian degeneration and cornification. Excitotoxicity is a form of death 
occurring in neurons as consequence of increase of cytosolic calcium in 
response to excitatory aminoacids-mediated opening of the N-methy-D-
aspartate (NMDA) channel. Wallerian degeneration is a poorly characterized 
death process where part of a neuron or axon degenerates without affecting 
the main cell body (Orrenius et al., 2003). Cornification or keratinisation is 
different from apoptosis, and results in the formation of the cornified 
envelope of the epidermis (Candi et al., 2005). In addition, attempts have 
been made to catalogue PCD according to different criteria, such as ordering 
caspase-independent cell death according to the cellular organelles involved 
(Ferri and Kroemer, 2001), or defining four subclasses of PCD (apoptosis, 
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apoptosis-like PCD, necrosis-like PCD and necrosis) in relation to nuclear 
morphology and chromatin condensation extent (Leist and Jäättelä, 2001). 
 
1.7.1. The apoptotic machinery 
 
Apoptosis is an energy-dependent type of cell death (Leist et al., 
1997) that plays an active role in cell turnover during adult life, embryonic 
development and normal functioning of the immune system (Thompson, 
1995). On the opposite, disruption of the apoptotic pathway is involved in 
the pathophysiology of different disorders like cancer, autoimmunity and 
neurodegenerative diseases (Meier et al., 2000). At the biochemical level, 
apoptosis of mammalian cells is triggered by variety of biological, chemical 
or physical stimuli, through different pathways that finally converge on 
massive caspase activation (Adams, 2003; Green and Kroemer, 1998). At 
present, 15 different mammalian caspases have been described and 
classified into initiator (caspase 1, 2, 4, 8, 9, 10 and 12) and effector 
(caspase 3, 6, 7, 11 and 13) caspases according to function and size of the 
N-terminal pro-domain. Caspases are synthesized as inactive zymogens and 
become active enzymes after proteolytic removal of the pro-domain and 
oligomerization into tetramer complexes. Initiator caspases possess a long 
N-terminal pro-domain responsible for interaction with adaptor proteins that 
regulate their activation. On the other hand, effector caspases are activated 
by other proteases, usually upstream active caspases, since their short pro-
domain does not interact with adaptor proteins (Ho and Hawkins, 2005). Two 
principal pathways control apoptosis, the intrinsic or mitochondria-mediated 
pathway that is triggered in response to intracellular insults, and the 
extrinsic pathway, responding to extracellular stimuli and initiated by the 
engagement of death receptors (Fig. 4). In addition, other intracellular 
organelles have been demonstrated to promote apoptosis via the activation 
of either the extrinsic and/or intrinsic signalling pathways (Guicciardi et al., 
2004; Orrenius et al., 2003). In example, upon severe or prolonged stress in 
the endoplasmic reticulum (ER), the unfolded protein response (UPR) causes 
Ca2+ release from the ER lumen, which activates calpain in the cytosol and 
triggers apoptosis via either direct Ca2+-mediated collapse of the inner 
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membrane potential, or sequential cleavage of caspase 12, 9 and 3 
(Schroder, 2006). 
The extrinsic pathway is a plasma membrane receptor-mediated 
mechanism that results in the activation of caspase 8 and/or 10. Is triggered 
by self-association of cell surface receptors belonging to the TNF superfamily, 
Cellular
Stress
Cellular
Stress
APOPTOSIS
Genotoxic
Stress
Death Receptors
Figure 4. Integration of the apoptotic pathways. Adapted from Kutuk and Basaga
(2006) Bcl-2 protein family: implications in vascular apoptosis and atherosclerosis. 
For abbreviations refer to text.
among which the best known in apoptosis are CD95 (designed also Apo-1 or 
Fas), TNF-α receptor 1 (TNFR1), and TRAIL (TNF-related apoptosis inducing 
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ligand) receptors DR4 and DR5. The extrinsic pathway is initiated in response 
to different stimuli like microbial and viral infections or oncogenic 
transformation. Upon binding of the respective ligand (i.e. Fas-L, TNF, 
TRAIL/Apo-2), the receptor undergoes oligomerization and recruits 
intracellular adaptor proteins, such as FADD and TRADD (Fas- and TNFR-
associated death domain, respectively). TNF receptor ligation is rarely 
enough on its own to initiate apoptosis as is the case with Fas-L and TRAIL, 
whose binding triggers rapid apoptosis in many cells. Adaptor proteins are 
associated with the receptor through an interaction between homologous 
death domains (DD) and recruit the initiator caspases 8 and 10 via a death 
effector domain (DED). The complex of receptor, adaptor proteins and pro-
caspases is known as death-inducing signalling complex (DISC) and is 
required for the efficient autoproteolytic activation of caspase 8 and 10 
(Chen and Wang, 2002). Along the TNFR1-mediated apoptotic pathway, 
TRADD also associates with FADD, which on the contrary has been shown to 
be not essential for TRAIL-promoted apoptosis, where no adaptor molecule 
has been identified yet. Cells that constitutively express TRAIL have 
developed an apoptosis protection mechanisms based on decoy receptors 
(DcR1 and DcR2) that compete with the DR4 and DR5 receptors. These 
receptors bind TRAIL, but do not initiate apoptosis since DcR1 lacks a 
cytoplasmic domain, while DcR2 has a truncated inactive death domain 
(Chaudhari et al., 2006). Signalling downstream of caspase 8/10 is cell type-
dependent: initiator caspases directly activate the effector caspases 3 and 7 
in type I cells, while converge on the intrinsic signalling pathway in type II 
cells through the cleavage of Bid, a member of the Bcl-2 family proteins 
(Scaffidi et al., 1998; Sprick and Walczak, 2004). 
The intrinsic pathway is functioning in response to various types of 
intracellular stimuli, like stress-inducing agents, DNA damage, and growth 
factor withdrawal (Adams, 2003). This apoptotic pathway is controlled by the 
balance between pro- and anti-apoptotic members of the Bcl-2 family. 
Majority of these proteins operate on the level of mitochondria, participating 
in the stabilization or destabilization of these organelles, but fulfill other 
functions in the ER and nucleus. Bcl-2 family members contain one or more 
conserved homology domains (BH1 to BH4) and a C-terminus 
transmembrane domain that anchors them to membranes. Pro-apoptotic Bcl-
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2 family proteins are divided into a first subgroup having two or three BH 
regions and sharing extensive structural similarity (i.e. Bax, Bcl-Xs, Bak), 
and a second subgroup containing only the short BH3 domain (i.e. Bid, Bad, 
Noxa, Puma) (Antonsson and Martinou, 2000). Following the identification of 
stress signals, pro-apoptotic Bcl-2 family proteins are translocated from the 
cytosol to the mitochondrial outer membrane to form pore-like structures 
that promote the release of apoptogenic factors, like cytochrome c, AIF 
(apoptosis inducing factor), Smac/DIABLO (second mitochondria-derived 
activator of caspases), endonuclease G and Omi/HtrA2 (Cory et al., 2003). 
Anti-apoptotic members of the Bcl-2 family (i.e. Bcl-2 and Bcl-xL) exhibit all 
four homology domains, with the BH1, BH2 and BH3 domains forming a 
hydrophobic pocket that is further stabilized by BH4 domain (Huang et al., 
2002). Structural analyses suggest that the anti-apoptotic Bcl-2 members 
act as functional traps by blocking the BH3 domain of pro-apoptotic 
members in the hydrophobic groove formed by their BH1-3 domains (Sattler 
et al., 1997). Through the formation of dimers, oligomers or high-order 
multimers, pro-apoptotic members of the Bcl-2 family undergo 
conformational changes that prevent this inhibitory mechanism (Griffiths et 
al., 1999; Ruffolo and Shore, 2003). Once released in the cytosol, 
cytochrome c forms the apoptosome complex by associating with the 
adaptor protein Apaf-1 (apoptotic protease-activating factor-1) and pro-
caspase 9, which upon cleavage directly activates the effector caspases 3 
and 7 (Wang, 2001).  
Effector caspases participate in the cell disassembly by both cleaving 
and inactivating inhibitors of apoptosis, dismantling cellular structures or 
regulating the activity of other proteins resulting in chromatin condensation, 
DNA fragmentation, and all the other morphological and functional changes 
associated with apoptosis (Degterev et al., 2003). Inhibitors of apoptosis 
proteins (IAPs) are a family of regulatory proteins controlling caspase 
processing and activation. All IAPs present baculoviral repeats domains 
(BIRs) that selectively mediate the binding to distinct caspases, while some 
members contain an additional zinc-binding motif (RING domain) that 
catalyze caspase ubiquitination for proteasome degradation (Vaux and Silke, 
2005). IAPs basal expression is ubiquitous while the high expression level of 
different family members is tissue specific. The effect of IAPs is antagonized 
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by Smac/DIABLO and Omi/HtrA2 after mitochondrial release (Saelens et al., 
2004). 
 
1.7.2. Macroautophagy 
 
Two major degradative pathways subsist in higher eukaryotic cells 
(Ciechanover and Schwartz, 1994): the proteasome is involved in the 
degradation of short-lived proteins (Wang and Maldonado, 2006), whereas 
the lysosomal system is responsible for the degradation of long-lived 
proteins and the turnover of organelles by several mechanisms collectively 
known as autophagy (Holzman, 1989). Beside the general default 
mechanism that delivers cell surface macromolecules to the lysosomes 
through endocytic vesicles, at least three other routes have been described 
for the lysosomal degradation. In the chaperone-mediated transport, 
cytosolic proteins are selectively imported into the lysosomal lumen upon the 
recognition of a KFERQ sequence motif by the lysosomal associated 
membrane protein Lamp2a and in presence of the heat-shock protein Hsc73. 
In microautophagy, cytoplasmic macromolecules and organelles such as 
peroxisomes are taken up by invaginations of the lysosomal membrane in a 
GTP-dependent process. Macroautophagy is the major non-selective 
vacuolar-mediated transport responsible for the turnover of mitochondria 
and other organelles, as well as the delivery of cytoplasmic material to 
lysosomes during periods of starvation. Macroautophagy, usually referred to 
simply as autophagy, is also involved in several pathophysiological processes 
such as cancer, cardiomyopathies and neurodegenerative diseases (Cuervo, 
2004). 
The molecular mechanism controlling the onset of autophagy has 
been initially discovered in yeast with the cloning of different genes that 
have been unified in the nomenclature as Atg (autophagy-related) genes 
(Klionsky et al., 2003). Mammalian orthologues of some of the Atg genes 
have been identified, and their function has been demonstrated to be 
preserved from yeast to mammals (Mizushima et al., 2003). The initiating 
event of macroautophagy is the formation of a membrane boundary called 
autophagosome that enwraps cytoplasmic constituents and organelles. The 
origin of the autophagosomal membrane is still unclear, as it has been 
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proposed to form from the endoplasmic reticulum, the Golgi, a not 
characterized membrane compartment called phagophore, or de novo 
through nucleation, assembly and elongation of small membrane structures 
(Noda et al., 2002). A multiprotein complex comprising class III PI3K, 
Beclin1, a p150 myristylated protein kinase, and UV irradiation resistance-
associated gene product (UVRAG) is involved in the formation of the 
autophagosome (Kihara et al., 2001; Liang et al., 2006; Petiot et al., 2000). 
In a second moment, the cytosolic protein MAP1LC3 (microtubule-associated 
protein 1 light chain 3), shortly LC3, undergoes ubiquitin-like post-
translational modifications and subsequent phosphatidylethanolamine 
conjugation that allow its tight association with the autophagosomal 
membrane (Kabeya et al., 2004). In the end, autophagosomes fuse with the 
outer membranes of endosomes or lysosomes to form autolysosomes where 
lysosomal hydrolases degrade the autophagosomal cytoplasm-derived 
content and inner membrane (Kondo et al., 2005) (Fig. 5).  
Autophagic response to amino acid starvation is regulated by the 
Ras/Raf-1/ERK1/2 signaling pathway. Raf-1 undergoes an amino acid-
dependent inhibitory phosphorylation, while in absence of amino acids 
ERK1/2 (extracellular signal-regulated kinases) get phosphorylated and 
trigger the activation of heterotrimeric G proteins localized to Golgi/ER 
membranes that promote the initiation of autophagy (Houri et al., 1993; 
Ogier-Denis et al., 2000; Pattingre et al., 2003). This signaling pathway can 
also be differently modulated by growth factors through the RTKs-mediated 
activation of both the ERK1/2 and Akt signalling cascades. Despite ERK1/2 
activation, under these circumstances autophagy is blocked since Akt on one 
side inactivates Raf-1 (Pattingre et al., 2003) while on the other side triggers 
mTOR (mammalian target of rapamycin) that inhibits autophagy via the 
phosphorylation of downstream proteins such as p70S6 kinase (p70S6K) and 
its target the ribosomal protein S6 (Blommaart et al., 1997). Since 
autophagy depends on both continuous protein synthesis and continuous 
presence of ATP, it is not surprising that mTOR, being an integrator of 
growth factor induced signals and a sensor for amino acids and ATP, acts as 
gatekeeper for initiation of the autophagic pathway (Kim and Klionsky, 
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Figure 5. Signalling pathways involved in the regulation of macroautophagy. Adapted from 
Kondo et al. (2005) The role of autophagy in cancer development and response to therapy. 
MEK; mitogen-activated protein kinase kinase. For other abbreviations refer to text.
2000b). Moreover, PTEN, which is a negative regulator of Akt, has been 
shown to stimulate autophagy (Arico et al., 2001) (Fig. 5). 
The regulation of autophagy in response to nutrient starvation and 
viral infection is dependent on the phosphorylation of the eukaryotic 
initiation factor 2α (eIF2α) on serine 51. This process is mediated by the 
eIF2α family of protein kinases and represents a central mechanism that 
induces a global arrest in translation under stress conditions. The 
mammalian family consists of four eIF2α kinases, among which the double-
stranded RNA-dependent protein kinase (PKR) has been observed to be 
essential for autophagy induction in response to HSV-1 infection (Talloczy et 
al., 2002) (Fig. 5). Interestingly, mRNAs translation is not completely shut 
down when autophagy is induced, but continues in a selective manner 
(Fernandez et al., 2002). 
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Death Associated Protein kinase (DAPk) and its highly homologous 
DAPk related protein (DRP-1) are two Ca2+/calmodulin-regulated 
serine/threonine kinases associated with the actin cytoskeleton (Kogel et al., 
2001). DAPk is a positive mediator of cell death in response to various 
stimuli such as inferferon γ, activation of Fas receptors, TNF-α/β (Cohen and 
Kimchi, 2001; Jang et al., 2002). DAPk and DRP-1 are two novel regulators 
of autophagy, and DRP-1 in particular has been found to localize in the 
lumen of the autophagic vesicles, raising the possibility that this kinase may 
have a direct role in autophagic vesicle formation (Inbal et al., 2002)      
(Fig. 5). 
Finally, autophagic type II cell death is promoted by BNIP3, a 
hypoxia-inducible BH3-like domain-containing protein that integrates into the 
mitochondrial outer membrane and induces the opening of the permeability 
transition pore without consequent cytochrome c release (Vande Velde et al., 
2002). A similar effect is promoted by the human orthologue of Drosophila 
Spin (HSpin1), a transmembrane protein that is necessary for programmed 
cell death in Drosophila reproductive and nervous systems (Yanagisawa et 
al., 2003). More complex is the role of Bcl-2 in autophagy regulation (Fig. 5), 
since this anti-apoptotic molecule blocks Beclin1 by direct binding (Pattingre 
et al., 2005), triggers autophagy when overexpressed in human leukaemic 
cells (Saeki et al., 2000), but enhances etoposide-induced autophagy when 
overexpressed in mouse embryonic fibroblasts (Shimizu et al., 2004). 
Past and present evidences demonstrate that autophagy is an 
adaptive response with a double potential, promoting programmed cell death 
or maintaining continual cell survival under stress conditions. The liver, for 
example, constitutes an extreme case in which amino acid deprivation-
induced autophagy provides essential elements for biosynthetic pathways in 
the entire organism. Besides, hepatocytes rapidly remove depolarized 
mitochondria by autophagy, suggesting that this process may be a shielding 
mechanism that prevents apoptosis by increasing the threshold of 
mitochondria-dependent cell death (Elmore et al., 2001; Lemasters et al., 
1998). On the contrary, autophagy plays a role in higher organism 
development, being involved in the death of central cells during intestine 
cavity formation, of Mullerian duct palatal epithelial cells during male sexual 
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development, and in hormone deprivation-induced regression of mammary 
glands or atrophy of prostate (Bursch, 2001). 
In several cellular contexts, apoptosis and autophagy may be 
interconnected and even simultaneously regulated by the same trigger. In 
neural growth factor-deprived primary sympathetic neurons, the execution of 
apoptosis is preceded by and dependent on the onset of autophagy, which 
can even induce a caspase-independent cell death if apoptosis is blocked 
(Xue et al., 1999). In HT-29 colon carcinoma cells, autophagy antagonizes 
sulindac sulfide-induced apoptosis, and the inhibition of autophagy along the 
ERK1/2 pathway increases the sensitivity of these cells to apoptotic signals 
by allowing a faster cytochrome c release (Bauvy et al., 2001). Finally, 
apoptosis and autophagy may occur in mutually exclusive manner; several 
malignant glioma cell lines exert autophagic cell death in response to arsenic 
trioxide but die from apoptosis when pre-treated with the autophagy 
inhibitor bafilomycin A1 (Kanzawa et al., 2003). In this perspective, the role 
of several proteins capable of inducing both apoptosis and autophagy, like 
DAPk and anti-apoptotic Bcl-2 family members, is currently under 
investigation to identify the molecular regulators controlling the switch 
between these two type of programmed cell death (Kondo et al., 2005). 
Bimodal is the role of autophagy in cancer development and 
maintenance. Cell growth is influenced by a balance between the rates of 
protein synthesis and autophagic degradation of long-lived proteins, the 
latter being considerably higher in stationary/quiescent than in proliferating 
cells (Lee et al., 1992). Indeed, in several cell lines tested in vitro and during 
animal experimental carcinogenesis, autophagic capacity and lysosomal 
enzymes activities have been observed to be often lower in transformed cells 
than in their normal counterparts (Canuto et al., 1993; Gronostajski and 
Pardee, 1984; Kisen et al., 1993; Yucel et al., 1989). Nonetheless, in rat 
pancreatic carcinogenesis cells show an increased autophagic capacity during 
premalignant stages and a decreased autophagic activity during 
malignant/terminal stages, suggesting that autophagy is necessary and/or 
compatible with malignant transformation but must be downregulated for 
cancer preservation (Toth et al., 2002). Along this line, autophagic cell death 
can be activated in cancer cells in response to various agents used in cancer 
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therapy, such as for instance radiation treatments in breast, glioma, prostate 
and colon cancer cell lines (Paglin et al., 2001). 
 
 
1.7.3. Cathepsins and the lysosomal pathway 
 
Lysosomes control cell death mainly at two levels. In the 
autolysosome, hydrolases participate in organelle and macromolecules 
turnover under physiological conditions and are thus actively involved in 
autophagic cell death. In response to endogenous or exogenous stress, 
lysosomal membrane permeabilization (LMP) leads to the release of catabolic 
hydrolases that mediate different types of cell death. In this case, lysosomal 
leakage can be a downstream event involved in the clean-up phase of 
apoptosis or in cellular autolysis during uncontrolled necrosis, but it can also 
initiate programmed cell death (Guicciardi et al., 2004; Shintani and 
Klionsky, 2004). Studies using detergents, lysosomotropic antibiotics and 
oxidative stress agents have demonstrated that LMP can trigger classical 
apoptosis as well as caspase-independent apoptosis and necrosis according 
to the amount of lysosomal rupture: a limited release of lysosomal contents 
to the cytoplasm induces apoptosis or apoptosis-like cell death, whereas a 
generalized lysosomal rupture results in rapid cellular necrosis (Brunk et al., 
1997; Kagedal et al., 2001) (Fig. 6). 
Among lysosomal hydrolases, cathepsin proteases have a central 
role in lysosomal control of cell death due to the fact that they have optimal 
enzymatic activity at the acidic pH of lysosomes (pH 4–5), but many of them 
can also function at neutral pH outside of the lysosomes, though with a 
decreased stability and/or altered specificity (Turk et al., 2001). Depending 
on their active-site functional amino acid, these proteins are generally 
divided into cysteine (B, C, H, F, K, L, O, S, V, W and X/Z), aspartate (D and 
E) and serine (G) cathepsins. The 11 human cysteine cathepsins are 
predominantly 40 kDa endopeptidases belonging to the papain subfamily of 
cysteine proteases. Some cathepsins are expressed constitutively and are 
thought to participate in protein turnover, in example cathepsin B and L 
(Rawlings et al., 2006). The expression of other cysteine cathepsins is 
regulated and cell type specific, for instance cathepsin K in osteoclasts 
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Figure 6. Lysosomes in cell death.
cystatins
(Saftig et al., 1998) and cathepsin S in immune cells (Shi et al., 1999). 
Despite cathepsins function primarily intracellularly within endolysosomal 
compartments, some of them are also secreted extracellularly: cathepsin K is 
involved in bone remodelling (Delaisse et al., 2000; Xia et al., 1999) while 
cathepsins B and L digest the extracellular matrix in physiological processes 
like wound healing as in pathological conditions such as cancer invasion 
(Buth et al., 2004; Mohamed and Sloane, 2006). Cathepsins are 
physiologically regulated by cystatins, a large group of evolutionary related 
competitive, reversible, tight-binding protease inhibitors (Rawlings et al., 
2006; Turk et al., 2002). Cystatins do not directly interact with the enzyme 
catalytic centre but bind adjacent to the protease active site, thus 
obstructing the access to the substrate (Bode and Huber, 2000). On the 
basis of sequence homology, the cystatin superfamily is divided into three 
groups that display considerable differences in amino acid sequence but 
present a conserved functional tertiary structure (Bode et al., 1988; Stubbs 
et al., 1990). Type 1 cystatins (or stefins, A and B) are 98 amino acid 
residues polypeptides which possess neither disulfide bonds nor 
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carbohydrate side chains and are located mainly intracellularly. Type 2 
cystatins (C, D, E/M, F, S, SN, and SA) are 120 amino acid residues 
polypeptides characterized by two conserved disulfide bridges and the 
presence of a signal peptide for extracellular targeting. Type 3 cystatins 
(kininogens) are 60–120 kDa multifunctional plasma proteins containing 
three type 2 cystatin-like domains (Rawlings et al., 2004).  
Whether LMP results in the selective release of certain cathepsins or 
whether all proteins are released simultaneously from the lysosomal lumen is 
still unknown, even if a selective release based on molecular size has been 
observed (Bidere et al., 2003). LMP might in part be triggered by oxidation 
of membrane lipids, resulting from the Fenton reaction between intra-
lysosomal iron and H2O2 accumulating from oxidative stress (Brunk et al., 
2001). The cytotoxic effects of LMP often rely on the activation of the 
mitochondrial cell death pathway through reactive oxygen species (ROS) and 
lipid mediators such as arachidonic acid, generated in a cathepsin B-
dependent manner (Boya et al., 2003; Kagedal et al., 2001) (Fehrenbacher 
et al., 2004; Guicciardi et al., 2000). A possible links between cathepsins and 
the loss of mitochondrial membrane potential might be represented by Bid, 
which can be processed and activated by several cysteine cathepsins at 
cytosolic pH (Cirman et al., 2004). Remarkably, the lethal effects of LMP and 
cytosolic cathepsins are not limited to the activation of the intrinsic apoptotic 
pathway. LMP and cathepsins also participate in the execution of cell death 
that is induced by classic apoptotic stimuli such as death receptors and p53 
activation (Foghsgaard et al., 2001; Nakayama et al., 2002; Yuan et al., 
2002). Following TNFR1 internalization, caspase 8 activation promotes LMP 
while Bid is cleaved by cathepsin D in the endo-lysosomes (Heinrich et al., 
2004; Schneider-Brachert et al., 2004). In cells treated with TNF in 
combination with inhibitors of transcription or translation, cathepsin B is 
responsible for apoptotic cell death, whereas the inhibition of caspase activity 
sensitizes TNF-treated cells to caspase-independent LMP and necrotic cell 
death (Khwaja and Tatton, 1999). 
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Current experimental data have demonstrated that parvovirus H-1  
(H-1PV) can efficiently kill different low-passage glioma cultures and 
established glioblastoma cell lines of human origin, but exerts no cytopathic 
effect on normal astrocytes. Moreover, the virus has proven to be effective in 
vivo, inducing full regression of implanted rat brain tumours into recipient 
animals. H-1PV seems therefore to be a promising candidate for brain cancer 
treatment. 
 Several gliomas are initially sensitive to standard therapeutic 
protocols but rapidly become resistant, mainly by escaping apoptosis 
execution. To define the application range of parvovirus H-1 in brain cancer 
virotherapy is first of all important to scrutinize the molecular mechanisms 
responsible for virus-mediated cell killing, and secondly to verify whether   
H-1PV is able to neutralize glioma cells attempts to evade induced death. 
Hence, this work has evaluated the death pathways triggered by the virus in 
NCH82 cells, a low-passage culture isolated from a glioma patient. In 
particular, the cleavage of caspase 3 and the role of anti-apoptotic molecules 
like Bcl-2 have been considered to ascertain the activation of classic 
apoptosis. The activity of cathepsins has also been investigated, as these 
lysosomal proteases can be triggers or central effectors of apoptosis as well 
as of alternative non-apoptotic death pathways. Additionally, the onset of 
autophagy upon H-1PV infection has been elucidated since this degradative 
pathway has been shown to be involved in both cell survival and death, in 
response to pathogens and during tumorigenesis. Ultimately, the reciprocal 
role of apoptosis, autophagy and lysosomal cathepsins activation has been 
determined to establish the sequence of events achieving virus-induced cell 
death. The activity of cathepsin B has been analyzed in tissue extracts of    
H-1PV-treated rat brain tumors, to complete the study with an overview on 
the in vivo oncosuppressive properties of the virus. 
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The capacity of glioma cells to acquire resistance towards conventional 
death-inducing agents also correlates with the appearance of multiple 
genetic alterations associated with and accumulating during tumor 
development. In order to evaluate H-1PV as possible therapeutic tool, it is 
crucial to identify the molecular changes that are associated with astrocytes 
malignant transformation and are necessary for the acquisition of 
sensitiveness to H-1PV-induced cell death. In addition, it is important to 
determine if the expression of different mutations correlates with the virus-
mediated activation of different killing mechanisms, to understand whether 
H-1PV could jeopardize cell survival by adapting to the host genetic profile. 
To these purposes, rat embryo fibroblasts (REFs) have been used as a well 
established cellular model for oncogene cooperation in malignant 
transformation, to conduct a preliminary study for unravelling the effects of 
cell immortalization and/or transformation on viral permissiveness. In 
particular, the aim has been to investigate whether cell transformation is 
strictly required or if cell immortalization in sufficient to render REFs 
permissive to H-1PV-induced killing. Furthermore, this simple study model 
has been used to evaluate the nature of the intracellular pathways utilized by 
the virus to achieve cell death, and how key oncogenes could affect the 
accomplishment of parvovirus H-1 life cycle.  
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3.1. Chemicals and reagents 
 
Complete-mini™ protease inhibitor cocktail, FuGENE 6™ and            
X-tremeGENE™ transfection reagents were purchased from Roche, 
Mannheim, Germany. Fetal Calf Serum (FCS) and adult Calf Serum were 
from Biochrom, Berlin, Germany; iodexanol 60% (w/v) water solution 
(OptiPrep™) came from Axis-Shield, Dundee, Scotland. Bacto™Agar was 
purchased by BD Bioscience, Heidelberg, Germany. Gentamicin sulfate 
solution (50 mg/ml), Hanks' balanced salt solution (HBSS), kanamycin 
sulfate solution (10 mg/ml), uncoloured minimum essential medium (MEM) 
containing Hanks' salts and L-glutamine, OptiMEM medium, and trypsin 
0.25% solution were obtained from GIBCO, Karlsruhe, Germany. Caspase 3 
inhibitor (DEVD-CHO, cell permeable), cathepsin B inhibitor (Ca-074 Me) and 
cathepsins inhibitor (E64d) were acquired from Calbiochem, Darmstadt, 
Germany. 3-methyladenine (3-MA), acridine orange dye, Dulbecco's modified 
Eagle medium (DMEM) high glucose (4.5 g/l), Neutral Red solution, 
paraformaldeyde (PFA), polybrene, puromycin dihydrochloride, Triton X-100, 
Trypan blue solution, and all other non mentioned chemicals, salt solutions 
and antibiotics were purchased from Sigma, Schnelldorf, Germany. 
 
 
3.2. Cell cultures 
 
Rat embryo fibroblasts (REFs) were isolated from Fisher rats (Charles 
River Laboratories, Sulzfeld, Germany) at 13-14 days gestation. Animals 
were sacrificed in a CO2 tank and dissected under sterile conditions; uteri 
were identified, cleaned from fat and resected. Embryos were then 
extracted, head and liver depleted, and tissue was minced with a scalpel in 5 
ml PBS 1x (NaCl 137 mM, KCl 2.7 mM, Na2HPO4 8.1 mM, KH2PO4 1.47 mM, 
pH 7.4). Tissue was digested 20 minutes at 37°C by adding 5 ml trypsin 
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0.25% and proteolysis was stopped with 5 ml DMEM. Tissue was afterwards 
disintegrated into single cells by forcing the homogenate throughout a 
narrow mouth pipette. Living cells were counted using a hemocytometer (0.1 
ml cell suspension, 0.9 ml PBS 1x and 1 ml Trypan blue) and plated in 
number of 3x107 per 15 cm (∅) dish. Cell stocks were prepared after 3-4 
days culturing by collecting cells at confluence from a 15 cm (∅) dish in 6 
cryovials (1 ml volume) and freezing them in liquid N2 in DMEM 
supplemented with 10 % (v/v) FCS and 1% (v/v) DMSO [Dimethyl 
Sulfoxide]. 
NCH82 low-passage cell culture was prepared from a glioblastoma 
patient and characterized at the Neurosurgery Department, Heidelberg 
University, as previously described (Herold-Mende et al., 1999). The RG2 rat 
glioma cell line was established almost 40 years ago from an 
ethylnitrosourea-induced glioma in Fischer 344 rats (Wechsler et al., 1969), 
and was reported to provide a reproducible model for experimental neuro-
oncology when inoculated into the brains of syngenic rats (Aas et al., 1995). 
RG2 cells were provided by Dr. K. Geletneky, Neurosurgery Department, 
Heidelberg University. 
Cells were cultured in DMEM supplemented with 10% (v/v) FCS, 
kanamycin (100 µg/ml) and gentamicin (50 µg/ml), maintained at 37°C 
temperature in 5% CO2 atmosphere. 
 
 
3.3. Retrovirus infection and plasmids transfection 
 
Murine leukaemia virus (MLV)-based pBabe-puro retroviral vectors 
were used to overexpress the following genes in NCH82 glioma cells: human 
Bcl-2 complete coding sequence (cds) inserted in the EcoRI site, human 
cystatin B complete cds cloned into BamHI-EcoRI restriction sites, and 
BamHI-EcoRI-inserted human Flip complete cds. The cystatin B expression 
vector, a gift from Dr. E. Spiess, DKFZ, Heidelberg, was tagged by green 
fluorescent protein (GFP – Clontech, St-Germain-en-Laye, France). For 
safety reasons, these replication-deficient ecotropic vectors comprise cis-
acting sequences (long terminal repeats [LTRs], primer binding sites and 
packaging signals) and need to be produced in packaging cells expressing 
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the trans-complementing genes (gag, pol and env). In this study, 
retroviruses were produced by transfection of helper-free ecotropic virus-
producing BOSC 23 cells using FuGENE 6™ reagent according to the 
manufacturer’s instructions. To allow the infection of human NCH82 cells, 
BOSC 23 cells were co-transfected with the pseudotyping vector pVSVg 
(Invitrogen, Karlsruhe, Germany) in the ratio of 3:1 (w/w), and supernatants 
were collected 48 h post-transfection. Recipient cells were incubated for 4 h 
with 3 ml inoculum supplemented with polybrene (6 µg/ml). NCH82 
transfected cells were selected in DMEM supplemented with 10% (v/v) FCS 
and puromycin (2.5 µg/ml); selection was terminated as control 
untransfected cells were killed. 
To transfect REFs, the following vectors have been used: pcDNA3.1(-) 
empty (Invitrogen), pEGFP-C1 (Clontech), pBabe-neo with Simian 
vacuolating virus 40 (SV40) large T antigen cds cloned in the BamHI-SalI 
site, pJ4Ω with human c-myc complete cds inserted in the BglII-HindIII site, 
pED-1 with EcoRI-XbaI-cloned p53 cds carrying a substitution of cysteine to 
serine at position 135 that encodes for a protein that oligomerize with wild-
type p53 thus rendering it biologically non-functional, pMOD-puro 
(Invivogen, Toulouse, France), and pUC with BamHI-EcoRI-cloned human ras 
cds carrying a substitution of glycine to valine at position 12 that renders the 
oncoprotein constitutively active. Despite more recent transfection 
procedures, for rat embryo fibroblasts the calcium phosphate precipitation 
method proved to be the most efficient. REFs were transfected by adapting a 
previously well established protocol (Land, 1995). Briefly, cells were seeded 
in number of 1.5x106 cells per 10 cm (Ø) dish in order to get 60–80% cell 
confluence after 24 hours. At this time point, 8-10 µg of plasmid DNA per 10 
cm (Ø) dish were mixed with 62.5 µl CaCl2 2 M in a final H2O volume of 500 
µl, and the CaCl2/DNA solution was added drop wise to 500 µl HBS 2x buffer 
(Hepes   [4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid] 50 mM, NaCl 
280 mM, Na2HPO4 1.5 mM, pH 7.05) while gently shaking. The solution was 
incubated 10–15 minutes at room temperature (RT) to allow the formation of 
the DNA/phosphate precipitates; in the meanwhile cells were re-fed with 10 
ml DMEM supplemented with 10% (v/v) FCS without antibiotics. 
DNA/phosphate precipitates mixture was afterwards distributed drop wise 
over the cells and incubated at 37°C temperature in 5% CO2 atmosphere. 
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Culture medium was changed at 24 h post transfection with DMEM 
supplemented with 10% (v/v) FCS and puromycin (1.5 µg/ml) to select 
stable transfectants; selection was terminated as control untransfected cells 
were killed. 
Small interfering RNA oligonucleotides targeting human cathepsin B 
(5’-GCU UGG AAC UUC UGG ACA ATT-3’) or L (5’-GAA CAU GAA GAU GAU 
UGA ATT-3’) transcripts (MWG, Ebersberg, Germany), and Luc (5’-AAC GUA 
CGC GGA AUA CUU CGA-3’) control oligonucleotide (Xeragon, Zürich, 
Switzerland) were transiently transfected using X-tremeGENE™ reagent 
according to the manufacturer’s instructions. In brief, cells were seeded in 
number of 5x103 cells per well (96-well plate) or 1x105 cells per 6 cm (Ø) 
dish in DMEM supplemented with 10% (v/v) FCS without antibiotics. After 24 
hours, 0.1 or 2 µg siRNA were combined with 0.8 or 10 µl X-tremeGENE™ 
reagent in a final volume of 30 or 200 µl in OptiMEM medium (per well or 
dish, respectively), incubated 15 minutes at RT, and subsequently added to 
cells. Culture medium was replaced at 24 h post transfection with DMEM 
supplemented with 10% (v/v) FCS, kanamycin (100 µg/ml) and gentamicin 
(50 µg/ml).  
Transfection vectors were prepared from mother stocks by 
transformation of E. coli DH10b strain bacteria (Invitrogen) using the heat-
shock method. 0.1 µg of purified plasmid DNA was added to 50-100 µl of 
competent bacteria (stored at -80°C in 10% [v/v] glycerol solution), 
incubated on ice for 30 minutes, then heated at 42°C for 2 minutes and 
rapidly cooled on ice for additional 2 minutes. The reaction mixture was 
afterwards diluted in 500-800 µl of Luria-Bertani (LB) broth (NaCl 5 g, yeast 
extract 5 g, bacto-trypton 5 g per H2O litre, autoclaved, pH 7.0), and 
incubated for 60-90 minutes at 37°C under shaking at 300-400 rpm. Finally, 
200-300 µl transformed bacteria were plated on LB-agar Petri dishes (1.5% 
[w/v] Bacto™Agar in LB broth) supplemented with kanamycin (50 µg/ml – 
pEGFP-C1 and pBabe-neo transformations) or ampicillin (100 µg/ml), and 
incubated overnight at 37°C. The following day, single colonies were picked 
from agar plates with a scraper or a pipette tip and cultured in suspension in 
5 ml LB broth with antibiotic, at 37°C under shaking at 200 rpm, till the 
culture reached an OD
600 (optical density at 600 nm) value of 0.6-0.8. A first 
1 ml aliquot was taken apart for mini-isolation of plasmid DNA, while a 
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second aliquot was diluted 1:250 in 250 ml LB broth with antibiotics, 
cultured overnight at 37°C under shaking at 200 rpm, and ultimately treated 
for plasmid DNA maxi-isolation. Plasmid DNA isolations and purifications 
from 5 or 250 ml bacterial cultures were respectively performed with a Mini- 
or Maxi-kit (Qiagen, Düsseldorf, Germany), according to manufacturer’s 
instructions. To control the quality of plasmid DNA, samples from mini-
preparations were digested with specific restriction enzymes to cut the 
inserted cds out of the vector. Plasmid digestion was carried out for 1h at 
37°C: 3 µl of enzyme buffer 10x were mixed with 1 µl of each restriction 
enzyme (10.000 U/ml) and 2 µg of plasmid DNA in a final volume of 30 µl 
H2O. All restriction enzymes and buffers were purchased from New England 
Biolabs (Frankfurt, Germany). At the end of the digestion period, 6 µl of 
agarose gel loading buffer 6x (EDTA [ethylenediaminetetraacetate disodium 
salt] 1 mM, 2% [w/v] SDS [sodium dodecyl sulphate], 0.5% [w/v] 
Bromophenol blue, 50% [v/v] glycerol) were added to all samples, 10-20 µl 
of which were separated and analyzed on an ethidium bromide (0.5 µg/ml)-
stained 1% (w/v) agarose gel. DNA concentration (µg/ml) was calculated by 
multiplying the samples absorbance at 260 nm by the dilution factor times 
50; DNA purity was evaluated considering that pure samples should have an 
absorbance ratio of around 1.8, measured at 260 versus 280 nm. Plasmids 
were stored at -20°C. 
 
  
3.4. H-1PV production and titering 
 
H-1PV was amplified on human NBK cells and purified on iodexanol 
gradients as previously described (Wrzesinski et al., 2003). Briefly, NBK cells 
were seeded in 20 dishes (10 cm ∅) in number of 106 cells/dish, and infected 
the following day in medium without serum or antibiotics for 1h at 37°C with 
parvovirus H-1 at a multiplicity of infection of 3x10-3 plaque forming units 
(pfu) per cell. Afterwards, cells were cultured for 4h at 37°C in DMEM 
supplemented with 10% (v/v) FCS and split 1:1 in 15 cm (∅) dishes. Cells 
were maintained in culture for 4-5 days, till they showed the first sights of 
lysis. Cells were then scraped in the medium, collected, lysed in 10 ml VTE 
buffer (Tris-HCl 50 mM, EDTA 0.5 mM, pH 8.7) and undertaken to three 
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cycles of freezing at –20°C and thawing at 37°C. Viral suspension was stored 
overnight at –20°C. The following day a purification gradient was generated 
by overlapping iodexanol 15%, 25%, 40% and 60% solutions to the virus 
suspension. Sample was centrifuged under vacuum at 50000 K for 2 hours at 
4°C, and the virus was extracted from the iodexanol 40% fraction with a 
syringe, avoiding mixing with the upper iodexanol 25% fraction, containing 
the empty capsids. The viral suspension was stored at 4°C, and H-1PV was 
then titrated on NBK indicator cells by plaque assay. Cells were seeded in 6 
cm (∅) dishes in number of 4.5x105 cells/dish, and infected the following day 
in medium without serum or antibiotics for 1h at 37°C with H-1PV at 10-7, 
10-8, 10-9, and 10-10 pfu/cell. Afterwards, cells were cultured for 3-4 days in 
5 ml MEM supplemented with 10% (v/v) FCS and 0.65% (w/v) Bacto™Agar. 
Plaque formation was detected by adding 2 ml of a PBS 1x solution 
containing 0.18% (v/v) Neutral Red and 0.8% (w/v) Bacto™Agar. Every 
single plaque was considered as coming from one viral particle; H-1PV was 
therefore used at multiplicities of infection expressed in pfu/cell. 
 
 
3.5. Flow cytometry analyses 
 
A FACScan (argon-ion lamp, 488 nm excitation laser line - BD 
Biosciences) was used to evaluate cell cycle perturbation, mitochondrial 
membrane depolarization, cell acidification, and NS1 viral protein expression 
in infected versus mock-treated cells by flow cytometry analysis. In all the 
assays, 106 cells per 10 cm (∅) dish were seeded, and infected the following 
day with H-1PV (5 pfu/cell) in DMEM supplemented with 10% (v/v) FCS, 
kanamycin (100 µg/ml) and gentamicin (50 µg/ml). Measurements were 
carried out at 24 h and/or 48 h after infection; data were acquired on 
homogeneous populations gated according to cell size (forward scatter – FSC 
– values) and granularity (side scatter – SSC – values), and processed with 
the CellQuest™ software (BD Bioscience). 
Propidium iodide (PI) binds to DNA by intercalating between the bases 
with little or no sequence preference and with a stoichiometry of one dye per 
4.5 base pairs of DNA (Waring, 1965). PI was therefore used to quantify the 
amount of cellular DNA, thus determining the cell cycle profile of the 
 47
                                   Materials and methods 
different cell populations. Briefly, cells were trypsinized, washed and 
resuspended in 200 µl PBS 1x, then fixed 30 minutes at –20°C in 800 µl 
MeOH 100% cold added drops wise. Cells were afterwards pelletted and 
treated with RNAse A (0.1 mg/ml final) in 500 µl PBS 1x for 30 minutes at 
37°C. Finally, cells were incubated on ice for 30 minutes with PI (20 µg/ml 
final) in 500 µl PBS 1x, passed through a mesh and analyzed at the flow 
cytometer. When bound to nucleic acids, the absorption maximum for PI is 
535 nm and the fluorescence emission maximum is 617 nm. DNA content 
distribution (PI fluorescence) was analyzed on the FL2-H (pulse high) 
histogram to distinguish apoptotic cells that have DNA content inferior to 2n. 
In parallel, data analysis was carried out on cells gated on an FL2-A (pulse 
area) channel versus FL2-W (pulse width) channel to exclude cell debris and 
clumped cells, and plotted on the Fl2-A histogram to better discriminate 2n 
from 4n subpopulations. 
Mitochondrial membrane depolarization assays were performed by 
measuring the potential-dependent accumulation of JC-9 cationic dye 
(Molecular Probes, Leiden, The Netherlands). A positive control of cells 
treated with H2O2 (5 mM) for 30 minutes was included. After 24 h infection, 
cells were gently harvested with trypsin, washed in PBS 1x, and incubated 
with JC-9 (5 µM) in PBS 1x for 10 minutes at 37°C. Cells were subsequently 
washed again in PBS 1x, passed through a mesh, and analyzed at the flow 
cytometer. JC-9 dye potential-dependent accumulation in mitochondria is 
indicated by a fluorescence emission shift from green (525 nm) to red (590 
nm), and mitochondrial depolarization is consequently associated to a 
decrease in the red/green fluorescence intensity ratio (Reers et al., 1991). 
Mitochondrial membrane depolarization was analyzed on a FL1-H versus  
FL2-H dot blot, and indicated by an increase in green fluorescence on the 
FL1-H histogram. 
Identification of acidic compartments by acridine orange staining was 
performed to estimate initially the occurrence of cell acidification and 
secondly the appearance of autophagic vesicles. In parallel to H-1PV 
infection, cells were treated with rapamycin (1 µM) for 24 h as positive 
control for autophagy. In cell rescue experiments, cells were incubated with 
3-MA (autophagy inhibitor, 500 µM), E64d (cathepsins inhibitor, 1 µM),    
Ca-074 Me (cathepsins B inhibitor, 10 µM), or DEVD-CHO (caspase 3 
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inhibitor, 20 µM) at 5 h post treatment. After 24 h infection, cells were 
harvested with trypsin, and incubated with acridine orange (10 µg/ml) in 
DMEM for 1 h at 37°C. Cells were then washed in PBS 1x, passed through a 
mesh, and studied at the flow cytometer on the FL3-H channel. Acidic 
compartments increase in number/size or leakage were respectively marked 
by a shift to the right or to the left in the red fluorescence (630 nm). 
To determine NS1 expression, 3x106 cells were collected in conical 
tubes, fixed 15 minutes on ice in 200 µl PFA 4% (w/v) in PBS 1x, washed 
with 1 ml SM buffer (HBSS 1x, calf serum 5%, Hepes 25mM), and re-fixed 
20 minutes on ice in 200 µl MeOH. Cells were subsequently washed in 1 ml 
PBS 1x and in 1 ml SM buffer, permeabilized 2 minutes on ice in 200 µl 
Triton X-100 0.1%, washed again in 1 ml PBS 1x and in 1 ml SM buffer and 
incubated 30 minutes on ice in 50 µl primary antibody solution (mouse 
monoclonal α-NS1 clone 3D9, diluted 1:25 in SM buffer). Afterwards, cells 
were diluted in 1 ml SM buffer plus 250 µl calf serum, pelletted and 
incubated 20 minutes on ice in secondary antibody solution (goat polyclonal 
α-mouse FITC-conjugated, diluted 1:250 in SM buffer). Finally, cells were 
diluted in 1 ml SM buffer plus 250 µl calf serum, pelletted and resuspended 
in 500 µl SM buffer, passed through a mesh and analyzed on the FL1-H 
channel. FITC (fluorescein isothiocyanate) fluorescence emission maximum is 
at 494 nm. 
 
 
3.6. Foci formation and soft agar cloning 
 
Compared to their normal derivatives, transformed cells are 
characterized by higher division speed, loss of cell contact growth inhibition, 
and survival in environmental prohibitive conditions. Two simple methods to 
verify the acquisition of a transformed phenotype are to evaluate the 
capacity to form foci in the culture dish and colonies in soft agar. 
In the first test, REFs transfectants were seeded in number of 106 cells 
per 10 cm (∅) dish and maintained at 37°C temperature, 5% CO2 
atmosphere in DMEM supplemented with 10% (v/v) FCS, kanamycin (100 
µg/ml) and gentamicin (50 µg/ml). Fresh medium was replaced every 3 
days, without splitting the cell cultures. Transformed cells rapidly reached 
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dish confluence and further developed tridimensional spherical structures 
(foci) that were counted at 14 days post seeding. 
In the second analysis, cells were resuspended in MEM supplemented 
with 10% (v/v) FCS, kanamycin (100 µg/ml), gentamicin (50 µg/ml) and 
0.4% (w/v) Bacto™Agar, and seeded in number of 5x105 cells per 6 cm (∅) 
dish on a bottom agar surface of MEM supplemented with 10% (v/v) FCS, 
kanamycin (100 µg/ml), gentamicin (50 µg/ml) and 0.625% (w/v) 
Bacto™Agar. Cultures were maintained at 37°C temperature and 5% CO2 
atmosphere, adding 0.2 ml of MEM supplemented with 10% (v/v) FCS, 
kanamycin (100 µg/ml) and gentamicin (50 µg/ml) every 5 days. 
Transformed cells were able to spread in the bottom agar stratum, expand 
clonogenically and form tridimensional spherical structures (clones) that 
were counted at 21 days post seeding. 
 
 
3.7. Cell fractionation and protease activity measurements 
 
In these analyses, 106 cells per 10 cm (∅) dish were seeded, and 
infected the following day with H-1PV (5 pfu/cell) in DMEM supplemented 
with 10% (v/v) FCS, kanamycin (100 µg/ml) and gentamicin (50 µg/ml). At 
24 h post infection, cells were collected in PBS 1x, pelleted by centrifugation 
(500 g, 10 minutes, 4ºC) and resuspended in 0.5 ml PBS 1x for the 
measurement of caspases activities or in 1.5 ml hypotonic buffer (sucrose 
0.25 M, Hepes-NaOH 10 mM, EDTA 1 mM, pH 7.4) for cathepsin B, 
hexosaminidase, acid phosphatase and catalase activities. 
One of the commonly used ways to detect caspases activities is to 
incubate synthetic substrates such as peptides conjugated to a fluorochrome 
(i.e. 7-amino-4-trifluoromethyl coumarin [AFC]), with lysates of apoptotic 
cells, and measure their cleavage. Substrate processing gives rise to 
increased fluorescence intensity, whose signal is proportional to the amount 
of cleaved substrate, which in turn is dependent on caspase activity and is 
related to the percentage of apoptotic cells in a cell population (Kohler et al., 
2002). Caspases activity was determined by adding 25 µl of whole-cell 
extract to caspase buffer (Hepes 50 mM pH 7.4, NaCl 150 mM, 0.1% [v/v] 
CHAPS, 0.1% [v/v] Triton X-100, EDTA 1 mM, 10% [v/v] Glycerol, DTT 10 
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mM) supplemented with caspase 3 (Ac-Asp-Glu-Val-Asp-AFC), 8 (Z-Ile-Glu-
Thr-Asp-AFC), or 9 (Ac-Leu-Glu-His-Asp-AFC) substrates (1 mM, 
Calbiochem). The reaction was monitored for 1 h on a Fluoroskan & FL 
(Thermolabsystem) measuring the emission at 510 nm wavelength with the 
excitation wavelength set at 390 nm. 
In cell fractionation assays for cathepsin B activity, cells were 
homogenized in a cell-cracker (bead diameter of 8.006 mm, 10 strokes). 
Nuclei and heavy mitochondria were pelleted by centrifugation at 2500 g for 
10 minutes at 4ºC. A 200 µl aliquot of the supernatant (post nuclear 
supernatant [PNS]) was kept and used to determine enzyme latency. The 
light mitochondrial fraction (LMF) was obtained by centrifugation of 1 ml PNS 
at 17000 g for 20 minutes at 4ºC. The supernatant was kept as a cytosolic 
extract and the LMF was either resuspended in 1-1.3 ml hypotonic buffer for 
the determination of enzyme activity or further fractionated. Lysosomes were 
purified from the LMF fraction (1.3 ml) on a self-generated gradient of 
iodixanol by adding 0.7 ml of 50% iodixanol in EDTA 1 mM, Hepes-NaOH   
10 mM pH 7.4, sucrose 42 mM, and centrifuging at 380000 g for 1 h 30 
minutes at 4ºC in a TLV100 rotor. Twelve 150-µl fractions were collected and 
analyzed by immunoblotting. Acidic phosphatase, hexosaminidase, cathepsin 
B and catalase activities were determined by adding 25 µl of whole cell 
extract, cytosolic extract or LMF sub-fractions to the respective reaction 
mixtures. For the measurement of acidic phosphatase activity, this mixture 
consisted of 0.2 ml of p-nitrophenyl phosphate 8 mM, sodium acetate-acetic 
acid 90 mM, pH 5.0; the reaction was stopped after 1 h at 37ºC by adding 
0.6 ml of NaOH 0.25 M, and absorbance was measured at 410 nm. 
Hexosaminidase activity was determined using 1 volume of                   
p-nitrophenol-N-acetyl-β-D-glucosaminide 3.75 mM in citrate buffer        
0.05 mM, pH 5.0 containing 0.25% (v/v) Triton X-100. The reaction was 
stopped after 3 h at 37ºC by adding 1.5 volumes of glycine 50 mM, EDTA    
5 mM, pH 10.4 and absorbance was read at 405 nm. For the measurement 
of catalase activity, the assay buffer was obtained by diluting 8.5 ml of H2O2 
30 mM in 91.5 ml of Tris-HCl 20 mM, pH 7.0 containing bovine serum 
albumin (BSA – 1 g/l). Cell fractions (25 µl) were mixed with an equal 
volume of 0.5% (v/v) Triton X-100 in Tris-HCl 20 mM, and 0.5 ml of assay 
buffer. After 10 minutes at room temperature, 1 ml of titanium oxysulphate 
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(2.25 g/l) in H2SO4 1M was added, and absorbance was measured at 405 
nm. Cathepsin B activities were determined by adding 25 µl whole-cell 
extract, cytosolic extract, or LMF subfraction to the reaction mixture, 
consisting of MES 50 mM pH 6.0, sucrose 0.25 M, EDTA 1mM, N-acetyl-L-
cysteine 2 mM. After a 10-minutes incubation, the substrate Z-Arg-Arg-AMC 
(Calbiochem) was added (1 mM) and the reaction was monitored for 1 h on a 
Fluoroskan & FL (Thermolabsystem) measuring the emission at 455 nm 
wavelength, 360 nm excitation wavelength. 
 
 
3.8. Immunoprecipitation and immunoblot analyses 
 
Cells were seeded in number of 106 per 10 cm (∅) dish, and infected 
24 h later with H-1PV (5 pfu/cell) in DMEM supplemented with 10% (v/v) 
FCS, kanamycin (100 µg/ml) and gentamicin (50 µg/ml). Cells were 
harvested with trypsin, washed in PBS 1x, and lysed 20 minutes on ice in 
400 µl RIPA buffer (Tris-HCl 50 mM pH 7.4, NaCl 150 mM, EDTA 1 mM, 1% 
[v/v] NP-40, 0.25% [w/v] Na-deoxycholate, Complete-mini™ protease 
inhibitor cocktail). Samples were centrifuged at 13000 rpm for 20 minutes at 
4ºC and supernatants were stored at -20°C; protein concentrations were 
estimated over bovine serum albumin (BSA) standards (0.2, 0.5, 0.8, 1.2, 
1.5 µg/µl) by using the DC Protein Assay (Bio-Rad Laboratories, Munich, 
Germany). 
For immunoprecipitation analyses, 200 µg total protein extracts were 
pre-cleaned with 40 µl Protein G Sepharose 80% (v/v) bead slurry (Upstate 
Biotech, Hamburg, Germany) for 1 h at 4°C. Pre-cleaned extracts were 
subsequently incubated 2 h at 4°C with 1 µg antibody against wild-type   
(Ab-6) or mutated p53 (Ab-3) (Calbiochem) bound to 50 µl Protein G 
Sepharose bead slurry (80%), and then separated by SDS-PAGE (SDS 
polyacrylamide gel electrophoresis). 
For the SDS-PAGE, a 5% polyacrylamide stacking gel (Tris-HCl       
125 mM pH 6.8, 0.1% [w/v] SDS, 0.1% [w/v] APS [ammonium persulfate], 
0.1% [v/v] TEMED) and 10-15% polyacrylamide resolving gels (Tris-HCl  
375 mM pH 8.8, 0.1% [w/v] SDS, 0.1% [w/v] APS, 0.04% [v/v] TEMED) 
were prepared; polyacrylamide here refers to a 30% (v/v) acrylamide and 
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0.8% (v/v) bis-acrylamide solution. Sample buffer (10% [v/v]                   
2-mercaptoethanol, 10% [w/v] SDS, 10% [v/v] glycerol, 0.1% [v/v] 
bromophenol blue) was mixed 1:1 with 40 up to 100 µg of total protein 
extracts, denaturated 5 minutes at 95°C and loaded on the gel. Chambers 
were filled in with reservoir buffer (Tris-HCl 25 mM pH 8.3, glycine 192 mM, 
0.1% [w/v] SDS), and proteins were separated overnight at 50 V, 100 mA. 
To perform the immunobloting, gels were detached from the glasses 
of the electrophoretic apparatus, cut in the required size and equilibrated in 
cathode buffer (Tris-HCl 25 mM pH 9.4, 10% [v/v] MeOH, glycine 40 mM) for 
at least 15 minutes. Nitrocellulose membranes (Protran, Schleicher & 
Schuell, Dassel/Relliehausen, Germany) were cut of the same sizes of the 
gel, hydrated 2 minutes in H2O, and equilibrated in anode buffer II (Tris-HCl 
25 mM pH 10.3, 10% [v/v] MeOH). 18 sheets of chromatography 3MM paper 
(Whatman, Dassel, Germany), were cut approximately 1cm larger than the 
gel sizes, and drenched in anode buffer I (Tris-HCl 300 mM pH 10.7, 10% 
[v/v] MeOH – 6 sheets), in anode buffer II (3 sheets), or in cathode buffer        
(9 sheets). A blotting sandwich was assembled by stratifying the anode 
buffer I sheets, the anode buffer II sheets, the nitrocellulose membrane, the 
gel and the cathode buffer sheets, and by wiping any bubble away with a 
roller. Proteins were transferred using a semidry blotting apparatus (Bio-Rad 
Laboratories) for 1 hour and 30 minutes at 24V, 250-300 mA. Membranes 
were afterwards stained 15 minutes in Ponceau Red Solution (0.2% [w/v] 
Ponceau-S red, 3% [v/v] trichloroacetic acid 30%, 3% [v/v] sulfosalicylic 
acid), cut according to protein marker weights, and incubated in blocking 
solution (4% [w/v] milk powder, 0.1% [v/v] Tween20 in Tris Buffered Saline 
– TBS: 50 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 1 hour at room 
temperature. Then, membranes were incubated with a primary antibody 
diluted 1:1000 in blocking solution for 1 hour at room temperature, and 
washed twice in washing buffer (0.1% [v/v] Tween20 in TBS) for 10 
minutes. Membranes were incubated with a secondary antibody diluted 
1:2500 in blocking solution for 1 hour at room temperature, washed twice in 
washing buffer for 10 minutes, and shortly air-dried. Immunodetection was 
performed with Chemiluminescence Reagent Plus/Western Lightning 
(PerkinElmer Life Sciences, Rodgau - Jügesheim, Germany). 
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The primary antibodies used for immunostaining were directed against 
β tubulin (Sigma), cystatin C (Upstate Biotech), Beclin1, GFP, Lamp2, LC3-
goat (for REFs transfectants), c-myc clone 9E10, Ha-ras (Santa Cruz, 
Heidelberg), Bcl-2 (Calbiochem), Flip (Apotech, Epalinges, Switzerland), 
SV40 large T antigen (Covance, Freiburg, Germany), LC3-rabbit (for NCH82 
cells - Biozol, Eching, Germany), NS1 (rabbit antiserum αSP8), or VP (rabbit 
antiserum polypeptide, nt 3610–4310 region of H-1PV genome). Human 
cathepsin B (clone CB 59-4B11), cathepsin L (clone CPLH 33/2), and cystatin 
B (clone RJMW 2E7) antibodies were a gift of Dr. E. Weber (Martin Luther 
University, Halle, Germany). Peroxidase-conjugated secondary antibodies 
were all purchased from Santa Cruz. Antibodies for immunoprecipitation 
against p53 (Ab-7), biotin-conjugated anti-sheep antibody, and peroxidase-
conjugated streptavidin were purchased from Calbiochem. 
 
 
3.9. Southern blot analyses 
 
Low-molecular-weight DNA was extracted from H-1PV and mock-
infected cell pellets by the Hirt procedure (Hirt, 1967). Cells were seeded in 
number of 106 per 10 cm (∅) dish, and infected the following day with H-1PV 
(5 pfu/cell) in DMEM supplemented with 10% (v/v) FCS, kanamycin        
(100 µg/ml) and gentamicin (50 µg/ml). 24 or 48 hours post infection cells 
were harvested, washed in PBS 1x, resuspended in 200 µl VTE buffer, and 
lysed by adding 200 µl Hirt buffer 2x (Tris-HCl 20 mM, 1.2% [w/v] SDS, 
EDTA 20 mM, pH 7.4). Samples were incubated with Proteinase K (400µg/ml 
final) overnight at 46°C under shaking at 200 rpm, and DNA was then 
fractionated with a syringe (0.5 and 0.4 µm needles, 5 strokes each). 2 µg 
DNA were diluted in 20 µl H2O, mixed with 4 µl agarose gel loading buffer 
6x, and run 5 h at 120 mA on a 0.8% (w/v) agarose gel. After 
electrophoresis, gel was incubated 30 minutes in Denaturation buffer (NaOH 
500 mM, NaCl 1.5 M), washed twice in H2O, incubated 1 h in Neutralization 
buffer (Tris-HCl 500 mM, EDTA 1 mM, NaCl 1.5 M, pH 7.2), and blotted 
overnight onto Hybond N+ nylon membranes (Amersham Pharmacia, Little 
Chalfont, United Kingdom). In synthesis, SSC 20x buffer (NaCl 3 M, 
trisodium citrate 300 mM) moves up by capillary action through moist 3MM 
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papers, carrying the single-stranded DNA from the gel to the membrane, 
where it is immobilised in the same position relative to where it had migrated 
in the gel. DNA was fixed on the nylon membrane by UV-crosslinking at 1200 
Joule (Stratalinker™ – Stratagene, Amsterdam, The Netherlands) and 
subsequently pre-hybridized in 50 ml hybridisation buffer (SSC 5x, Hepes  
50 mM pH 7.4, 1% [w/v] SDS, herring sperm DNA 100 µg/ml, Denhardts 
solution 1.5x [a 10x solution was prepared by dissolving 2 g Ficoll™ 400, 2 g 
polyvinylpyrrolidone, and 2 g BSA in 1 litre water]) for 3 hour in agitation at 
65°C. Membrane was hybridized with a specific 32P-labeled NS1 DNA probe 
consisting of a 703-bp EcoRV-EcoRI restriction fragment of H-1PV-derived 
phH1∆800 vector (Wrzesinski et al., 2003). The probe was labelled with the 
Megaprime Labeling Kit (Amersham Pharmacia), collected in TE Buffer   
(Tris-Cl 10 mM, EDTA 1 mM, pH 7.5), directly added to the membrane in 
hybridisation buffer, and incubated overnight in agitation at 65°C. The 
following day, membrane was washed 15 minutes in 50 ml washing buffer I 
(SSC 2x, 2% [w/v] SDS) and 15 minutes in 50 ml washing buffer II       
(SSC 0.2x, 0.2% [w/v] SDS), air dried, and exposed to a radiographic film 
(Amersham Pharmacia) for at least 5 h at -80°C; the radiographic cassette 
was finally de-frozen 1 hour at -37°C and the film was developed in a Classic 
E.O.S. processor (AGFA, Cologne, Germany). 
 
 
3.10. Assessment of cell viability and lysis 
 
To determine cell viability and lysis upon H-1PV infection, cells were 
seeded in number of 3000 per well (96-well plates) and infected after 24 h 
with H-1PV at different multiplicities of infection in DMEM supplemented with 
10% (v/v) FCS, kanamycin (100 µg/ml) and gentamicin (50 µg/ml). In cell 
rescue experiments, cells were treated with 3-MA (1 mM, 500 or 100 µM), 
E64d (1 µM), Ca-074 Me (10 µM), or DEVD-CHO (20 µM) 5 h post infection. 
Viability was evaluated using the hexosaminidase assay, performed at 
48 h post infection according to a previously well established protocol. 
Briefly, cultures in 96-well plates were washed twice in PBS 1x, and lysed in 
100 µl reaction buffer (p-nitrophenol-N-acetyl-β-D-glucosaminide 3.75 mM in 
sodium citrate 0.05 mM, 0.25% [v/v] Triton X-100, pH 5.0) per well. After 1 
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h (REFs transfectants) or 3 h (NCH82 cells and derivatives) incubation at 
37ºC, the assay was terminated and the color developed by adding 150 µl 
STOP solution (glycine 50 mM, EDTA 5 mM, pH 10.4) per well. The 
absorbance was read at 405 nm. 
Cell lysis was determined by measuring the release of glucose          
6-phosphate dehydrogenase (G6PD) into culture medium, using the Vybrant 
Cytotoxicity Assay Kit (Molecular Probes) according to the manufacturer’s 
instructions. This assay was preferred to the more frequently used lactate 
dehydrogenase (LDH) assay (Promega, Mannheim, Germany) because low-
passage glioma cells needed to be maintained in DMEM supplemented with 
10% (v/v) FCS, a serum concentration that often results in a high 
background noise from control cells LDH basal release, thus compromising 
the data processing. 
 
 
3.11. Immunofluorescence analyses, electron and optic microscopy 
 
To study cathepsin B intracellular localization, cells were seeded in 8 
chambers/slides in number of 1x104 cells per chamber, and infected or not 
with H-1PV (5 pfu/cell) in DMEM supplemented with 10% (v/v) FCS, 
kanamycin (100 µg/ml) and gentamicin (50 µg/ml) for 24 h. Cells were then 
washed twice in 200 µl PBS 1x, fixed for 10 minutes on ice in 400 µl 2% 
(v/v) PFA in PBS 1x, washed once in 200 µl PBS 1x, and re-fixed 10 minutes 
on ice in 500 µl MeOH cold. Cells were permeabilized 5 minutes in 400 µl 
0.1% (v/v) Triton X-100 in PBS 1x, washed once in 200 µl PBS 1x, and 
incubated 30 minutes at RT in 150 µl 2% (v/v) NGS (normal goat serum – 
Santa Cruz) in blocking solution (1% [w/v] BSA in PBS 1x). Cells were 
afterwards incubated 30 minutes at RT with the cathepsin B (clone CB      
59-4B11) antibody diluted 1:200 in 50 µl blocking solution, washed three 
times in 200 µl PBS 1x and once in 200 µl MeOH cold. Cells were then 
incubated 30 minutes at RT with α-rabbit FITC- or Cy3-conjugated antibody 
diluted 1:250 in 50 µl blocking solution, washed three times in 200 µl PBS 1x 
and once in 200 µl MeOH cold. Finally, cells were incubated 30 minutes at RT 
in 200 µl Dapi (4',6-diamidino-2-phenylindole; 1µg/λ in MeOH solution), 
washed three times in 200 µl MeOH cold, air dried and sealed in ProLong™ 
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Gold antifade reagent (Molecular Probes). Slides were analyzed with a     
DM-RBE automated fluorescence microscope (Leica, Wetzlar, Germany) and 
images were processed with the Openlab™ software (Improvision, Tübingen, 
Germany). 
Electron microscopy analyses were performed by Dr. H. Zentgraf 
(DKFZ, Heidelberg). Briefly, cells were seeded in number of 106 per 10 cm 
(∅) dish, infected h with H-1PV (5 pfu/cell) in DMEM supplemented with 10% 
(v/v) FCS, kanamycin (100 µg/ml) and gentamicin (50 µg/ml), and fixed 
after 24 h with 2.5% (v/v) glutaraldehyde in sodium cacodylate 0.1 mM    
(pH 7.2), overnight at 4°C. After washing in sodium cacodylate 50 mM, cells 
were post-fixed in 2% (w/v) osmium tetroxide and 0.5% (w/v) uranyl-
acetate, dehydrated through ascending alcohol concentrations and propylene 
oxide, and embedded in Epon (Carl Roth, Karlsruhe, Germany). Ultrathin 
sections were cut with a Reichert-Jung microtome (Leica) and examined with 
an EM-10A electron microscope (Carl Zeiss, Esslingen, Germany) at 80 kV. 
The magnification indicator was routinely controlled by the use of a grating 
replica. 
To identify lysosomes and autophagic compartments, mock-treated 
and H-1PV-infected cells were stained with acridine orange (10 µg/ml) in PBS 
1x for 2-3 minutes, washed in PBS 1x, and directly analyzed with a DM-IL 
inverted microscope (Leica) using filters for red fluorescence. Images were 
acquired with a DFC350-FX monochrome digital camera (Leica) and 
processed with the Openlab™ software (Improvision). 
 
 
3.12. Animal treatment 
 
Rat glioma (RG2) cells were intracerebrally implanted (3000 
cells/animal) into Wistar Kyoto inbred rats, and tumor development was 
monitored by magnetic resonance imaging. On day 11 post-implantation, 
both the tumor and its corresponding portion in the tumor-free hemisphere 
were stereotactically injected with H-1PV (1 pfu/cell) or mock treated. 
Animals were sacrificed on day 3 post-infection and protein extracts from 
resections of tumors and healthy brains were prepared for measuring 
cathepsin B activity and expression. 
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  Results 4 
 
Parvovirus H-1 kills permissive glioma cells by triggering an 
autophagic cell death dependent on cathepsins cytosolic activation 
 
 
4.1. Apoptosis activation is a minor event occurring during 
parvovirus H-1 infection of glioma NCH82 cells 
 
Parvovirus H-1 (H-1PV) exerts an efficient lytic action on primary 
cultures of human glioma cells that had proven to be resistant to DNA 
damaging agents and soluble death ligands (Di Piazza et al., 2007). Thus, to 
strengthen the feasibility of H-1PV application in brain cancer virotherapy, a 
priority was to scrutinize the death pathways activated by the virus in order 
to determine whether human glioma cells could acquire resistance and 
escape H-1PV-mediated killing. Rodent parvovirus infections can induce 
either necrosis or apoptosis, depending on the tumor model considered. After 
infection with H-1PV, human monoblastic leukaemia cells (U937) and several 
hepatocarcinoma cell lines die from apoptosis (Moehler et al., 2001; Rayet et 
al., 1998), while transformed rat fibroblasts and human keratinocytes show 
signs of necrosis (Ran et al., 1999). The question arose whether parvovirus 
H-1 would trigger an apoptotic death in NCH82 cells, a low-passage human 
glioma culture that was chosen in this study because of its sensitiveness 
towards the virus, cisplatin and, to some extent, TRAIL (Di Piazza et al., 
2007). 
A mechanism developed by tumor cells to prevent caspases activation 
is the overexpression of polypeptides that directly inactivate caspases or 
their activating complexes. In particular, Flip was demonstrated to interact 
with the cytoplasmic domain of death receptors, preventing the cleavage and 
activation of caspase 8 (Xiao et al., 2002b). Bcl-2 instead prevents the outer 
mitochondrial membrane depolarization and the relocation of cytochrome c 
to the cytosol, and had been shown to interfere, depending on the cell type, 
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with both the intrinsic and extrinsic apoptotic pathways (Fulda et al., 2001; 
Scaffidi et al., 1998). It was therefore tested if H-1PV-induced glioma cell 
death could be modulated by the overexpression of these inhibitors. Flip or 
Bcl-2 were overexpressed in NCH82 cells, and the expression of these 
polypeptides was confirmed by immunobloting not to be affected by cells 
treatment with H-1PV at a multiplicity of infection of 5 infectious particles per 
cell, expressed in plaque forming units (pfu/cell) (Fig. 7A). The ability of     
H-1PV to trigger apoptosis was studied in the NCH82 transfectants by 
measuring the induction of caspase 3 activity in infected cells, in comparison 
to cultures treated with cisplatin or TRAIL (Fig. 7B). The ability of these 
agents to cause cell death (Fig. 7C) tightly correlated with the induction of 
caspase 3 activity. Bcl-2 overexpression prevented caspase 3 activation after 
exposure of the cells to H-1PV, cisplatin and TRAIL while Flip overexpression 
inhibited caspase 3 activation in response to TRAIL but not cisplatin, as 
expected, and only to a limited extent upon H-1PV infection. Caspase 3 
activation after infection of the cells with H-1PV seemed therefore to be 
mostly dependent on the loss of the mitochondrial membrane potential 
(∆Ψm). 
Remarkably, ∆Ψm resulted not to be strongly disturbed upon H-1PV 
infection of NCH82 cells (data not shown). Moreover, although Bcl-2 
overexpression was generally able to block caspase 3 activation, it only 
protected the cells against the cytotoxic effect of the two drugs but not 
against H-1PV-induced killing (Fig. 7C). It was thus hypothesized that 
caspase 3 cleavage might be a side effect of H-1PV infection and reflect the 
activation of proteases in response to the viral infection of glioma cells. In 
agreement with this possibility, previous reports had shown that members of 
the cathepsin cysteine proteases family can participate in caspase 3 
induction and, as a result, promote cell death (Hishita et al., 2001; 
Johansson et al., 2003; Nagaraj et al., 2006). To test this assumption, 
caspase 3, 8 and 9 activation was evaluated in NCH82 glioma cells infected 
with H-1PV with or without co-treatment with the cathepsin B inhibitor      
Ca-074 Me (Fig. 7D). Caspase 3 and 9 activation was promoted by viral 
infection, but greatly reduced after exposure to Ca-074 Me, suggesting that 
caspases were indeed direct or indirect targets for cellular cathepsins. 
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Figure 7. H-1PV-induced glioma cell killing subsists when apoptosis is inhibited. (A) 
Western blot analysis for the accumulation of Bcl-2, Flip, and the parvoviral protein NS1 
after H-1PV or mock infection, in primary and Bcl-2 or Flip stable transductants of NCH82 
glioma cells. (B) Caspase 3 activation after 24 h treatment of these cells with H-1PV       
(5 pfu/cell) or cisplatin (2.5 µg/ml) and TRAIL (100 ng/ml). Caspase 3 activity is 
expressed in relative fluorescence units (RFU) per minute. Statistically significant 
differences between treated and control samples (p<0.05) are indicated by a star (*).   
(C) Effect of TRAIL, cisplatin, and H-1PV on cell survival; hexosaminidase assay, average 
values and standard deviation bars from three independent experiments, each in 
triplicate. (D) Caspase 3, 8, and 9 activation in NCH82 glioma cells 24 h after H-1PV 
infection (5 pfu/cell), in presence or absence of Ca-075 Me (10 µM).
A. B.
C.
*
*
*
*
D.
NCH82
NCH82 +
Ca-074 Me
 
In summary, parvovirus H-1 promoted pro-caspase 3 cleavage 
through mitochondrial depolarization but this process was not required for  
H-1PV-induced glioma cell death. A non-apoptotic type of cell death, 
cathepsin B-dependent and accountable for efficient cell killing, was 
activated upon H-1PV infection of NCH82 glioma cells. 
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4.2. Organelles integrity and accumulation of acidic vesicles in      
H-1PV-infected NCH82 cells  
 
The alteration of ∆Ψm had been often related to the permeabilization 
of the outer mitochondrial membrane and the production of reactive oxygen 
species (ROS) and lipid peroxidation during the apoptotic process, a 
phenomenon that was observed to cause organelle swelling and 
morphological disruption (Kim et al., 2006; Simon et al., 2000). The integrity 
of several organelles was therefore analyzed in H-1PV-infected NCH82 
glioma cells. Cell extracts were cleared from nuclei and further fractionated 
into cytosolic and organelle fractions by centrifugation. The integrity of 
organelles proved to be conserved in H-1PV-infected cells as shown by the 
confined activity of catalase to peroxysomes, and of acid phosphatase and 
hexosaminidase to lysosomes (Fig. 8A). However, it was noted that in        
H-1PV-infected cells the proportion of total cathepsin B activity present in the 
cytosol was increased by more than 2-fold. This could be due to a specific 
relocation of the lysosomal cathepsins in the cytosol, or to a disruption of the 
trafficking network between the Golgi and the lysosomes for the delivery of 
newly synthesized cathepsins. But acid phosphatase, whose molecular 
weight is similar to that of cathepsin B, remained inside the lysosome in     
H-1PV infected cells, arguing against a virus-induced early permeabilization 
of the lysosomal membrane. 
To confirm this, cells were stained with acridine orange, a fluorogenic 
weak base that chelates nucleic acids emitting in the green field, but also 
accumulates inside acidic vesicles where it becomes protonated and 
undergoes a shift to red-orange fluorescence. As a result, acidic 
compartments fluoresce red-orange against a green background (i.e. 
cytoplasm). NCH82 cells were infected with H-1PV (5 pfu/cell) and acridine 
orange staining was monitored by flow cytometry (Fig. 8B) and visualized by 
microscopy (Fig. 8C) at different times points after infection. An increase in 
red fluorescence that could be explained as an augment in either the number 
or the size of acidic vesicles was detected at 24 h post infection. At later 
times (48 h) post infection a double peak became visible, indicating that 
when cells were actually dying, their vesicles content eventually dropped 
(Fig. 8B). Indeed, the accumulation of acidic vesicles in the cytoplasm of 
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Figure 8. Organelles integrity and accumulation of acidic vescicles in the cytosol of H-1PV-
infected NCH82 cells. (A) Relative enzymatic activities in the cytosol versus lysosomes 
(cathepsin B, hexosaminidase, acid phosphatase) or peroxysomes (catalase) of NCH82 cells, 
calculated as ratio in H-1PV-infected (24 hpi, 5 pfu/cell) over mock. (B) Acidic vesicles content, 
measured by flow cytometry after acridine orange staining [FL3-H channel], and Western 
blotting detection of Lamp2 in NCH82 glioma cells at 24 and 48 h after H-1PV (5 pfu/cell) or 
mock treatment. (C) Acridine orange staining of NCH82 cells that were either mock-treated or 
analyzed 9, 20 and 30 h after H-1PV infection. Fluorescence microscopy, magnification 800x; 
acidic vesicles appear as red dots, nucleic acids are stained in green.
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infected NCH82 cells was observed as early as 9 h post infection and became 
massive at 20 h post infection. The cytosol appeared yellow in the majority 
of infected cells at 30 h post infection, as result of vesicles content release 
and dye shift of fluorescence in the more alkaline cytosolic environment (Fig. 
8C). At this stage, the expression of lysosomal trans-membrane protein 
Lamp2 did not change in infected versus mock-treated cells, suggesting that 
the virus induced a leakage of acidic compartments rather than their 
blebbing (Fig. 8B). Thus glioma infection with H-1PV did not disrupt the 
membrane boundary of cellular organelles but increased the number of acid 
vesicles, a process that was reminiscent of macroautophagy. 
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4.3. Autophagic cell death is promoted after parvovirus H-1 
infection of NCH82 glioma cells 
 
The evidence of H-1PV-induced accumulation and later leakage of 
acidic vesicles potentially contributing to virus-mediated cell death required 
further analysis in order to ascertain the nature of these compartments. 
Acridine orange was previously used as lysosomotropic agent to detect the 
development of acidic vesicular organelles, which were subsequently 
identified as autophagic vesicles (Kanzawa et al., 2004).  
Autophagy or type II cell death is characterized by the appearance of 
cytoplasmic vesicles called autophagosomes. These contain cytoplasm and/or 
cytoplasmic organelles and eventually fuse with lysosomes, leading to the 
formation of autophagic vacuoles where the autophagosome content is 
notably degraded by proteolysis. Autophagy was demonstrated to be either 
promoted and/or inhibited during tumor progression, depending on 
environmental conditions and the genetic alteration status of transformed 
cells (Kondo et al., 2005). Moreover, the formation of autophagic vesicles in 
response to human parvovirus B19 (Nakashima et al., 2006) and other 
pathogens (Kirkegaard et al., 2004) infection was reported to be a defense 
mechanism by which cells digest infectious agents. Besides, some viruses 
were shown to hijack the autophagic machinery to the benefit of their life 
cycle (Jackson et al., 2005). These observations raised the question whether 
H-1PV triggered autophagy to kill infection-permissive cells. 
NCH82 glioma cells were infected for 24 h with parvovirus H-1          
(5 pfu/cell) and subsequently prepared for electron microscopy analysis. 
Compared to mock-treated cells (Fig. 9A and B), infected NCH82 cells 
displayed a completely different morphology, appearing to be filled in with 
vesicles and vacuoles (Fig. 9C and F). In infected cells, autolysosomes were 
identified as single membrane structures containing electron-dense material, 
pinpointed as cytoplasmic components at various stages of degradation (Fig. 
9E). Autophagosomes were characterized as transient double membrane 
structures containing undigested cytoplasmic material and including portions 
of mitochondria (Fig. 9H), and appeared rather different in comparison to 
normal mitochondria (Fig. 9G). Partial chromatin condensation, an event 
which had been defined as one of the hallmarks of autophagy (Bursch et al., 
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Figure 9. Autophagy is triggered upon parvovirus H-1 infection of NCH82 glioma cells. 
Electron microscopy images of cells (A, B) mock-treated or (C, F) infected 24 h with   
H-1PV (5 pfu/cell). Scale bar: 1,5 µm. Autolysosomes (D, E), a mitochondria (G) and an 
autophagosome (H) are indicated  Scale bars: 600 nm (E); 300 nm (D  G  H)   
Figure 9. Autophagy is triggered upon parvovirus H-1 infection of NCH82 glioma cells. 
Electron microscopy images of cells (A, B) mock-treated or (C, F) infected 24 h with   
H-1PV (5 pfu/cell). Scale bar: 1,5 µm. Autolysosomes (D, E), a mitochondria (G) and an 
autophagosome (H) are indicated. Scale bars: 600 nm (E); 300 nm (D, G, H).  
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2000), was observed in the nuclei of NCH82 cells infected with H-1PV (Fig. 
9C). Notably, the presence of structures resembling autolysosomes was 
detected even in mock-treated NCH82 cells (Fig. 9A and D), suggesting that 
this process was already activated in this cancer cell line, most likely at a 
basal level to sustain survival in low-oxygen and nutrient in vivo growth 
conditions (Kondo et al., 2005) and after cell adaptation to in vitro culturing. 
Anyway, autophagic compartments increased noteworthy in number after 
parvovirus H-1 infection. 
To further support the hypothesis of type II cell death activation upon 
H-1PV infection, the expression of different proteins involved in autophagy 
was analyzed in NCH82 cell 24 h after treatment with H-1PV at 5 pfu/cell 
(Fig. 10). In parallel, it was decided to test as positive control the effect of 
rapamycin (1 µM), an inhibitor of the PI3K–Akt–mTOR signalling pathways 
that had been recently shown to induce autophagy in glioma cells (Iwamaru 
et al., 2006). 
Microtubule-associated protein 1 light chain 3 (LC3) is a good marker 
protein for autophagic membranes since it is synthesized as cytosolic form 
(LC3-I, apparent mobility of 18 kDa) and specifically processed, upon 
activation by the mammalian Atg7 (Tanida et al., 2001), into a membrane-
bound form (LC3-II, apparent mobility of 16 kDa) that associates tightly to 
the autophagosomal membrane. The amount of LC3-II or the LC3-II/LC3-I 
ratio correlates with the number of autophagosomes (Kabeya et al., 2000). 
The LC3-II isoform was already detected in the mock-treated NCH82 cells, 
confirming that this glioma cell population was prone to the activation of 
autophagy in absence of H-1PV infection. Nevertheless, in cells infected with 
the virus the conversion of LC3-I to LC3-II was almost total and markedly 
stronger than in cells treated with rapamycin (Fig. 10, 3rd lane). 
The pro-autophagic factor Beclin1 was shown to localize in the trans-
Golgi network where it might be involved in sorting putative autophagosomal 
components thus initiating the autophagic process (Kihara et al., 2001). In 
agreement with data in the literature (Liang et al., 1999), Beclin1 expression 
levels were low in cultured NCH82 tumor cells but increased 24 h after 
infection with parvovirus H-1 (Fig. 10, 2nd lane). Surprisingly, no changes in 
Beclin1 expression were observed upon treatment of these glioma cells with 
rapamycin. This compound blocks the activity of mTOR, a negative regulator 
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of autophagy considered a key factor for the initiation of the autophagic 
pathway. Nonetheless, despite the fact that Beclin1 siRNA was recently 
demonstrated to inhibit rapamycin-induced autophagy (Iwamaru et al., 
2006), a direct relationship between mTOR and Beclin1 has not been yet 
proven. 
Altogether, these data indicated that autophagy was already present 
in NCH82 glioma cells but that H-1PV infection triggered the activation levels 
of this process. 
Figure 10. Autophagy activation following 
parvovirus H-1 infection. Western blot analysis for 
the expression of NS1, Beclin1, LC3 I and II 
isoforms in NCH82 cells at 24 h after treatment 
with H-1PV (5 pfu/cell) and/or 3-MA (500 µM) or 
rapamycin (1 µM); β tubulin was used as a 
standard for protein load matching.
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4.4. Lysosomal cathepsins accumulate in the cytosol of parvovirus 
H-1-infected NCH82 cells 
 
In H-1PV-infected NCH82 glioma cells, caspases 3 and 9 activation 
was demonstrated to be cathepsin B-dependent (Fig. 7D) and a 2-fold 
increase in the cytosolic fraction of total cathepsin B activity was observed 
(Fig. 8A). Cathepsins are normally located inside lysosomes, and their 
targeted transport from the endoplasmic reticulum to these organelles 
minimizes their impact on the cytosol. Under stress, i.e. exposure to 
lysosomotropic agents or starvation, the integrity of the lysosomal 
membrane is lost, and the release of cathepsins into the cytosol induces cell 
necrosis (Guicciardi et al., 2004; Jäättelä, 2004). This did not appear to 
occur in H-1PV-induced death, as immediately after infection acidic vesicles 
accumulated in, instead of disappearing from, the cytoplasm. It was 
nonetheless important to investigate what was the role of this imbalance in 
cytosolic vs. lysosomal cathepsin B activity in H-1PV-triggered cell killing, 
and whether it was a common parvovirus-induced phenomenon. 
To this purpose, NCH82 glioma cells were infected with H-1PV          
(5 pfu/cell) and samples were analyzed by cell fractionation at 24 h after 
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infection. Post-nuclear extracts were centrifugated to separate the 
lysosomal/organelle and the cytosolic fractions, and cathepsin B activity was 
measured by a fluorescence-based enzymatic assay. H-1PV-infected NCH82 
cells showed a much higher level of cathepsin B activity in the cytosolic 
fraction as compared to mock-treated cells (Fig. 11A), and immuno-
fluorescence analysis was performed to further confirm H-1PV-induced 
Figure 11. Cathepsins cytosolic activation and cystatins 
down-regulation 24 h after H-1PV infection (5 pfu/cell) of 
NCH82 glioma cells. (A) Distribution of cathepsin B 
activity between the cytosol and vesicle fractions after 
separation by iodexanol gradient centrifugation. RFU, 
relative fluorescence units. The lysosomal trans-
membrane protein Lamp2 was used as marker to identify 
individual fractions (B) Immunofluorescence assay for 
cathepsin B localization. An anti-rabbit Cy3-conjugated 
secondary antibody was used; nuclei were stained with 
DAPI. (C) Effect of H-1PV, cisplatin (2.5 µg/ml) and 
TRAIL (100 ng/ml) on cathepsin B lysosomal and 
cytosolic activity in NCH82 cells. (D) Western blotting
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cytosolic activation of cathepsin B. Mock-treated samples displayed a dotted 
pattern while infected cells showed a diffuse staining, indicating an 
intracellular relocation of cathepsin B from the lysosomes to the cytosol after 
H-1PV infection (Fig. 11B). Moreover, cathepsin B cytosolic activation was 
proved to be exclusively dependent on parvovirus H-1 infection, since any 
difference was observed in the levels of lysosomal and cytosolic cathepsin B 
activity of cells treated with cisplatin (2.5 µg/ml) or TRAIL (100 ng/ml)    
(Fig. 11C). Finally, also active cathepsin L was detected in the cytosol of 
infected but not of mock-treated NCH82 cells (Fig. 11D). 
Altogether, these data lead to the conclusion that H-1PV infection 
resulted in an alteration of the distribution of lysosomal proteases, an 
enhanced proportion of these enzymes being present and active in the 
cytosol. It has to be specified that the modification of cathepsin distribution 
and concomitant death of glioma cells were not observed after treatment 
with empty (genome-free) capsids or UV-inactivated virus, nor after infection 
with full virions and co-treatment with bromodeoxyuridine (BrdU; 30µM) or 
aphidicolin (20µM), conditions allowing viral entry but preventing the onset 
of genome replication (Kwant and van der Vliet, 1980; Rhode, 1974) (data 
not shown). Thus, H-1PV DNA replication, gene expression, or both appeared 
to be required for these virus effects.  
 
 
4.5. Physiological inhibitors of cathepsins are down-regulated in 
parvovirus H-1-infected NCH82 cells 
 
Cathepsin activity is tightly regulated by pH and by polypeptides of 
the cystatin family. Among these, cystatin C has a signal peptide for 
extracellular transport and controls secreted cathepsins activity, while 
cystatin B is intracellularly located and inhibits cytosolic cathepsins 
accidentally released from or not delivered to the lysosomes (Rawlings et al., 
2004). To evaluate whether parvovirus H-1 could regulate cathepsins activity 
through the modulation of their inhibitors, cathepsin B and cystatin B and C 
levels were measured by Western blotting in NCH82 glioma cells infected 
with H-1PV at 5 pfu/cell (Fig. 11E). The expression of both cystatin B and C 
was clearly down-regulated in infected versus mock-treated cells, while 
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cystatin C expression was even up-regulated after infection of human 
astrocytes that were demonstrated not to be permissive to H-1PV (data not 
shown). Moreover, cathepsin B levels were slightly reduced in infected 
NCH82 cells (Fig. 11E), and the overall expression of cathepsin L did not 
undergo any substantial change after infection (Fig. 11D), suggesting that 
parvovirus H-1 did not control the activity of lysosomal proteases by 
regulating their transcriptional levels. 
It was therefore decided to investigate the reciprocal role of lysosomal 
proteases and their physiological inhibitors in H-1PV-triggered cell death to 
further substantiate their involvement during viral infection of gliomas. 
NCH82 cells were infected, or not, with a recombinant retrovirus driving 
overexpression of either a cystatin B-GFP fusion protein or control GFP alone 
(Fig. 12A). Afterwards, cathepsin B and L expression was transiently down-
regulated by siRNA knockdown in NCH82 cells (Fig. 12B) and their 
derivatives overexpressing cystatin B or control GFP. Cells were infected 24 h 
after siRNAs treatment with H-1PV at 5 pfu/cell for other 48 hours, and      
H-1PV-induced cell lysis was measured by mean of the G6PD assay (Fig. 
12C). NCH82 cells transfected with cathepsin-specific siRNA proved less 
sensitive to H-1PV-induced killing than the corresponding parental cells, 
confirming the involvement of cathepsins in viral cytopathic effects. 
Interestingly, the efficacy of cathepsin B or L siRNA in terms of cell rescue 
from H-1PV infection was roughly identical, and was not enhanced by the 
combined siRNAs treatment. Moreover, cells overexpressing cystatin B were 
also less sensitive than control cells to H-1PV-induced killing, and could not 
be further protected from the viral toxic effects by means of cathepsin-
specific RNAi. Notably, cathepsin-specific siRNAs had no detectable 
consequence on viral protein expression (Fig. 12D) while reduced the 
efficacy of viral genome replication and progeny production (Fig. 12E), an 
effect that was considered not to be relevant, and related to a nonspecific 
outcome of the RNAi approach, as it could be detected in the control (Luc) 
siRNA as well. 
Since NF- B signalling pathway controls cell survival in response to a 
variety of immune and inflammatory stimuli (Baldwin, 2001; Ghosh et al., 
1998), and NFκB-responsive genes were also reported to inhibit cathepsin B 
activation (Liu et al., 2003), NCH82 cells were examined to verify whether  
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H-1PV infection might modulate NFκB activity. No significant changes in 
NFκB activity were observed upon infection, indicating that virus-induced 
activation of cathepsins was not mediated by this factor (data not shown). 
In summary, cathepsin inhibitors were down-regulated upon 
parvovirus H-1 infection. Both cathepsins inactivation and cystatin B 
overexpression were sufficient to rescue NCH82 glioma cells from H-1PV-
triggered cell death. 
 
 
C.
Figure 12. Effect of cystatin B 
overexpression and cathepsins siRNA on 
H-1PV infection. Western blot analysis 
for (A) the production of a GFP-cystatin 
B fusion protein and control GFP in 
NCH82-transfected cells, and for (B) 
cathepsin B and L expression at 24 or 48 
h after mock treatment or transfection 
with non-specific (Luc) or specific 
siRNAs. (C) Effect of cathepsin B and/or 
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4.6. Both autophagy and cathepsins inhibitors protect glioma cells 
from H-1PV-induced oncolysis  
 
It became at this point necessary to distinguish between the putative 
roles of cytosolic cathepsins and autophagic vesicles in the death of H-1PV-
infected glioma cells. To this purpose, chemical inhibitors of both autophagy 
and cathepsins were compared for their ability to rescue cells from H-1PV-
induced killing. 3-methyladenine (3-MA), a widely used inhibitor of 
autophagy, exerts its action by blocking the class III PI3 kinase complex, 
which promotes the formation of autophagosomes (Petiot et al., 2000; 
Seglen and Gordon, 1982). E64d [(2S,3S)-trans-Epoxysuccinyl-L-
leucylamido-3-methylbutane Ethyl Ester Loxistatin], an analogue of the 
natural peptidyl epoxide E64, is a general inhibitor of cathepsins B, H, and L 
(Kirschke and Barret, 1987). It has to be noted that E64d is also used, at a 
10-fold higher concentration, to inhibit the fusion between the 
autophagosome and the lysosome, and detect LC3-II accumulation at cellular 
level (Tanida et al., 2005). Ca-074 Me [[L-3-trans-(Propylcarbamoyl)oxirane-
2-carbonyl]-L-isoleucyl-L-proline Methyl Ester], methyl ester of the E64 
derivative Ca-074, had been initially synthesized as cathepsin B specific 
inhibitor (Buttle et al., 1992). Despite recent in vivo observations on Ca-074 
Me as non-selective inhibitor of lysosomal cysteine proteinases (Montaser et 
al., 2002), this compound is still considered as mainly even if not specifically 
inhibiting cathepsin B activity (Bang et al., 2004). 
NCH82 cells were infected with H-1PV (5 pfu/cell) and cultured under 
standard growth conditions or in medium supplemented with 3-MA (1mM and 
100 µM), E64d (1 µM), or Ca-074 Me (10 µM). In parallel, cells were treated 
with rapamycin 1 µM in presence or absence of 3-MA (500 µM), and the 
caspase 3 inhibitor DEVD-CHO (20 µM) was added as further control. 
Hexosaminidase measurements, performed at 48 h post treatment, 
demonstrated that both 3-MA and Ca-074 Me exerted almost full protection 
(Fig. 13A). E64d was less efficient but still significantly able to rescue cells 
from virus-induced death, while DEVD-CHO had no shielding effect. 3-MA 
showed a dose-dependent protection capacity (Fig. 13A), and interfered with 
the conversion of LC3-I to LC3-II after infection of NCH82 cells (Fig. 10), 
thus blocking H-1PV-induced accumulation of acidic vesicles (Fig. 13B). 
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Figure 13. Rescue of NCH82 glioma cells from parvovirus H-1-
induced killing after co-treatment with autophagy or cathepsins 
inhibitors. Hexosaminidase assays at 48 h after treatment with 
rapamycin (1 µM) or infection with H-1PV (5 pfu/cell). 3-MA, E64d, 
Ca-074 Me and DEVD-CHO were added 5 h post treatment at the 
indicated concentrations. Cell survival is expressed as percentage of 
vital staining in infected versus mock cultures. Average values and 
standard deviation bars from three independent experiments, each
indicated
A.
H1-PV
H1-PV + 3-MA
mock
B.
H-1PV (5 pfu/cell)
control
3-MA 1 mM
3-MA 100 µM
E64d 1µM
Ca-074 Me 10µM
DEVD-CHO 20µM
*
*
*
*
*
rapamycin 1µM
control
3-MA 500 µM
C.
 triplicate. Statistically significant differences (p<0.05) are indicated by a star (*).   
(B) Acridine orange staining 24 h after treatment with H-1PV (5 pfu/cell) with or without 3-MA 
(500 µM). Fluorescence microscopy, red filter, magnification 800x. (C) Western blotting 
detection for NS1 to test the effect of above mentioned inhibitors on H-1PV protein expression. 
β tubulin was used for protein load matching.
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Remarkably, 3-MA, E64d and Ca-074 Me were likely to interfere directly with 
the H-1PV-triggered death pathway rather than with production of cytotoxic 
viral intermediates, as no change in H-1PV protein synthesis was detected in 
the presence of these drugs (Fig. 13C). 
Moreover, 3-MA counteracted rapamycin-mediated initiation of 
autophagy in NCH82 glioma cells, which proved to be sensitive to the drug, 
as denoted by a 60% decrease in cell survival (Fig. 13A). It has to be 
specified that 3-MA most commonly used working concentrations of 5 mM 
(Paglin et al., 2001) and 10 mM (Boya et al., 2005) turned to display an 
overall toxicity on the cells. In this analysis, 3-MA concentrations of 1 mM 
and 100 µM resulted to provide respectively the higher and lower protective 
effect while being essentially harmless. The intermediate 3-MA working 
concentration of 500 µM was therefore chosen for further tests.  
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Altogether these data indicated that newly formed autophagosomes 
and cytosolic cathepsins were both indispensable components of a distinct 
pathway leading to the death of H-1PV-infected glioma cells.  
 
 
4.7. Cathepsins B cytosolic activation in H-1PV-infected NCH82 cells 
is prevented when autophagy is inhibited 
 
In order to obtain a complete overview on the non-apoptotic cell death 
mechanism triggered by parvovirus H-1, the reciprocal role of autophagy 
activation and cathepsins B and L lysosomal release needed to be clarified. 
It was first decided to investigate whether autophagy still occurred 
when virus-promoted cell death was blocked by the inhibition of cathepsins 
or the overexpression of cystatin B. NCH82 cells and derivatives 
overexpressing cystatin B were treated for 24 h with parvovirus H-1           
(5 pfu/cell) or with rapamycin (1 µM) with or without co-incubation with     
3-MA (500 µM). In parallel, NCH82 cells were infected for 24 h with 
parvovirus H-1 (5 pfu/cell) in medium complemented with E64d (1 µM) or 
Ca-074 Me (10 µM). Flow cytometry analysis was performed to quantify their 
acidic vesicles content (Fig. 14A). In agreement with the previous 
observations, an increase in the number/size of autophagic vacuoles was 
detected in NCH82 cells either infected with the virus or stimulated with 
rapamycin. Moreover, this phenomenon was prevented by the action of 3-MA 
while both E64d and Ca-074 Me did not exert an inhibiting effect on H-1PV-
induced initiation of autophagy. More surprisingly, an augment in acidic 
vesicles content was noticed at 24 h post infection or rapamycin treatment of 
NCH82-cystatin B cells. Again, it was possible to identify acidic 
compartments as autophagic vacuoles since 3-MA treatment resulted in a 
back-shift of the red fluorescence to the mock peak position (Fig. 14A, right 
panels) and an increase of LC3-II isoform expression was detected by 
Western blot analysis (Fig. 14B). In synthesis, avoidance of cathepsins 
cytosolic activation by chemical inhibition or cystatin B overexpression did 
not impede the onset of autophagy after H-1PV infection. 
Then, the question arose whether cathepsins were still present in the 
cytosolic fraction of infected NCH82 glioma cells when autophagy was 
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Figure 14. Cathepsins inhibition or cystatin B overexpression does not prevent autophagy 
activation upon H-1PV infection. NCH82 cells and derivatives overexpressing cystatin B were 
infected with parvovirus H-1 (5 pfu/cell) or treated with rapamycin (1 µM) for 24 h; 3-MA   
(500 µM), E64d (1 µM), and Ca-074 Me (10 µM) were added at 5 h post treatment. (A) Acidic 
vesicles content, measured by flow cytometry after acridine orange staining; FL3-H channel. 
(B) Western blot analysis for the expression of NS1, β tubulin, LC3 I and II isoforms. (C) 
Cathepsin B total activity in lysosomal and cytosolic fractions. RFU, relative fluorescence units.
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inhibited. To verify this, cells were incubated with 3-MA (500 µM) or Ca-074 
Me (10 µM), 5 h post infection with parvovirus H-1 at 5 pfu/cell. Cathepsin B 
activity was measured at 24 h post infection, after samples cell fractionation 
(Fig. 14C). In addition, the assay was conducted on cell treated for 24 h with 
rapamycin (1 µM), to ascertain if the outcome of autophagy on cathepsin B 
cytosolic activation was virus-specific or not. Cathepsin B activities in the 
lysosomal fractions of mock-, rapamycin- and H-1PV-treated NCH82 cells 
were almost equal, while an evident increase of activity in the cytosolic 
fraction occurred only in H-1PV-infected cells. 3-MA appeared to negatively 
affect cathepsin B overall activity, supporting the hypothesis of an intrinsic 
toxicity of this chemical. Indeed, 3-MA was reported to have some effects on 
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membrane trafficking including endocytosis (Punnonen et al., 1994), and to 
mildly alkalinise the lysosomal lumen (Caro et al., 1998). Nonetheless, 
autophagy inhibition drastically reduced cathepsin B activity in the cytosol of 
infected cells. Co-treatment with Ca-074 Me completely abolished cathepsin 
B lysosomal and cytosolic activities, confirming the efficiency of the 
compound in inhibiting this cysteine protease. 
In summary, it was possible to establish the sequence of events 
leading to virus-induced cell death, demonstrating that autophagy played a 
primary role in the killing mechanism initiated by H-1PV infection. Cathepsins 
cytosolic activation occurred after and as consequence of the onset of 
autophagy. 
 
 
4.8. H-1PV-induced tumor regression is associated with cathepsin B 
activation in vivo 
 
A rat syngenic glioma model has been developed by Dr. K. Geletneky 
(Neurosurgery Department, University of Heidelberg) in the context of a 
collaboration to test parvovirus H-1 in vivo capacity of tumor cell killing. In 
this model, rat glioma cells (RG2) were intracerebrally implanted into 
recipient animals and tumor development was monitored by magnetic 
resonance imaging. After 11 days, a distinct tumoral mass was observed at 
the implantation site, and both the tumor and its corresponding portion in 
the tumor-free hemisphere were stereotactically injected with H-1PV          
(1 pfu/cell) or PBS (1x - mock). Parvovirus H-1 injection resulted in a 
striking and irreversible tumor regression, which was massive already at day 
5 post infection and became almost complete by day 7 post infection      (Fig. 
15A) (Geletneky et al., 2007; manuscript in preparation). 
For that reason, it was interesting to determine if the effect of H-1PV 
intratumoral injection on glioma regression correlated with a differential 
expression of cathepsin B in tumors versus healthy brains. Animals were 
sacrificed on day 3 post infection and cathepsin B expression (Fig. 15B) and 
activities (Fig. 15C and D) were measured in protein extracts from resections 
of the tumor-bearing and tumor-free hemispheres, either infected with       
H-1PV at 1 pfu/cell or mock-treated. H-1PV-induced glioma regression in 
 75
                                                                                                                                                        Results 
Tumor-free Hemisphere
0
50
100
150
200
0 1000 2000 3000 4000
time (s)
C
at
h
ep
si
n
 B
 A
ct
iv
it
y
(F
lu
or
es
ce
n
ce
)
mock
H-1PV
A. C.
D.
Figure 15. In vivo activation of cathepsin B by  
H-1PV infection of tumor cells. (A) Magnetic 
resonance monitoring of tumor development and 
regression after rat glioma cells intracerebral
implantation in recipient rats and infection with  
H-1PV (1 pfu/cell). (B) Western blot for cathepsin 
B and β tubulin expression and (C, D) 
measurement of cathepsin B activity in protein 
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H-1PV injection
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injection
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extracts isolated 3 days after infection or mock treatment from the tumor and its 
corresponding portion in the tumor-free hemisphere. Protein amounts were normalized 
according to tissue masses and volumes of the extracts.
Courtesy of Dr. K. Geletneky
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vivo was found to be associated with cathepsin induction. In contrast to the 
data obtained in vitro, the total amount of cathepsin B was increased in 
tumors infected with H-1PV (Fig. 15B). In addition, cathepsin B expression 
levels in the infected tissue extracts from the tumor-free hemisphere were 
similar to those in the mock-treated preparations from the tumor-bearing 
hemisphere, both relevantly higher than the mock-treated tissue extracts 
from the tumor-free hemisphere. Indeed, cathepsins had been observed to 
be highly expressed in high-grade gliomas and participate in malignant cells 
invasion and migration (Mohanam et al., 2001; Rempel et al., 1994). As 
confirmation, glioma-bearing hemispheres showed an enhanced cathepsin B 
activity, detected already in mock-infected tumors but resulted to be 
dramatically greater in regressing H-1PV-treated tumors (Fig. 15C). 
Remarkably, cathepsin B activity was very low and not significantly affected 
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by H-1PV intracerebral injection in tissue extracts from the tumor-free 
hemisphere (Fig. 15D) and from the healthy brains (data not shown).  
Considering that cathepsins are often secreted by tumor cells to digest 
the extracellular matrix, it was possible to conclude that the observed 
cathepsin B in vivo accumulation, probably both intra- and extracellular 
(after cell death), might have contributed to tumor regression and 
participated to the formation of an empty cavity in the place of the tumor. 
 
 
c-myc overexpression sensitizes rat embryo fibroblasts to the 
activation of a non-apoptotic death pathway upon parvovirus H-1 
infection 
 
 
4.9. Immortalization and transformation of rat embryo fibroblasts 
 
Parvovirus H-1 is poorly infecting primary human fibroblast and 
without cytopathic effect, but malignant transformation increases their 
susceptibility to the lytic action of the virus, a possible component of its 
mediated oncosuppression observed in vivo (Cornelis et al., 1988; Op De 
Beeck et al., 2001). Nonetheless, it was still unclear how oncogenes 
expression renders transformed cells more permissive to H-1PV and if this is 
related to the acquisition of a precise transformed phenotype. A previous 
report claimed that p53 mutation, in combination with ras activation, is 
necessary for rat embryo fibroblasts to become sensitive to H-1PV-induced 
killing (Telerman et al., 1993). It remained to be shown if cell full 
transformation by oncogene cooperation is generally necessary to sensitize 
REFs to H-1PV cytotoxicity and if, in this context, oncogenes of the same 
class (immortalizing versus transforming) are exchangeable or if the 
activation of specific oncogenes is strictly required. 
Rat embryo fibroblasts isolated from 14 days old embryos were 
transfected with vectors expressing different oncogenes (c-myc, Ha-ras, 
SV40 large T antigen) and a dominant negative mutant form of the tumor 
suppressor p53 (p53dn), alone or in different combinations, together with a 
puromycin resistance gene harbouring vector. Stable transfectants were 
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selected by culturing the cells in medium supplemented with FCS 10% (v/v) 
and puromycin (1.5 µg/ml) for 7-8 days, an incubation period sufficient for 
the drug to completely kill normal and GFP-transfected REFs control 
populations. Western blot and immunoprecipitation analyses were performed 
to confirm the expression of the respective proteins (Fig. 16A and B). 
Figure 16. Selection of REFs stable 
transfectants. (A) Western blot 
analysis for c-myc, Ha-ras and
SV40-largeT antigen expression. (B) 
Immunoprecipitation analysis for 
the expression of the wild-type or 
the dominant negative mutant form 
of p53. β tubulin is used as a 
standard for protein load matching.
B.
A.
 
REFs transfection with different combinations of oncogenes and 
oncosuppressor led to cell immortalization or transformation, and the 
acquisition of one or the other phenotype was determined according to 
several criteria. In terms of cell morphology, Ha-ras-transfected REFs (ras*) 
appeared undistinguishable from the primary cells whereas cells transfected 
with c-myc (myc), p53dn or SV40 large T antigen (largeT), alone or in 
combination (myc/p53dn and myc/largeT) became immortalized (Fig. 17). 
These cultures were still dividing 35 days post transfection, and did not show 
signs of senescence when compared to control cells; interestingly, double 
oncogene transfection seemed to confer stronger immortalization features, 
as cells displayed a notably higher division speed in comparison to single 
transfectans (Fig. 18A). The acquisition of a transformed phenotype was 
discerned in ras*/p53dn, ras*/myc and ras*/largeT transfected REFs. These 
cells were able to proliferate in absence of growth factors, to spread in the 
culture dish thus developing foci at high density, and to form clones in soft 
agar (Fig. 17). However, ras*/p53dn transfected cells showed a less 
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REFs p53dn ras*
ras*/p53dnmyc/p53dn
myc/largeTmyc
ras*/myc
largeT
ras*/largeT
Figure 17. Effect of different oncogenes activation on rat 
embryo fibroblasts morphology. Cells isolated from 14 days 
old rat embryos were transfected with vectors 
overexpressing c-myc, Ha-ras, SV40-largeT antigen or a 
dominant negative mutant form of p53, alone and in 
different combinations. Stable transfectants were selected 
for 7 days in culture medium supplemented with puromycin 
1.5 µg/ml. Optic microscopy, magnification 400x.
aggressive behavior, characterized by slower growth and weaker formation, 
in number and size, of foci in cell culture and clones in soft agar (Fig. 18B 
and C). Compared to ras*/largeT transfected cells, ras*/myc transfectans 
were found to stronger exhibit transformed features, having a similar growth 
speed but developing bigger foci and soft agar clones (Fig. 18B). 
Altogether, these ten REFs subpopulations displayed diverse 
phenotypes due to the combined/differential expression of key oncogenes 
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involved in cell cycle control, apoptosis regulation, cell proliferation, survival 
and differentiation. This cell collection reflected a combination of mutation 
commonly observed in many types of tumours, and appeared therefore to be 
suitable to test the effect of genetic alterations on REFs permissiveness to 
parvovirus H-1-induced killing. 
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Figure 18. Effect of different oncogenes activation on rat embryo fibroblasts behaviour. (A) 
Cell growth was followed up to 5 weeks after isolation of stable transfectants. (B) Transformed 
REFs spread and formed clones after 3 weeks seeding in agar 0.625% solution. Optic 
microscopy, magnification 100x and 200x. Scale bars: 600 µm (white) and 300 µm (black). (C) 
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4.10. c-myc overexpression sensitizes rat embryo fibroblasts to 
parvovirus H-1 oncotoxic action 
 
To evaluate cell sensitivity to viral infection, transfectants and primary 
REFs were seeded in 96 wells/plates in number of 3000 cells/well and 
infected with H-1PV at multiplicities of infection of 0.625, 1.25, 2.5, 5 and 10 
pfu/cell. Hexosaminidase and G6PD (glucose 6-phosphate dehydrogenase) 
assays were carried out at day 2 post infection. The cytophatic effect of the 
virus was calculated by mean of the hexosaminidase assay, and expressed in 
terms of cell survival as percentage of vital staining (i.e. total living cells) in 
treated versus mock cultures. The cytolytic action of the virus was instead 
measured by the G6PD assay, and estimated as percentage of fully lysed 
cells (i.e. total enzymatic activity) in infected versus mock populations. Data 
from the hexosaminidase measurements are shown for multiplicities of 
infection from 0.625 to 10 pfu/cell (Fig. 19A) while the most representative 
differences on cell permissiveness to H-1PV are further displayed in parallel 
with the G6PD data at 5 pfu/cell (Fig. 19B and C). 
The experiments confirmed the fact that normal untransfected REFs 
were poorly sensitive to H-1PV-induced killing. GFP-transfected control REFs 
did not show an increased susceptibility to H-1PV, excluding a side effect of 
the transfection procedure on the phenotype acquired by the selected cells 
(data not shown). In agreement with the literature (Franza et al., 1986; 
Serrano et al., 1997), ras overexpression alone drove cells to senescence 
and did not induce changes in REFs behaviour toward H-1PV infection. 
Surprisingly, single oncogenes of the same class played selective roles. On 
the one hand, immortalization through p53 inactivation was not sufficient to 
boost cell sensitivity to H-1PV, and SV40-largeT overexpression rendered 
REFs more prone to the killing but the overall effect was not statistically 
significant. On the other hand, c-myc overexpression alone was enough to 
sensitize REFs to the virus cytotoxic action (Fig. 19B). 
The nature of oncogene cooperation affected the outcome of cell 
permissiveness to the virus. Remarkably, full cell transformation was not 
necessary for the acquisition of permissiveness to the virus, since cells 
immortalized by the activation of multiple oncogenes were powerfully killed.  
ras activation increased cells sensitivity when expressed in cooperation with 
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Figure 19. H-1PV-induced killing of REFs transfectants. Cell were analyzed by means of the 
hexosaminidase assay 48 h after infection with parvovirus H-1 at multiplicities of infection from 
0.625 to 10 pfu/cell (A) or 5 pfu/cell (B). Cell survival is expressed as percentage of vital staining 
(i.e. total living cells) in infected versus mock cultures. (C) Cell lysis was detected by measuring 
the release of G6PD into the medium 48 h after H-1PV infection (5 pfu/cell). Data are expressed as 
total G6PD activity in mock versus infected cultures, normalized with respect to a fully lysed 
positive control. Statistically significant differences (p<0.05) are indicated by a star (*). Average 
values and standard deviation bars from three independent experiments, each in triplicate.
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c-myc and SV40 large T immortalizing oncogenes, but not with p53dn. 
Indeed, ras*/myc and ras*/largeT REFs were characterized by the most 
enhanced transformed phenotype, and were sensitive to H-1PV already after 
infection at 0.625 pfu/cell. On the contrary, ras*/p53dn transformed REFs 
were almost as susceptible as myc, myc/p53dn and myc/largeT immortalized 
cells (Fig. 19A). 
Interestingly, H-1PV acquisition of an oncolytic capacity responsible 
for active cell killing was dependent on c-myc and/or SV40-largeT 
overexpression. After infection at 5 pfu/cell, the inhibition of cell growth 
correlated almost completely with the ability of H-1PV to induce lysis in 
largeT, myc, myc/largeT, myc/p53dn, ras*/largeT and ras*/myc transfected 
REFs. In contrast, G6PD release accounted for only 20% fully lysed cells in 
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the ras*/p53dn transfectants versus a 60% decrease in cell survival. Hence, 
the nature of cell sensitivity to the virus (necrosis vs. active cell lysis) was 
also associated to the activation of selective oncogenes. The amount of G6PD 
activity measured in the supernatant of infected normal, p53dn and ras* 
transfected REFs was estimated as basal release resulting from experimental 
handling (Fig. 19C). 
In order to exclude the possibility that the higher sensitivity of certain 
transfectants was due to multiple cycles of infection, hexosaminidase and 
G6PD assays were further performed on cells infected for 48 h with H-1PV 
(0.625 to 10 pfu/cell), and incubated with neutralizing antibodies raised 
against H-1PV capsid proteins, diluted 1:200 in the culture medium 5 h post 
infection (data not shown). The concentration of neutralizing antibodies was 
chosen according to a preliminary optimization experiment, as to be the 
minimal quantity sufficient to block viral infection, and exclude a second 
round of infection occurring during 2 days incubation. The outcome of the 
experiments was not different from that already described, thus confirming 
that the observed effects of different oncogenes on REFs permissiveness to 
H-1PV-induced killing were consequence of a single viral infection. 
In conclusion, even if the lytic action of the virus was supported also 
in cells where SV40-largeT was overexpressed alone, only c-myc was 
capable of significantly sensitizing rat embryo fibroblasts to parvovirus H-1-
dependent cytotoxicity. 
 
 
4.11. Oncogenes differently impinge on parvovirus H-1 capacity of 
inducing cell cycle arrest in infected rat embryo fibroblasts 
 
Parvoviral infections provoke cell cycle perturbations, since both 
autonomous parvovirus minute virus of mice and human parvovirus B19 
have been show to induce a multistep cell cycle arrest in G1-, S-, and        
G2-phase after infection of permissive cells (Morita et al., 2003; Op De Beeck 
et al., 1995). In general, S- and G2-phase arrest has been well documented, 
the former confirmed to be p53-dependent, the latter to be both p53- and 
p21-dependent (Op De Beeck and Caillet-Fauquet, 1997). More recently,   
G1-phase arrest has been observed to be mediated by the viral protein NS1 
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(Op De Beeck et al., 2001). It was therefore decided to analyze whether    
H-1PV triggered a DNA damage checkpoint by activating a p53-dependent 
pathway. 
Cell cycle distribution was studied in transfected REFs to investigate if 
different oncogenes could play a role in the way cells would eventually 
undergo a virus-mediated phase arrest. After 24 h infection with H-1PV      
(5 pfu/cell), cells were harvested and stained with propidium iodide (20 
µg/ml) in order to determine their DNA contents by flow cytometry. Neither 
infected normal REFs nor both p53dn and ras* transfectants did show 
substantial perturbation in the cell cycle distribution with respect to the mock 
populations (Fig. 5A and C). SV40-largeT overexpression instead induced cell 
arrest at the G2/M phase transition, and proved to have a higher impact in 
the double transfectants than myc and ras* activation (Fig. 5C). Besides,    
c-myc overexpression mediated cell arrest at the G0/G1 phase transition, 
while the fully transformed ras*/myc and ras*/p53dn transfected REFs 
displayed a more classical behavior, undergoing respectively S- and           
S-G2/M-phase arrest (Fig. 5B and C). 
A 4% increase in the G2/M portion of the myc/p53dn infected 
population was noted. This increment was observed in the p53dn and ras* 
REFs as well, but in the myc/p53dn transfectants corresponded to a doubling 
of the G2-phase subpopulation. Moreover, the percentage of the G1 mock 
population was higher in these transfectants than in the other cells, 
suggesting that more cells might have been resting in the G0/G1-phase (Fig. 
20C, underlined). Since the low genetic complexity of parvoviruses renders 
them highly dependent on cellular factors that are expressed during the     
S-phase of the cell cycle (Cotmore and Tattersall, 1987; Deleu et al., 1998), 
the percentage of myc/p53dn REFs in S-phase was compared with the total 
portion of infected cells in order to estimate the importance of the G2-phase 
increase. If the two percentages had been almost equal, all infected cells 
would have been in S-phase and eventually undergone a G2-phase arrest. 
Because H-1PV infected the 63% of myc/p53dn transfected cells (Fig. 21B), 
a fraction 2.5 times bigger than the S-phase subpopulation (Fig. 20C, 
underlined), it was possible to conclude that the cell arrest at the G2/M phase 
transition was in this context not significant. 
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Figure 20. H-1PV-induced cell cycle arrest. Propidium iodide staining was performed on REFs 
transfectants 24 h after infection with parvovirus H-1 (5 pfu/cell). Flow cytometry panels for 
normal (A) and ras*/p53 transfected (B) REFs are shown [FL2-H and FL2-A channels]. Data for 
all transfectants (C) are reported as average values ± standard deviations from three 
independent experiments. myc/p53 REFs are underlined, for explanations refer to text.
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Taken together, the data revealed that all REFs transfectants were 
proliferating prior to H-1PV infection; hence, the percentage of cells in        
S-phase could not explain the differences in permissiveness to parvovirus   
H-1. Moreover, virus-induced cell death was not associated with a particular 
perturbation of the cell cycle and therefore occurred independently of p53. 
 
 
4.12. REFs immortalization by single oncogene transfection 
differently affects parvovirus H-1 life cycle 
 
It was at this point important to investigate if oncogenes or 
tumorsuppressor expression differently affected H-1PV life cycle. REFs 
transfectants were therefore assessed for the expression of the viral non 
structural protein NS1 and the replication of the viral genome. 
First of all, it was considered whether the reduced cytopathic effect 
observed in certain REFs transfectants correlated with a lower number of 
infected cells. FITC-conjugated monoclonal antibodies against NS1 were used 
to evaluate viral protein expression by flow cytometry, 24 h after infection of 
normal and transfected REFs with H-1PV  (5 pfu/cell). Data were processed 
with the CellQuest™ software from BD Bioscience (Fig. 21A and B). In the 
transfectants permissive to H-1PV, the portions of NS1-expressing cells 
correlated with the percentages of the infected subpopulations, as deducted 
by the survival curves (Fig. 21B, compared to Fig. 19B). NS1 was found to 
be expressed in 30-35% of normal and p53dn transfected REFs as well, 
although these cells proved to be insensitive to the virus, supporting the 
hypothesis that NS1 cytotoxic action is enhanced by cell transformation 
(Mousset et al., 1994). Most interestingly, NS1 expression was almost absent 
in ras* transfected REFs, being detected only in 10% of the cell population 
(Fig. 21B). This data suggested that ras activation alone induced changes in 
REFs genetic expression profile that interfered with the early steps of viral 
infection, while in combination with other oncogenes it triggered viral protein 
expression. 
A second aim was to study oncogenes effect on H-1PV genome 
replication, to evaluate viral DNA conversion into a monomeric replicative 
form after host cell entry, and viral single-stranded DNA production later 
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Figure 21. H-1PV genome replication and protein expression. FITC-NS1 
staining was performed on normal and transfected REFs 24 h after infection 
with parvovirus H-1 (5 pfu/cell). Flow cytometry panels for ras*/myc REFs (A) 
are shown [FL1-H channel]. Data for all transfectants (B) are reported as 
average values ± standard deviations from three independent experiments. (C) 
Southern blotting analysis of H-1PV replication in REFs transfectants, 24 h 
after mock treatment or infection (5 pfu/cell). dRF = dimer replicative form; 
mRF = monomer replicative form; SS = single-stranded DNA.
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after infection. Low-molecular-weight DNA was extracted from cell pellets 24 
hours after H-1PV (5 pfu/cell) or mock treatment, and analysed by Southern 
blot performed using an NS1 gene-specific DNA probe. The monomeric 
replicative form of viral DNA (mRF) was detected in all transfectants, though 
the respective bands were weak for normal and p53dn transfected REFs, and 
barely visible for ras* transfected cells (Fig. 21C). After infection, the input 
single-stranded DNA of H-1PV (ssDNA) is first converted into a monomeric 
form in a process mediated by several host S-phase factors that does not 
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rely on viral proteins (Cotmore and Tattersall, 1995). In the largeT REFs and 
in all the transfectants sensitive to H-1PV, a marked mRF band plus a ssDNA 
and a dimeric replicative form (dRF) bands were observed, even if unsteady 
in intensity (Fig. 21C). These data were in accordance with the observations 
on NS1 expression (Fig. 21B), since the elongation mechanism resulting in 
the formation of double stranded monomeric and multimeric intermediates 
as well as the encapsidation process of the viral progeny have been 
demonstrated to be NS1 dependent (Cotmore and Tattersall, 1995). The 
synthesis of progeny ssDNA appeared nonetheless to be more pronounced in 
the fully transformed and in the myc/p53dn REFs. 
In summary, immortalization through single oncogenes expression 
had different effects on the capacity of REFs to support full viral infection.   
H-1PV was not able to replicate in cells where p53 was inactivated, in 
agreement with the lack of cell permissiveness previously discussed, while it 
could produce a progeny ssDNA in cells sensitized by c-myc or SV40-largeT 
overexpression, alone or in combination with ras activation. Furthermore, the 
quality of oncogene cooperation seemed to play a role since ssDNA synthesis 
was comparable between the single transfectans and the double 
immortalizing myc/largeT REFs while it became massive in the double 
immortalizing myc/p53dn as in fully transformed cells. 
 
 
4.13. Apoptosis is triggered after parvovirus H-1 infection of 
ras*/p53dn transfected REFs 
 
Once evaluated the effect of genetic alterations on REFs 
permissiveness to parvovirus H-1-induced cytosuppression and active killing, 
it was decided to investigate the death pathways activated after infection of 
these cells to study if and how the different oncogenes were influencing the 
intracellular signaling controlling programmed cell death.  
To determine whether parvovirus-induced death was of apoptotic 
type, the induction of caspase 3 activity was monitored 24 and 48 h post 
infection of REFs transfectants with H-1PV (5 pfu/cell) incubating cell lysates 
with a synthetic substrate and measuring the fluorescence intensity of the 
cleaved product (Fig. 22A). Infected populations were compared with 
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untreated control samples and a 4–5 fold increase in caspase 3 activity levels 
was considered a hallmark of strong apoptosis induction. This threshold was 
established upon the observations obtained in a preliminary experiment in 
which apoptotic cell death was detected in normal REFs 48 h post treatment 
with cisplatin (2.5 µg/ml) according to several parameters: activation of 
caspases 3 and 9, DNA ladder formation after genomic DNA extraction, 
presence of apoptotic bodies after Hoechst staining of infected cell (data not 
shown). 
Figure 22. Apoptosis is triggered in ras*/p53dn transfected REFs 
after H-1PV infection. (A) Caspase 3 activity was monitored at 24 and 
48 h after H-1PV infection (5 pfu/cell) of normal and transfected 
REFS. Average values and standard deviation bars from three 
independent experiments. (B) ∆Ψm permeabilization was analyzed by 
JC-9 staining of REFs transfectants 24 h post infection with 
parvovirus H-1 (5 pfu/cell - blue) or 30 min after treatment with H2O2
(5 mM - red). Flow cytometry panels for normal and myc REFs   
[FL1-H channel] versus ras*/p53 transfectants [FL1-H or FL1-H vs. 
FL2-H channels].
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Apart for a marginal activation of caspase 3 measured in normal REFs 
between 24 and 48 h after H-1PV infection, signs of ongoing apoptosis were 
not identified in any of the other transfectants, with the exception of 
ras*/p53dn REFs. In these cells, caspase 3 activation fold did not notably 
increased at 24 h post infection with H-1PV but showed a significant boost at 
48 h post infection, leading to the hypothesis that ras*/p53dn transfectants 
underwent apoptosis at a late time point after infection. 
To confirm this assumption, it was tested whether the virus was 
triggering the activation of caspase 3 via the intrinsic pathway, thus inducing 
an alteration of the mitochondrial membrane potential. Mitochondrial 
membrane depolarization assays were performed by flow cytometry 24 h 
after infection of REFs transfectants with parvovirus H-1 (5 pfu/cell), 
measuring the potential-dependent accumulation of JC-9 dye. Positive 
control cells treated with H2O2 5 mM were included; data for normal, myc 
and ras*/p53 transfected REFs are shown (Fig. 22B). The appearance of a 
distinct sub-population with increased FL1-H values, an indication of the 
occurrence of ∆Ψm alteration, was recorded in the ras*/p53 transfectants 
after stimulation with H2O2 or viral infection. Moreover, the two peaks almost 
overlapped, suggesting that the degree of mitochondrial membrane 
depolarization in the infected cells was rather massive, comparable with the 
positive control situation where H2O2 high concentration was used to induce 
a strong effect on the disruption of ∆Ψm. On the contrary, in all the other 
REFs transfectants the FL1-H peak of the infected population overlapped with 
that of the mock population and only the H2O2-treated cells showed an 
increased value. 
In conclusion, in the ras*/p53dn transfected REFs a permeabilization 
of outer mitochondrial membrane occurred at 24 h post infection, which was 
followed by caspase 3 activation at 48 h post infection. Independently of the 
effect of the different oncogenes towards the acquisition of sensitiveness to 
the virus, apoptosis was not found to be triggered after parvovirus H-1 
infection in any of the other REFs transfectants. Therefore, the virus 
jeopardized the survival of these cells through another death pathway. 
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4.14. Acidic compartments swelling and leakage after H-1PV 
infection of permissive REFs  
 
Given H-1PV-induced activation of non-apoptotic pathways in human 
glioma cells, it was decided to investigate the accumulation of acidic vesicles 
upon viral infection in the REFs system, to verify whether this novel death 
mechanism occurred in other cell type or was limited to brain tumor cells. 
REFs transfectants were infected with H-1PV (5 pfu/cell) and acridine orange 
staining was analyzed by flow cytometry (Fig. 23A) and fluorescence 
microscopy (Fig. 23B) at 24 and 48 h post infection. Neither acridine orange 
shifts of fluorescence nor changes in the morphology of dye-positive 
compartments were recorded in H-1PV-resistant primary REFs (Fig. 23A and 
B), or p53dn and ras* transfected cells (data not shown). On the contrary, 
already at 24 h post infection a double peak was detected in the FL3-H 
profile of largeT transfected REFs and all the transfectants sensitive to H-1PV 
(Fig. 23A; displayed only myc, myc/p53dn and ras*/largeT transfected cells) 
with the exception of ras*/p53dn-REFs. A double peak corresponded to both 
increase in number and/or size of acidic vesicles and leakage of acidic 
compartments, indicating that following H-1PV infection the accumulation of 
acidic vacuoles was occurring faster in the REFs system than in the glioma 
NCH82 cells (Fig. 8B). In fact, a 48 hours infection led to the leakage of 
acidic compartments in the whole infected cell population (Fig. 23A; shown 
for ras*/largeT transfectants). Remarkably, at this time point a left shift in 
the acridine orange fluorescence was observed also in the ras*/p53dn REFs, 
a possible indication of membrane blebbing in the last stage of virus-induced 
apoptosis (Fig. 22A and 23A). 
It became at this point evident that REFs transfected with SV40 largeT 
antigen only, though showing a highly variable and not statistically 
significant response to H-1PV infection, behaved at a molecular level like all 
the other transfectants sensitive to H-1PV-induced killing. Upon parvovirus 
H-1 infection of these cells, acidic compartments initially increased in number 
and accumulated in infected cells, finally leaking and releasing their content 
in the cytosol. Moreover, the mock population basal amount of acidic vesicles 
was progressively higher in the single oncogene immortalized-, in the double 
oncogene immortalized- and in the transformed-REFs as compared to 
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Figure 23. Accumulation of acidic vescicles in the cytosol of REFs transfectants sensitive 
to H-1PV infection. Acridine orange staining of normal and largeT, myc, myc/p53dn, 
myc/largeT, ras*/p53dn, ras*/largeT and ras*/myc transfected REFs infected or not with 
H-1PV (5 pfu/cell). (A) Flow cytometry analysis at 24 and 48 h post infection; FL3-H 
channel. (B) Fluorescence microscopy at 24 h post infection; red filter, magnification 
800x. 
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primary cells (Fig. 23B; displayed only largeT, myc/largeT and ras*/myc 
REFs). The different oncogenes therefore appeared to influence this virus-
induced mechanism, in terms of rendering the cells less or more prone to its 
activation by modulating their acidic vesicles physiological levels. This 
observation pointed to the identification of the acidic compartments with 
autophagy-like vesicles and to the hypothesis that H-1PV was triggering a 
non-apoptotic cell death through the activation of autophagy. 
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4.15. Autophagy is triggered upon parvovirus H-1 infection of 
permissive REFs 
 
To verify whether REFs adapted to changes in the cellular metabolism 
induced by oncogene-driven immortalization and/or transformation through 
the activation of autophagic degradative pathways (Cuervo, 2004), 
parvovirus H-1-induced activation of autophagy was further investigated in 
the REFs system. Primary cells and transfectants permissive to the virus 
were infected with H-1PV (5 pfu/cell) for 24 h and the expression of Beclin1 
and LC3 I/II isoforms was analyzed by Western blot. 
When compared to the normal phenotype, Beclin1 basal expression 
was slightly increased in all REFs transfectants tested, with the exception of 
ras*/p53dn-transfected cells. Nevertheless, considering the different cell 
populations one by one, no change in Beclin1 expression was observed in 
mock-treated versus infected cells (Fig. 24, 2nd lane). It was therefore 
concluded that oncogene-driven immortalization or transformation did not 
impinge on the expression of this pro-autophagic factor, which was not 
influenced by parvovirus H-1 infection too. 
LC3-I expression turned out to be affected by the induction of an 
immortalized or transformed phenotype in rat embryo fibroblasts, since it  
was stronger in all transfectants tested compared to normal REFs (Fig. 24, 
4th lane). In agreement with the data collected so far, the appearance of the 
LC3-II band was observed 24 h after infection with H-1PV (5 pfu/cell) in 
largeT and myc single-transfected REFs, in the double oncogenes 
immortalized- and in transformed-cells, but not in the ras*/p53dn 
transfectants. Besides, when analyzing myc transfected versus largeT 
transfected cells, and ras*/myc versus ras*/largeT REFs, the conversion of 
LC3-I to LC3-II seemed to be more pronounced in myc overexpressing cells. 
Since the formation of the autophagosome and its fusion with lysosomes is a 
rather fast and dynamic event, the basal activation of autophagy in the mock 
populations was most likely behind the threshold for the detection of a 
second band corresponding to the LC3-II isoform. This non-apoptotic 
programmed cell death pathway was then triggered after parvovirus H-1 
infection in cells not predisposed to the activation of apoptosis. Moreover, a 
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Figure 24. Autophagy activation following parvovirus H-1 infection of REF transfectants. Western 
blot analysis for the expression of NS1, Beclin1, LC3 I and II isoforms in cells infected for 24 h with 
H-1PV (5 pfu/cell) or mock-treated. β tubulin was used as a standard for protein load matching.
barely visible band for the LC3-II isoform was noticed in infected normal 
REFs as well, indicating that autophagy and not apoptosis was the 
preferential killing mechanism promoted by the virus.  
In summary, immortalization and transformation modulated the basal 
levels of the autophagic process in REFs transfectants. Autophagy was 
boosted upon parvovirus H-1 infection in REFs overexpressing c-myc and/or 
SV40 large T antigen. 
 
 
4.16. Parvovirus H-1 infection of sensitive REFs induces cathepsin B 
cytosolic activation and cystatin B down-regultation  
 
With the exception of ras*/p53dn transfected cells, parvovirus H-1 
appeared to trigger in permissive REFs transfectants a non-apoptotic 
mechanism similar to that observed in NCH82 glioma cells. To corroborate 
this hypothesis, cathepsin B intracellular activity was analyzed 24 h after 
infection with H-1PV (5 pfu/cell). An average 2-fold increase in cathepsin B 
cytosolic activity was detected in infected REFs overexpressing c-myc and/or 
SV40 large T antigen (Fig. 25A). The cytosolic versus lysosomal cathepsin B 
ratio was instead not affected by H-1PV infection of normal, p53dn, and ras* 
transfected REFs, in agreement with the previous data. In contrast to what 
observed in human gliomas (Fig. 7D), apoptosis initiation in ras*/p53dn REFs 
seemed interestingly to occur independently of cathepsin B activation, as no 
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Figure 25. Cathepsin B cytosolic activation and cystatin B down-regulation upon H-1PV infection 
in REFs transfectants. Cells were infected for 24 h with H-1PV (5 pfu/cell). (A) Cathepsin B activity, 
expressed as relative amount in cytosol versus lysosomes. RFU, relative fluorescence units; 
average values and standard deviation bars from three independent experiments, each in triplicate.
(B) Immunofluorescence assay for cathepsin B localization in normal and ras*/myc REFs; an anti-
rabbit FITC-conjugated secondary antibodies were used; nuclei were stained with DAPI.   
(C) Western blot analysis for the expression of cathepsin B and its inhibitor cystatin B; the
parvoviral NS1 protein served as a marker for H-1PV infection while β tubulin was used as a 
standard for protein load matching.
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difference in the cytosolic versus lysosomal amount of this protease was 
detected (Fig. 25A). H-1PV-induced cytosolic activation of cathepsin B was 
additionally substantiated in ras*/myc transfectants versus normal REFs by 
immunofluorescence analysis (Fig. 25B). Furthermore, cathepsin B and 
cystatin B levels were measured by Western blotting in the REFs 
transfectants infected for 24 h with H-1PV (5 pfu/cell), to evaluate whether 
parvovirus H-1 could regulate cathepsin activity through the modulation of 
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its inhibitor (Fig. 25C). The expression of cystatin B was clearly down-
regulated in infected versus mock-treated cells. Surprisingly, H-1PV-
dependent cystatin B down-regulation was observed even in primary REFs 
and cells that were insensitive to virus-induced killing. Cathepsin B levels 
resulted to be in average almost unchanged, slightly reduced in normal and 
ras*/p53dn REFs, increased in infected p53dn, myc and ras*/largeT 
transfectants. 
In summary, cathepsin B cytosolic activation occurred in all REFs 
sensitive to H-1PV with the exclusion of ras*/p53dn transfected cells. On the 
contrary, the reduction in the expression levels of the cathepsins inhibitor 
cystatin B was a general effect of parvovirus H-1 infection, occurring even in 
cells that were not killed by the virus. 
 
 
4.17. Autophagy inhibition rescues permissive REFs transfectants 
from H-1PV-mediated cell killing 
 
To substantiate the previous findings on the assumed roles of cytosolic 
cathepsin B and autophagic vesicles in H-1PV-dependent cell killing, the 
capacity of autophagy and cathepsins inhibitors to prevent parvovirus H-1-
induced cell death was finally analyzed in the REFs study system. 
All transfectants were infected for 48 h with H-1PV (5 pfu/cell) and co-
incubated with 3-MA (500 µM), E64d (1 µM), Ca-074 Me (10 µM), or DEVD-
CHO (20 µM); cell survival was quantified by mean of the hexosaminidase 
assay (Fig. 26A). Supporting the evidence on autophagy activation upon    
H-1PV infection, all transfectants sensitive to virus-induced cell killing were 
protected by 3-MA treatment, with the exception of ras*/p53dn transfected 
REFs. On the contrary, the latter was the only cell population to be rescued 
from death by incubation with the caspase 3 inhibitor DEVD-CHO. Cathepsin 
B inhibitor Ca-074 Me was almost as effective as 3-MA in myc/p53dn REFs 
while exerted a partial protection in largeT, myc, and ras*/largeT 
transfectants. Finally, E64d was able to moderately block H-1PV cytotoxicity 
in myc and ras*/largeT transfected REFs. 
Taken together, these data indicated that in general it was possible to 
prevent virus-promoted cell killing by chemically blocking the initiation event 
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Figure 26. Effect of autophagy and cathepsins inhibitors on cell rescue from H-1PV-induced killing. 
REFs transfectants were incubated with 3-MA, E64d, Ca-074 Me and DEVD-CHO at the indicated 
concentrations, 5 h post infection with parvovirus H-1 (5 pfu/cell). (A) Hexosaminidase assay 
performed 48 h after infection of the cells. (B) Acridine orange staining 24 h after treatment of 
myc/p53dn and ras*/largeT REFs. Fluorescence microscopy, red filter, magnification 800x.
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of the autophagic process. Oncogenes combined or independent 
overexpression differently affected REFs responsiveness to cathepsins 
inhibitors Ca-074 Me and E64d, but it was not possible to assign an 
oncogene a key role or determine a specific effect in response to the 
acquisition of a particular phenotype. Nevertheless, cathepsins inhibitors’ 
capacity of rescuing REFs transfectants from cell death was reduced, with a 
few exceptions, in respect to the effect of these compounds in NCH82 glioma 
cells, and to 3-MA overall action. 
Above observations pointed towards the initiation of autophagic cell 
death as early step during viral infection. It was therefore supposed that 
cathepsins inhibitors Ca-074 Me and E64d would not have prevented the 
formation of autophagic vesicles in REFs transfectants infected with 
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parvovirus H-1. To verify this, acridine orange staining was performed on 
myc/p53dn and ras*/largeT trasfected REFs at 24 h post infection with       
H-1PV (5 pfu/cell) and co-culture with 3-MA (500 µM), E64d (1 µM), or     
Ca-074 Me (10 µM) (Fig. 26B). As already reported, an increased amount of 
acidic vesicles was observed in the cytosol of infected versus mock-treated 
cells. As expected, incubation with 3-MA markedly reduced the number of 
acridine-positive compartments while both Ca-074 Me and E64d did not 
inhibit their accumulation. 
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  Discussion 5 
 
5.1. Autophagy activation in NCH82 human glioma cells infected 
with parvovirus H-1 
 
The action of successful anticancer drugs depends largely on their 
ability to trigger cell death, in particular apoptosis, in tumor cells. Their 
efficacy is often impaired by death escape mechanisms developed by cancer 
cells to evade anti-tumorigenic signals (Hanahan and Weinberg, 2000). 
Drugs inducing apoptosis fall into two classes according to their ability to 
activate either the extrinsic receptor-dependent apoptotic pathway, as do 
TRAIL and TNFα (Lavrik et al., 2005), or the intrinsic pathway, as do cisplatin 
and other DNA-damaging agents (Danial and Korsmeyer, 2004). Parvovirus 
H-1 is able to kill human glioma cells by circumventing their resistance to 
inducers of both the intrinsic and extrinsic apoptotic pathways (Di Piazza et 
al., 2007). H-1PV activates a type of death that resembles autophagy but 
shows exclusive features. This uniqueness enables H-1PV to kill glioma cells 
even though autophagy, like apoptosis, is usually down-regulated in human 
tumors including high-grade gliomas (Gozuacik and Kimchi, 2004). 
Investigation of the interaction of H-1PV with gliomas can thus help to 
unravel of novel facets of cell death mechanisms and to develop new 
therapeutics likely to be effective against tumors that resist conventional 
anticancer treatments. 
H-1PV-induced glioma cell death differs from apoptosis, since 
organelle membrane integrity is maintained and the killing effect does not 
depend on caspase 3 activation. Besides, infected cells exhibit several 
hallmarks of autophagy: increased acidic vesicle content, structural 
identification of acidic compartments with autophagosomes and 
autolysosomes, increased conversion of LC3-I to II isoform, Beclin1 
overexpression. Autophagy is an evolutionarily conserved and highly 
regulated homeostatic process that degrades cytoplasmic components and 
damaged or surplus organelles for protein removal or turnover (Levine and 
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Klionsky, 2004). Autophagy is believed to play a fundamental but 
controversial role in cancer development, having been involved in tumor cells 
killing but also protection from unfavourable conditions (Kondo et al., 2005). 
Surprisingly, H-1PV can still kill glioma cells that are deficient in autophagic 
processes. In particular, NCH82 cells lack the PTEN phosphatase (Di Piazza 
et al., 2007), which triggers autophagy by interfering with the class I PI3-
kinase / Akt survival pathway (Arico et al., 2001). Moreover, Bcl-2 is 
suggested to play a major role in the control of autophagy, being able to 
either sensitize cells to autophagy (Shimizu et al., 2004), inhibit autophagy 
(Boya et al., 2005), or permit autophagy to develop by inhibiting apoptosis 
(Degenhardt et al., 2006). Interestingly, Bcl-2 overexpression does not 
hamper the induction of autophagic death in H-1PV-infected glioma cells, 
even though it does prevent H-1PV from causing permeabilization of the 
outer mitochondrial membrane and hence from triggering caspase 3 
activation. Parvovirus H-1 is thus unable to interfere with the anti-apoptotic 
function of Bcl-2, but it bypasses its protective effect against autophagy. 
Consequently, H-1PV can kill glioma cells under conditions where caspase 3 
is not activated. In apoptosis-competent glioma cells, H-1PV infection leads 
to the activation of effector caspases. In apoptosis-resistant glioma cells, the 
activation of effector caspases may reinforce the cytotoxic action of the virus 
but is not necessary for cell killing through autophagy. 
A possibility to explain how parvovirus H-1 triggers a Bcl-2-
independent non-apoptotic death is that cell infection by H-1PV induces a 
starvation-like status leading to induction of autophagy. The formation of 
autophagic vesicles is reported to be activated in response to stress 
conditions like nutrient starvation or viral infection, the initiating event being 
the phosphorylation of translation factor eIF2α by the RNA-dependent 
protein kinase (PKR) (Talloczy et al., 2002). Although it is unknown whether 
H-1PV can activate PKR, it has been reported that cells resistant to the virus 
do not express TCTP, a factor involved in tumor cell control of translation 
(Tuynder et al., 2004). Starvation-associated autophagy begins with the 
isolation of double-membrane-bound structures inside an intact cell (Kihara 
et al., 2001). This process is initiated by a dynamic multiprotein complex 
between class III PI3K, Beclin1, UVRAG and Bcl-2 (Liang et al., 2006) that 
can be suppressed by 3-MA, an inhibitor of class III PI3K (Petiot et al., 
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2000). 3-MA blocks the formation of acidic vesicles upon H-1PV infection 
increasing cell survival and rescuing glioma cells from virus-induced death. 
Autophagy induction by H-1PV might be mediated by Beclin1, since the 
expression of this pro-autophagic factor is increased after parvovirus H-1 
infection of glioma cells while on the opposite the low levels of Beclin1 in 
tumor cells correlate with reduced sensitivity towards starvation-induced 
autophagy (Liang et al., 1999). Against this hypothesis, Beclin1 can be 
sequestrated by Bcl-2 (Pattingre et al., 2005), which is shown not to 
interfere with parvovirus H-1 cytotoxicity. Nevertheless, the formation of 
autophagic vacuoles occurs also upon parvovirus H-1 infection of NCH82 
glioma cells overexpressing Bcl-2 (data not shown). Despite the fact that a 
direct investigation of the effect of parvovirus H-1 on the interaction between 
Beclin1 and Bcl-2 is missing, it is logical to suppose that Beclin1 is involved 
in the autophagic death mechanism triggered by parvovirus H-1 after 
infection of glioma cells. To further confirm this assumption, it would be 
interesting to evaluate whether Beclin1 knockdown by a siRNA approach is 
blocking parvovirus H-1-induced cell death by impeding the onset of 
autophagy. The signaling pathway composed of PI3-kinase/Akt/mammalian 
target of rapamycin (mTOR) plays a central role in the regulation of cell 
proliferation, growth, differentiation and survival (Oldham and Hafen, 2003; 
Vogt, 2001). Rapamycin specifically inhibit the function of mTOR by blocking 
the phosphorylation of downstream molecules like p70S6 kinase (p70S6K) 
and eukaryotic initiation factor 4E-binding protein 1 (4EBP1) (Huang and 
Houghton, 2003; Sawyers, 2003), thus controlling the activation of 
autophagy. Indeed, treatment of human glioma cell with mTOR inhibitor, 
alone or in synergistic combination with PI3-kinase/Akt inhibitors (Takeuchi 
et al., 2005) or mTOR siRNA (Iwamaru et al., 2006), induces autophagic cell 
death. In NCH82 glioma cell, starvation-like autophagy is triggered after 
treatment with either H-1PV or rapamycin. Moreover, preliminary 
experiments indicate that parvovirus H-1 infection correlates with a 
decreased phosphorylation level of p70S6K but not of 4EBP1 (data not 
shown) as recently reported to occur upon rapamycin treatment of 
established glioma cell lines (Iwamaru et al., 2006). Altogether, H-1PV 
appears to trigger autophagy in infected glioma cells inducing a starvation-
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like status leading to the negative regulation of the mTOR pathway and to 
Beclin1-promoted formation of autophagosomes. 
Interestingly, oncolytic myxoma virus has been shown to kill 
glioblastoma-derived cultures (Lun et al., 2005), and tumor cell 
sensitiveness to the virus has been recently demonstrated to be dependent 
on the interaction between the Akt kinase and the viral M-T5 protein, which 
is required for viral replication (Wang et al., 2006). Myxoma virus-induced 
autophagy has not been investigated, but a recent publication reports on the 
possibility to extend the host range of this virus to non-permissive tumor 
cells by rapamycin co-treatment (Stanford et al., 2007). Other pathogens 
besides parvovirus H-1 have been shown to activate autophagy. This process 
may be a defense mechanism by which cells digest infectious agents 
(Kirkegaard et al., 2004; Liang et al., 1998) or generate an immune 
response (Lee et al., 2007; Paludan et al., 2005), the mechanism being 
hijacked by some viruses to the benefit of their life cycle (Belov et al., 2007; 
Jackson et al., 2005; Wileman, 2006). Remarkably, human parvovirus B19 
kills erythroid progenitor cells by triggering apoptosis, but mitochondrial 
autophagy is activated in a erythroid cell line resistant to the virus 
(Nakashima et al., 2006). Moreover, a conditionally replicating adenovirus 
has been observed to induce glioma in vitro suppression and in vivo 
regression by inducing mTOR inhibition-dependent autophagy (Ito et al., 
2006). It might be speculated that in H-1PV-infected glioma cells, autophagy 
inhibition allowing uncontrolled proliferation is counteracted by autophagy 
induction in response to the pathogen. Whether autophagy contributes to the 
multiplication or propagation of nuclear-replicating parvoviruses remains a 
matter of debate. 
 
 
5.2. Cathepsins and cystatins contribution to the autophagic death 
triggered by parvovirus H-1 in NCH82 glioma cells  
 
Another unique feature of H-1PV-induced glioma cell killing is its 
requirement both for the formation of acidic vesicles and for activation of 
cathepsins in the cytosol. Lysosomes have been linked to cell death in 
multiple ways, as they are direct components of the autophagy machinery 
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(Mizushima et al., 2002) but can also promote programmed cell death 
execution through lysosomal membrane permeabilization (LMP) and resulting 
release of lysosomal enzymes into the cytosol (Foghsgaard et al., 2001; 
Guicciardi et al., 2000). Chemically-induced inhibition of autophagy or 
lysosomal cathepsins blocks respectively the early and the late steps of viral 
infection and rescues glioma cell from death. In fact, autophagy still occurs 
when cytosolic cathepsins are inactivated while cathepsins are prevented to 
be activated in the cytosol of infected cells when autophagy is inhibited. 
Thus, in the sequence of events leading to cell death, parvovirus H-1 
promotes the onset of autophagy, which in turn is involved in lysosomal 
membrane permeabilization and cathepsins release. Moreover, the inhibition 
of “free” cathepsin activity in apoptosis-competent NCH82 cells reduces      
H-1PV cytotoxic activity and prevents the virus from processing effector 
caspases. Yet cathepsin-dependent caspase activation is not essential to 
virus-induced glioma cell death, since Bcl-2 suppresses the former but not 
the latter. Further study is thus needed to identify the cellular targets of 
cytosolic cathepsins mediating H-1PV cytotoxicity. 
Since cathepsins are normally confined to the lysosomes, their 
presence in an active form in the cytosol of infected cells implies that H-1PV 
causes their release by LMP. Interestingly, this relocation is specific, since 
the intracellular distribution of other lysosomal enzymes of similar molecular 
weight is not altered in infected cells. Furthermore, acidic vesicles containing 
lysosomal enzymes remain structurally intact until the cells eventually die. 
This means that cytosolic cathepsin activation takes place before the onset of 
detectable cell degeneration. H-1PV thus does not appear to induce an 
overall destabilization of lysosomal membranes. Permeabilization of vesicles 
may result from reactive oxygen species (ROS) production (Antunes et al., 
2001) or from the activation of cellular phospholipases (Zhao et al., 2001). 
H-1PV has been shown to block ROS generation in HeLa cells (Ran et al., 
1999), and inhibition of cPLA2 by chemical agents has no effect on H-1PV-
induced cell killing in NCH82 glioma cells (data not shown). Yet a domain 
displaying PLA2 activity has been identified within the capsid protein VP1. 
Under acidic conditions (e.g. in endosomes), the capsid structure is modified, 
resulting in exposure of this domain and enabling the virus to exit from the 
acidic vesicles (Farr et al., 2005; Suikkanen et al., 2003; Zadori et al., 
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2001). Should neosynthesized VP proteins or progeny particles transit 
through autophagic vesicles, VP1 might imaginably affect the stability of 
vesicle membranes and, as a result, alter the trafficking of cathepsins 
between the cytosol and the organelles. This hypothesis is consistent with 
the detection of viral proteins in the vesicles of H-1PV-infected glioma cells, 
particularly in the Lamp2-positive fraction (Di Piazza et al., 2007). Acidic 
vesicles accumulating in the cytoplasm of H-1PV-infected glioma cells might 
interconnect with the “free”-cathepsin-dependent death pathway by 
providing a source of active enzyme. 
The degree of LMP is proposed to determine the balance between 
apoptotic and necrotic death, with partial lysosomal permeabilization 
favoring the former and extensive lysosomal destabilization leading to the 
latter (Guicciardi et al., 2004). This study suggests that limited and very 
selective permeabilization of lysosomes might be enough to trigger a necrotic 
type of death, as observed in H-1PV-infected glioma cells. The dominance of 
necrosis in this system may be due, at least in part, to the presence of anti-
apoptotic signals in glioma cells. Other cells, such as U937 cells derived from 
a myeloid leukemia, have indeed been shown to die of apoptosis upon H-1PV 
infection (Rayet et al., 1998). LMP is reported to be triggered by various 
inducers of p53- dependent and independent death, including TNF and pro-
apoptotic drugs, in rodent fibroblasts (Foghsgaard et al., 2001), colon cancer 
cells (Erdal et al., 2005), and myeloid leukemic cells (Yuan et al., 2002). It is 
particularly noteworthy that H-1PV cytotoxicity does not appear to be 
associated with the induction of detectable TNF production, that U937 cell 
variants surviving H-1PV infection are also resistant to death induction by 
TNF (Rayet et al., 1998), and that TNF-induced killing of U937 cells depends 
on the expression of cathepsins (Deiss et al., 1996). Thus, cathepsin 
activation appears to be a key element in parvoviral cytotoxicity, although 
the type of ensuing cell death may vary according to other cellular 
determinants. TRAIL is also unlikely to mediate redistribution, since this 
ligand has recently been shown to promote cell death through caspase 8-
induced cathepsin B activation (Nagaraj et al., 2006). Generally speaking, 
the cytosolic accumulation of cathepsins in H-1PV-infected glioma cells 
occurs under conditions where effector caspases are not activated. It can be 
distinguished from LMP caused by the above-mentioned agents. Inhibitors of 
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NAD-consuming enzymes have also been shown to affect the balance 
between apoptosis and necrosis after cell infection with H-1PV (Ran et al., 
1999). This may be due to the role of lysosomes in parvovirus-induced cell 
death, since the NAD+/NADH system is involved in electron transport and 
acidification in these organelles (Gille and Nohl, 2000). 
Another interesting finding of the present study is that induction of 
glioma cell death by H-1PV correlates not only with cytosol enrichment in 
cathepsins, but also with reduced levels of the cathepsin inhibitors cystatin B 
and cystatin C. This reduction presumably contributes to the striking increase 
in cathepsin activity in the cytosol of infected cells, and is necessary for their 
killing. This points to a role for cystatin-family proteins in the survival of 
cancer cells. In keeping with this, cystatin C and cystatin B are 
overexpressed in gliomas (Zhang et al., 2003), accounting for the resistance 
of these tumors to LMP-inducing agents. It is noteworthy that highly 
malignant gliomas show lower cystatin C levels than astrocytomas 
(Nakabayashi et al., 2005), suggesting that the oncolytic activity of H-1PV 
may be even stronger against high-grade than low-grade gliomas. Successful 
H-1PV-induced glioma cell killing thus requires both relocation of cathepsins 
and their relief from cystatin inhibition. Nevertheless, autophagy still occurs 
when NCH82 cells are prevented from H-1PV cytotoxic action by cystatin B 
overexpression, pointing to a central role for autophagy in the initiation of 
parvovirus-induced cell death. Then, it cannot be excluded that parvovirus  
H-1 infection triggers the formation of autophagic vesicles and the 
modulation of cystatins, cathepsins lysosomal release being a consequence 
of the autophago-lysosomal trafficking and cathepsins cytosolic activation 
occurring because of cystatins decreased expression. 
 
 
5.3. Parvovirus H-1 as therapeutic tool for glioma treatment  
 
The concept of oncolytic virotherapy implies the use of viruses to 
specifically infect and kill tumor cells (Kirn et al., 2001). The current 
tendency in this field is to test replication-competent viruses naturally 
selective for cancerous cells and non cytophatic toward healthy tissues 
(Parato et al., 2005). A comparison of parvovirus H-1 versus other oncolytic 
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viruses’ cytotoxic potential against human gliomas will be helpful in the 
assessment of this virus as promising candidate for a virotherapy approach. 
An advanced study has evaluated the antitumor efficiency of nine unrelated 
viruses with oncolytic potential in two glioblastoma cell lines (Wollmann et 
al., 2005). Vesicular stomatitis virus (VSV) has displayed the greatest 
potential, being able to target different glioma phenotypes, to release 
progeny from a small number of cells, to rapidly spread throughout the 
culture and efficiently kill the cells. On the opposite, Sindbis virus (SIN) and 
both the fibrotropic prototype and an immunosuppressive strain of MVM 
prefer specific glioblastoma genotypes, and only SIN exerts self-amplification 
of the antineoplastic effect. In this respect, parvovirus H-1 successfully 
suppresses several established and low passage human glioma cell lines 
displaying different mutation profiles. H-1PV progeny spreading capacity has 
not been tested in vitro, but when intracranially injected into glioma-bearing 
rats the virus obviously diffuses inside the tumoral mass and induces the 
regression of the neoplasm. 
As already mentioned, a main limitation of anticancer treatments is 
represented by side effects produced on healthy tissues. SIN, the two MVM 
strains and passage-adapted VSV have shown not to significantly infect 
human fibroblasts, used as control, while VSV progeny has been on the 
contrary hypothesized to be implicated in latent cell death among control 
cells (Wollmann et al., 2005). Indeed, a more recent investigation has 
proposed to combine VSV infection with interferon pathway inducers in order 
to kill human glioma cells but preserve glial cells (Wollmann et al., 2007). A 
more appropriate in vitro control for human non-malignant brain tissue is 
provided for parvovirus H-1 studies. Previous (Herrero y Calle et al., 2004) 
and current (Di Piazza et al., 2007) data show that H-1PV infection does not 
jeopardize the survival of normal human astrocytes. In particular, infected 
normal astrocytes do not fill up with acidic vesicles and do not show any 
other sign of autophagy, even though they sustain detectable levels of H-1PV 
DNA replication and gene expression (Di Piazza et al., 2007). This 
oncospecificity of H-1PV cytotoxic effects may be due to various factors, as 
normal mouse and human astrocytes differ from glioma cells by their lower 
permissiveness to parvovirus multiplication (Abschuetz et al., 2006; Herrero 
y Calle et al., 2004), their lower level of cathepsin B, and their lack of 
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cystatin B down-regulation upon infection. Further work in this direction 
should evaluate parvovirus H-1 lack of affinity for neurons, since a possible 
therapeutic application of the virus must exclude the eventuality of damage 
to the central nervous system. Moreover, given the evidence of the existence 
of a brain cancer stem cell pool responsible for tumor development and 
maintenance (Singh et al., 2004), it would be important to scrutinize H-1PV 
sensitivity of neural versus cancer stem cells. 
 In conclusion, H-1PV has developed an efficient strategy for killing 
human glioma cells. It targets lysosomal proteases from two sides: 
accumulation of autophagic vesicles and cathepsins functional cytosolic 
activation. Cathepsins are highly expressed in high-grade tumors and 
participate in invasion by malignant cells (Mohanam and Jas, 2001; Rempel 
et al., 1994). A strategy taking advantage of this overexpression to induce 
killing of tumor cells seems particularly attractive. The evidence presented 
here suggests that parvoviruses are especially relevant to the treatment of 
gliomas, through their ability to efficiently hijack the lysosomal/cathepsin 
pathway and kill tumor cells, whether or not they are resistant to 
conventional death inducers. 
 
 
5.4. Genetic determinants of rat embryo fibroblasts sensitiveness 
to parvovirus H-1-induced killing  
 
Proliferating transformed cells are efficiently killed by parvoviruses 
because they provide an environment suitable to viral multiplication and 
spreading. In particular, cell transformation contributes to the oncotropic and 
oncolytic activities of parvoviruses by inducing changes in the structure, 
regulation and/or activity of the viral non-structural protein NS1, which is 
considered the major effector of virus-mediated cytotoxicity (Caillet-Fauquet 
et al., 1990; Li and Rhode, 1990; Moffatt et al., 1998; Mousset and 
Rommelaere, 1982). Several studies have suggested that cell 
immortalization could in certain contexts be sufficient to sensitize cells to 
parvovirus-induced cell killing (Salomè et al., 1990). Fisher rat fibroblasts 
have been shown in example to be naturally resistant to parvovirus minute 
virus of mice (MVM) but to exhibit a progressive increased susceptibility to 
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infection when transfected with immortalizing or transforming oncogenes 
(Legrand et al., 1992). 
The present study focuses on parvovirus H-1 because of its potential 
as therapeutic tool for an alternative approach in the treatment of gliomas 
(Di Piazza et al., 2007; Herrero y Calle et al., 2004). Cell sensitization to    
H-1PV infection has been studied in rat embryo fibroblasts since they 
constitute a simple model for oncogene cooperation in malignant 
transformation. Immortalized or transformed phenotypes have been induced 
in these cells by using, in single overexpression or in different combination, 
c-myc, SV40 large T antigen and activated Ha-ras oncogenes, and a 
dominant negative mutant form of the anti-oncogene p53. These genes have 
been chosen because they are frequently mutated in the majority of human 
cancers (Nesbit et al., 1999; Sahai and Marshall, 2002; Vousden and Lu, 
2002), but also in the perspective of applying the knowledge grasped from 
REFs experiments on the study of human and rat astrocyte transformation in 
correlation to acquisition of permissiveness to H-1PV. In fact, Ras is the 
downstream main effector of the signalling network activated by receptor 
tyrosine kinases (RTKs) whose genes are frequently overexpressed/amplified 
in gliomas (Tysnes and Mahesparan, 2001). Additionally, Ras triggers the 
Akt/PKB survival pathway that is negatively regulated by PTEN, a 
phosphatase whose loss of function is often detected in human gliomas (Zhu 
and Parada, 2002). The inactivation of p53 has been reported in both 
primary and secondary gliomas, directly through locus mutation or indirectly 
due to Mdm2 overexpression or loss of the INK4a/ARF locus (Zhu and 
Parada, 2002). Mutation occurring to c-myc expression are rare in high-
grade adult brain tumors (Maher et al., 2001), but there is a tight connection 
between control of c-myc functions and loss of p19ARF (Qi et al., 2004; Zindy 
et al., 1998). Finally, a truncated form of SV40 large T antigen has been 
already used to study the inactivation of pRb proteins in the development of 
high-grade astrocytomas (Biernat et al., 1997b; Xiao et al., 2002a). 
Evidence is here given that c-myc overexpression is sufficient to 
sensitize rat embryo fibroblasts to parvovirus H-1-induced cell lysis. Indeed, 
c-Myc oncoprotein enhances immortalized rat fibroblasts susceptibility to the 
killing effect of parvoviruses (Salomè et al., 1990), and it has been proposed 
to mediate apoptotic cell death induction after H-1PV infection of human 
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promonocytic U937 cells (Rayet et al., 1998), whose virus-resisting clones 
show a significant decrease in the accumulation levels of c-Myc (Lopez-
Guerrero et al., 1997). On the opposite, p53 inactivation or Ha-ras 
overexpression are not sufficient to render REFs permissive to viral infection. 
Therefore, differences in the modes of action of single oncogenes seem to 
ascribe for distinct responses in terms of cell sensitivity to H-1PV. 
Viral genome amplification has been considered as a critical step that 
can be modulated by malignant transformation (Rommelaere and Cornelis, 
2001). In agreement with this statement, the present work underlines that 
the quality of the immortalized/transformed status of the cell has a different 
effect on parvovirus H-1 protein expression and capacity to fulfil its life cycle. 
Specific oncogenes have been shown to directly enhance parvovirus genome 
replication: NS1 synthesis is driven by the early parvoviral promoter P4, 
which contains several binging sites, conserved between MVM and H-1PV, for 
transcription factors activated by Ras through the MAPK signalling pathway 
(Fuks et al., 1996; Perros et al., 1995), by c-Myc (Plaza et al., 1991) and 
SV40 large T (Gu et al., 1999; Gu et al., 1995). It is therefore not surprising 
that REFs transfected with c-myc or SV40 large T antigen alone are able to 
sustain H-1PV genome replication. This event is then rendered progressively 
more pronounced in cells restraining the combined double oncogene 
expression, and in transfectants transformed by these oncogenes in 
cooperation with ras*. Indeed, increased viral genome amplification and 
proteins translation has been already documented in association with 
parvovirus infection of transformed cells (Cornelis et al., 1988; Cornelis et 
al., 1990). Human lung fibroblasts transformed with SV40 and infected with 
MVM support a 10-fold-higher level of DNA replication than their 
untransformed progenitors (Cornelis et al., 1988), and processing of viral 
multimeric replicative intermediates has been correlated with SV40-induced 
malignancy (Kuntz-Simon et al., 1999). Finally, p53 exerts a direct or p21-
mediated inhibition of cell growth (Lundberg et al., 2000), and the blockage 
of parvovirus infection in primary cells may be at least partly resulted from 
p53-induced cell cycle arrest (Op De Beeck et al., 2001). Despite of this 
argumentation, p53 inactivation alone is not promoting viral replication, but 
it could contribute to it in cells overexpressing c-myc, ras* or SV40 large T 
antigen by stimulating cell proliferation. 
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The data presented in the current investigation are partially in 
contrast with an analogous report on rat embryo fibroblasts sensitiveness to 
parvovirus H-1 (Telerman et al., 1993). In that study stable transformed 
REFs subpopulations were generated by c-myc overexpression and Ha-ras 
activation plus p53 concomitant inhibition with a dominant negative mutant 
or an inactive form carrying a point mutation. A vector coding for a short 
form of p53 incapable of abrogating wild-type p53 DNA binding activity was 
used as control. Since only this last sub-population resisted to H-1PV 
infection, the conclusion was that there is a close relationship between wild-
type p53 function and resistance to parvovirus H-1-induced killing. Besides, 
c-myc alone was failing in sensitizing ras-transformed REFs to viral infection. 
The possibility of disturbances on the intracellular signalling network and 
metabolism due to triple-oncogene transformation has not been considered. 
However, rat embryo fibroblasts have shown a highly variable behaviour in 
response to the introduction of genetic alterations. In example, primary REFs 
cultures resist specific oncogene-induced transformation (Inoue et al., 1995), 
while REF52 cells are immortalized fibroblasts but require co-expression of a 
cooperating oncogene for transformation by ras, thus acting similarly to 
primary cells (Franza et al., 1986). Hence, it is possible that the transfected 
short form of p53, despite not inactivating wild-type p53 functions, induced 
an aspecific cell reaction that affected the outcome of REFs sensitivity to viral 
infection. Moreover, in that work cells were infected with H-1PV at an MOI of 
100 for 7 days, while the transfectants here analysed have been treated with 
an amount of virus ranging from MOI 0.625 to 10 for a period of 2 days, 
even excluding a second round of replication. Altogether, it should be 
concluded that the experimental setting used in this study has allowed a 
more precise evaluation of the molecular events conferring permissiveness to 
parvovirus H-1. 
Altogether, the acquisition of cell permissiveness to the virus seems to 
correlate with the extent of single oncogene efficacy in evading mechanisms 
controlling cell division and proliferation, and preventing the activation of 
programmed cell death pathways. In general, p53 acts as a transcription 
factor: its cellular levels increase following DNA damage and result in cell 
cycle arrest followed by either DNA repair or, if the damage is irremediable, 
apoptosis (Vousden and Lu, 2002). The regulation of cell cycle progression 
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by p53 mainly occurs by affecting the phosphorylation status of 
retinoblastoma proteins (pRbf) through the induction of growth arrest 
effectors, principally p21cip1 (Johnson et al., 1993) but also p15INK4b and 
p16INK4a (Lundberg et al., 2000). The perturbation on cell cycle control 
introduced by inactivating p53 with a dominant negative mutant can be 
further enhanced by overexpressing SV40 large T antigen. In addition to 
binding and blocking p53 (Ali and DeCaprio, 2001), SV40 large T can 
sequestrate pRb proteins independently of their phosphorylation status 
(Whyte et al., 1989), thus promoting E2F transcription factor-mediated gene 
expression, which trans-actives among others c-myc (Hiebert et al., 1989). 
c-Myc is a multifunctional transcription factor regulating the expression of a 
broad number of genes involved in cell proliferation, differentiation and 
growth (Henriksson and Luscher, 1996), and even apoptosis (Evan et al., 
1992). Previous reports have proposed that the mechanisms for c-myc-
stimulated apoptosis are distinct from c-myc-induced hyperproliferation 
pathways (Conzen et al., 2000; Qi et al., 2004; Xiao et al., 1998). On the 
one hand, c-Myc directly stabilizes p53 and triggers p53-dependent 
transcription (Hermeking and Eick, 1994; Wagner et al., 1994). On the other 
hand, c-Myc can induce p53 through activation of the tumor suppressor 
p19ARF, which in turn can inhibit c-myc expression and its transactivation of 
key target genes by acting independently from p53 (Qi et al., 2004; Zindy et 
al., 1998). Indeed, cells transfected with c-myc are initially sensitive to 
apoptosis, but may overcome cell arrest crisis and acquire immortalized 
properties upon loss of p19ARF (Zindy et al., 1998). Furthermore, c-Myc can 
commit mammalian somatic cells to DNA replication by regulating the cyclin 
E-CDK2 complex independently and in parallel to the pRb/E2F pathway 
(Santoni-Rugiu et al., 2000), thus overcoming p16INK4a-induced cell cycle 
arrest (Alevizopoulos et al., 1997). 
In summary, c-Myc mediates on the one hand the disruption of 
molecular mechanisms controlling cell growth and proliferation that involve 
also the alteration of p53 and pRb signalling pathways. Nevertheless, this 
overall synergistic action seems not to account for the acquisition of cell 
sensitivity to parvovirus H-1, as the present study demonstrate that the 
virus is not inducing significant cell cycle perturbations and normal, p53dn or 
ras* REFs proliferate in culture despite being insensitive to viral infection, 
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thus excluding an effect of the cell cycle. On the other hand, c-myc 
overexpression selects for additional not completely determined genetic 
changes that can predispose cells to the activation of the apoptotic signalling 
pathway. In particular, c-myc sensitizes immortalized cells to death by 
destabilizing mitochondrial integrity; this process can be activated in 
response to TNF or TRAIL (Klefstrom et al., 2002), is mediated by pro-
apoptotic members of the Bcl-2 family such as Bak and Bax (Juin et al., 
2002), and is inhibited by anti-apoptotic members of the same family like 
Bcl-XL or Bcl-2 (Finch et al., 2006; Iaccarino et al., 2003). In contrast, ras* 
overexpression promotes cell survival through the PI3K/Akt pathway, which 
antagonizes apoptosis initiation (Giehl, 2005). A consideration of the 
consequence of ras activation on the predisposition to sensitization provided 
by p53dn and c-myc overexpression strengthens this assumption. ras 
oncogene transducted alone has been demonstrated to push rat embryo 
fibroblasts to senescence, partially by inducing p16INK4a expression (Serrano 
et al., 1997). It is therefore not surprising that ras*-transfected REFs do not 
support viral infection. On the other side, cells are highly sensitive to H-1PV-
induced killing when transformation is achieved by ras and c-myc 
concomitant activation, while ras*/p53dn-transfected REFs are less 
susceptible to parvovirus H-1, not more than REFs transfectants sensitized 
by c-myc single overexpression. Therefore, c-myc-overexpressing cells, 
apart from being immortalized, appear also to be more prone to the 
activation of programmed cell death pathways in response to external 
stimuli. 
 
 
5.5. Oncogenes impact on the activation of apoptotic or alternative 
death pathways upon REFs infection with parvovirus H-1 
 
Parvoviruses have been reported to promote the initiation of apoptosis 
(Moehler et al., 2001; Rayet et al., 1998), necrosis (Ran et al., 1999) and 
autophagy (Nakashima et al., 2006). Upon infection of rat embryo fibroblasts 
overexpressing c-myc and/or SV40 large T antigen, the virus promotes the 
activation of a non-apoptotic cell death characterized by the appearance of 
autophagic vesicles, the cytosolic activation of lysosomal cathepsin B and the 
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down-regulation of cathepsins inhibitors. In REFs transformed by ras 
overexpression and p53 inactivation, H-1PV induces apoptosis via 
mitochondrial outer membrane permeabilization and caspase 3 cleavage. 
Interestingly, virus-mediated cystatin B modulation occurs also in these 
cells, thus appearing to be a general direct effect of parvovirus H-1 infection. 
On the contrary, it is not possible to identify a virus-intrinsic killing 
mechanism activated in response to the acquisition of a precise phenotype. 
As already mentioned, the hypothesis is that single oncogenes differently 
impinge on cells predisposition to the activation of an apoptotic or 
autophagic programmed death pathway to counteract viral infection. 
In the cell populations analyzed, the basal content of acidic vesicles is 
higher in c-myc and/or SV40 large T immortalized and transformed REFs as 
compared to primary cells. The state of tumoral cell differentiation is 
certainly a factor that may influence the autophagic response (Houri et al., 
1995; Houri et al., 1993). In this perspective, c-myc overexpression induces 
autophagy in established rat fibroblasts that retain primary embryonic 
features, and sensitizes these cells to a stronger activation of autophagy 
under serum starvation conditions (Tsuneoka et al., 2003). More recently, a 
shorter isoform of the tumor suppressor p19ARF (smARF) has been shown to 
induce autophagic cell death upon mitochondrial translocation and p53 or 
Bcl-2/Bax independent partial dissipation of the outer membrane potential 
without cytochrome c release (Reef and Kimchi, 2006). It has to be noted 
that smARF is rapidly degraded by the proteasome, but accumulates after 
inappropriate proliferative signals generated by SV40 large T, c-myc and 
E2F-1 oncogenes (Reef et al., 2006) that have also been demonstrated to 
induce p19ARF longer isoform (Bates et al., 1998; Zindy et al., 1998). 
Controversial is instead the role of Ras in the regulation of the autophagic 
process. It has been initially shown that autophagy is triggered by ras 
overexpression in human glioma and gastric cancer cell lines (Chi et al., 
1999) while more recently Ras has been identified as a negative regulator for 
nutrient deprivation-induced autophagy in NIH3T3 cells (Furuta et al., 2004) 
and in yeast (Budovskaya et al., 2004; Schmelzle et al., 2004) by acting 
respectively through the class I PI3-kinase and the PKA signalling pathways. 
In addition, Ras downstream signalling controls autophagy activation in 
cancer cells response to amino acids and nutrient starvation by differently 
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influencing respectively the ERK or the Akt pathway (Pattingre et al., 2003). 
It is therefore possible that ras exerts a synergizing effect increasing the 
tendency of c-myc or SV40 large T overexpressing REFs to activate 
autophagy as degradative pathway. On the contrary, transformed 
ras*/p53dn REFs seem to be over-protected against p53-dependent 
apoptosis to achieve uncontrolled cell proliferation, due to p53 inactivation 
and Ras-mediated anti-apoptotic effect. However, it has not to be excluded 
that they cannot antagonize p53-independent apoptotic reaction to external 
stimuli like H-1PV infection, since ras has been demonstrated to activate 
p19ARF (Groth et al., 2000), which can promote the induction of apoptosis in 
a p53-independent manner (Lowe and Sherr, 2003). Indeed, REF52 cells 
stably transformed by ras oncogene have a limited ability to proliferate in 
response to mitogenic signals and require the continuous expression of a 
collaborating oncogene, such as SV40 large T, to be maintained in culture 
(Ragozzino et al., 1991). It thus seems that primary cells try to counteract 
transformation by inducing alternative mechanisms to restore disrupted 
pathways controlling cell cycle progression and programmed cell death. 
Lysosomal proteases, cathepsins, may play a role in immortalized 
and/or transformed REFs proneness to the activation of an apoptotic or 
autophagic programmed death pathway after parvovirus H-1 infection. In 
particular, cathepsins B and L translocate from lysosomes to the cytosol in 
reaction to a large array of death-inducing stimuli and trigger different types 
of death, from classic apoptosis (Boya et al., 2003; Foghsgaard et al., 2001) 
to necrosis (Kagedal et al., 2001), depending on the extent of the lysosomal 
membrane permeabilization and the amount of cathepsins released to the 
cytosol (Guicciardi et al., 2004). Moreover, cathepsin B seems to act as 
molecular switch between apoptosis and autophagy, the former being 
favoured by cathepsins chemical inhibition (Lamparska-Przybysz et al., 
2005). Most interestingly, immortalization and transformation have been 
demonstrated to sensitize murine embryonic fibroblasts (MEFs) to cathepsin 
B and L dependent cell death (Fehrenbacher et al., 2004). While primary 
MEFs are not susceptible to tumor necrosis factor (TNF)-mediated killing, 
cathepsins-promoted and caspase 3-independent apoptosis is triggered after 
TNF incubation of MEFs spontaneously immortalized through either p53 
mutation or p19ARF loss. ras*-induced but not SV40 large T-driven 
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transformation of immortalized MEFs increases cathepsins expression and 
provides cells with additional sensitization to TNF treatment (Fehrenbacher et 
al., 2004). Remarkably, TNF-mediated killing of transformed MEFs is 
reported to activate a cathepsins-dependent programmed cell death 
(Fehrenbacher et al., 2004; Gyrd-Hansen et al., 2004), allowing the 
conclusion that a non-apoptotic process is promoted in this context. Hence, 
oncogene selective activation could influence cell sensitization to an 
autophagic death promoted by cathepsins via either mitochondrial 
permeabilization (Jäättelä, 2004) or lysosomal leakage leading to 
intracellular acidification and stabilization of pro-autophagic members of the 
Bcl-2 family (Kubasiak et al., 2002). However, various genetic backgrounds 
could differently impinge on lysosomal death pathways at the level of 
lysosomal membranes sensitivity to permeabilization-inducing events, grade 
of lysosomal membrane permeabilization, type of activated downstream 
effector mechanisms (Fehrenbacher and Jäättelä, 2005). 
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The present work studied the capacity of parvovirus H-1 to kill human 
glioma cells and identified a new viral cytopathic pathway and a novel 
regulatory mechanism of virus-induced cell death. H-1PV triggered a non-
apoptotic type of death characterized by both the accumulation of autophagic 
vesicles and the activation of lysosomal cathepsins in the cytosol of infected 
cells. On the basis of the presented experimental data, a model for H-1PV-
mediated cell killing is proposed (Fig. 27). In addition, the present study 
tested the effect of genetic alterations on cell permissiveness to parvovirus 
H-1-induced killing. To this purpose, rat embryo fibroblasts were 
immortalized or transformed by overexpressing c-myc, activated Ha-ras, and 
SV40 large T antigen oncogenes, or a dominant negative mutant form of 
p53. A second model describing how different oncogenes affect H-1PV-
mediated cell killing is depicted (Fig. 28). 
 
Parvovirus H-1 infection triggers an autophagic and cathepsins-
dependent cell death in glioma cells. In cultured NCH82 cells cathepsins are 
confined within lysosomes and are neutralized by cystatins, their 
physiological inhibitors, in case of an eventual release into the cytosol. 
Autophagy is activated as default mechanism involved in nutrient recycling 
and protein turnover. Upon parvovirus H-1 infection, autophagosomes 
formation is stimulated along the conventional pathway depending on 
Beclin1, but independently of Bcl-2. The cytosol of infected cell is rapidly 
filled in with acidic vesicles, as result of the dynamic fusion of 
autophagosomes with lysosomes. By 24 h after infection, acidic 
compartments start to leak thus releasing their content into the cytosol. 
Since parvovirus H-1 down-regulates cystatins expression, cytosolic 
cathepsins are no more counterbalanced and exert their proteolytic activity 
digesting the cell from inside. Whether cathepsins lysosomal release is a 
selective process or an event due to a more general permeabilization of the 
lysosomal membrane is still a matter of debate. Anyway, cathepsins cytosolic 
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activation takes place after and as consequence of H-1PV induction of 
autophagy. Besides, cathepsin B promotes the onset of apoptosis by 
mediating mitochondrial membrane depolarization and downstream 
activation of caspase 3. Cell lysis is accomplished in 80% of the cultured 
NCH82 cell population by 48 h after parvovirus H-1 infection. 
Figure 27. Activation of autophagy-like cell 
death in gliomas following H-1PV infection.
Beclin1
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Bcl-2
X
Caspase 3
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Bcl-2
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Autophagosomes Autolysosomes
Lysosomes Cystatins
 
Oncogene selective sensitization of rat embryo fibroblasts to 
parvovirus H-1-induced killing. Primary untransfected REFs and ras*-
senescent cells are insensitive to H-1PV infection. Immortalization because of 
p53 inactivation is not sufficient to render cells permissive to the virus but, 
 117
                                                                                                                                               Conclusions 
remarkably, c-myc overexpression alone in enough  to  sensitize  REFs  to  
H-1PV cytolytic action. Immortalization through double oncogene expression 
and cell full transformation enhance furthermore the cytotoxic power of the 
virus. As in the glioma model, parvovirus H-1 infection triggers a non-
apoptotic death pathway in REFs overexpressing c-myc and/or SV40 large T 
antigen, alone or in combination with another oncogene. This process is 
distinguishedRby acidic compartments multiplication, accumulation and final 
disruption. Cathepsin B is therefore active in the cytosol of infected cell and 
initiates a proteolytic process that leads to cell rupture. Surprisingly, H-1PV 
promotes the activation of a classical apoptotic pathway in REFs transformed 
Figure 28. Oncogene-driven activation of 
cell death in REFs following H-1PV infection.
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by p53 inactivation in combination with a second oncogene overexpression. 
Particular is the case of cells transfected with SV40 largeT antigen only. At a 
molecular level, these cells are susceptible for H-1PV activation of autophagic 
and cathepsin B-dependent cell death. At a cellular level the overall 
behaviour of the cultured population toward H-1PV infection is highly 
variable and therefore the sensitivity of these cells to the virus is not 
statistically significant. 
 
The cellular and molecular disturbances triggered by parvovirus H-1 in 
tumor cells shed new light on the interplay between apoptosis and 
alternative death pathways in tumor development, an emerging topic with 
interesting potentials for novel therapeutic applications. Considering the 
abilities of this virus to distinguish neoplastic (sensitive) from normal glial 
cells (resistant), and to overcome the resistance developed by gliomas and 
many other tumors to death inducers, the present work opens up future 
prospects for the use of H-1PV in cancer virotherapy. 
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